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Metabolic disorders can present with virtually any clinical symptom. Combining the bio-
chemical and clinical findings, and recognizing a distinctive disease pattern is a powerful 
approach to solve the genetic background. 
In the urine of healthy individuals the branched chain organic acid 3−methylglutaconic acid 
(3−MGA) is found only in trace amounts. Elevated urinary excretion of 3−MGA 
(3−MGA−uria) is a powerful diagnostic clue for several rare, but highly characteristic, 
neurometabolic syndromes like Barth syndrome (3−MGA−uria, cardiomyopathy, 
neutropenia; MIM #302060) or Costeff syndrome (3−MGA−uria, optic atrophy, ataxia, MIM 
#258501). On the other hand 3−MGA−uria is seen in a rapidly growing heterogeneous 
group of patients, mostly with progressive neurological signs and symptoms, designated 
type IV 3−MGA−uria. 
The pathomechanism leading to 3−MGA−uria is poorly understood. Only in the rare case of 
3−methylglutaconyl−CoA-hydratase deficiency (MIM #250950) 3−MGA is known to 
originate from leucine catabolism. In all other conditions the origin of 3−MGA is completely 
unknown but seems to be related to mitochondrial dysfunction. 
This thesis describes the results of a thorough (re)-investigation of the 3−MGA−urias, the 
known, the unknown and the unknowable. 
Chapter 1 presents the current knowledge on the different 3−MGA syndromes. The clinical 
and biochemical findings in patients with the known 3−MGA syndromes are reviewed. 
Chapter 2 focuses on 3−methylglutaconyl−CoA-hydratase deficiency, which was thought 
to be a childhood onset disorder with non-specific symptoms or even a non-disease. We re-
define 3−methylglutaconyl−CoA-hydratase deficiency as a clinically and radiologically 
highly characteristic syndrome with adult-onset of symptoms. From Chapter 3 onwards we 
have a closer look on the rapidly expanding group of 3−MGA−uria type IV patients (MIM 
250951). Chapter 3 presents a successful diagnostic strategy for the patient with 
3−MGA−uria type IV based on the biochemical and clinical findings, which can spare 
children the invasive procedure of a muscle biopsy. Chapter 4 shows that facial dysmorphic 
features may accompany these findings and may be helpful in diagnostics. Chapter 5 
describes the clinical, biochemical and radiological phenotype of a new and highly 
characteristic 3−MGA syndrome, the MEGDEL syndrome (MIM #614739). These patient 
present with mitochondrial dysfunction, dystonia, deafness and Leigh syndrome on MRI. In 
Chapter 6 we elucidate the genetic background and its functional consequences. The gene 
involved is SERAC1, a gene of formerly unknown function, encoding a phospholipid 
remodeler at the crossroads of mitochondrial function and intracellular cholesterol 
trafficking. In Chapter 7 we analyse nearly 400 patients with 3−MGA−uria referred to our 
centre, thereby showing in which disorders 3−MGA−uria can be found. Interestingly it did 
not only occur in patients with mitochondrial disorders but also in several other metabolic 
and non-metabolic disorders that had not been associated with 3−MGA−uria before. 
Additionally, this paper shows that 3−MGA−uria is a marker not only for mitochondrial dys-
function in general, but for specific mitochondrial disorders. Our findings on the 
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3−MGA−urias finally lead to a proper, pathomechanism based, classification of this group 
of disorders, which is presented in Chapter 8. 
 
  
  
Chapter 1 
 
The 3−methylglutaconic acidurias: what’s new? 
 
S. Wortmann1, L. Kluijtmans2, U. Engelke2, R. Wevers2, E. Morava1 
 
1Nijmegen Centre for Mitochondrial Disorders at the Department of Pediatrics and the 
Institute of Genetic and Metabolic Disease (IGMD), 2Department of Laboratory Medicine, 
Radboud University Nijmegen Medical Center, Radboud University Nijmegen Medical 
Centre, Nijmegen, The Netherlands. 
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Abstract 
 
The heterogeneous group of 3−methylglutaconic aciduria syndromes includes several in-
born errors of metabolism biochemically characterized by increased urinary excretion of 
3−methylglutaconic acid. Five distinct types have been recognized: 3−methylglutaconic 
aciduria type I is an inborn error of leucine catabolism; the additional four types all affect 
mitochondrial function through different pathomechanisms. We provide an overview of 
the expanding clinical spectrum of the 3−methylglutaconic aciduria types and provide the 
newest insights into the underlying pathomechanisms. A diagnostic approach to the 
patient with 3−methylglutaconic aciduria is presented, and we search for the connection 
between urinary 3−methylglutaconic acid excretion and mitochondrial dysfunction. 
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Branched-chain organic acid 3−methylglutaconic acid: the biochemical basis 
 
The branched-chain organic acid 3−methylglutaconic acid (3−MGA) is an intermediate of 
the mitochondrial leucine catabolism. Figure 1 shows the metabolic pathway of leucine; 
3−MGA, 3−methylglutaric acid (3−MG), and 3−hydroxyisovaleric acid (3−HIVA) accumulate 
when the conversion of 3−methylglutaconyl−coenzyme A (CoA) to 3−hydroxy−3−methyl-
glutary−CoA (HMG−CoA) by the enzyme 3−methylglutaconyl−CoA hydratase (3−MGH, EC 
4.2.1.18) is disturbed. This is the underlying cause in 3−MGA−uria type I. As we show in 
detail upon describing the different subtypes of 3−MGA−uria, there is no evidence that the 
3−MGA−uria types II–V are caused by a disturbed leucine catabolism. Notably, subtypes II–
V affect mitochondrial function through different pathomechanisms. But how can 
mitochondrial dysfunction lead to elevated urinary excretion of 3−MGA? 
 
 
 
Figure 1. Leucine catabolism and possible shunts to cholesterol biosynthesis. 1 = 
Transaminase, 2 = branched-chain 2-oxo-acid dehydrogenase, 3 = isovaleryl-CoA 
dehydrogenase, 4 = 3-methylcrotonyl-CoA carboxylase, 5 = 3−methylglutaconyl−CoA-
hydratase, 6 = 3-hydroxy-3-methylglutaryl-coenzyme A (HMG−CoA) lyase, 7 = HMG−CoA 
synthase, 8 = HMG−CoA-reductase. PPi pyrophosphate. 
 
In the urine of healthy individuals, 3−MGA is found only in traces (< 20 mmol/mol 
creatinine). In patients with 3−MGA−uria, concentrations can (intermittently) rise above 
1000 mmol/mol creatinine. The urinary excretion of 3−MGA is generally higher in type I 
than in the other types1-4. Patients with 3- MGA-uria type I excrete even higher amounts of 
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urinary 3−MGA after a leucine-rich, or in general, a protein-rich meal5, 6. This is not the case 
in patients with the other types of 3−MGA−uria, which emphasizes that the excreted 
3−MGA does not originate from leucine degradation (Barth syndrome7, 8; type IV9; 
Wortmann et al. unpublished data). Interestingly, in these patients, the excretion can be 
highly variable or intermittently absent, even within 24 h, seemingly unrelated to the 
clinical course or severity of the metabolic derangement1, 3, 8, 10, 11. 
Patients with 3−MGA−uria type II (Barth syndrome) have both increased 3−MGA and low 
cholesterol levels. Therefore, it was speculated that some of the idiopathic syndromes with 
3−MGA−uria may be caused by defects of sterol or isoprenoid metabolism causing 
overflow of mevalonate carbon through the so-called mevalonate shunt (Figure 17, 12). In 
this shunt, dimethylallyl pyrophosphate is dephosphorylated in two steps to the free 
alcohol, oxidized to 3-methylcrotonic acid, and then activated with CoA to form 
3−methylcrotonyl−CoA, the precursor of 3−MGA-CoA in the regular leucine catabolic 
pathway13. Other links between the two pathways at the level of higher-order isoprenoids, 
such as geraniol and farnesol, have been described (Figure 113, 14). Also, a direct shunt 
between mevalonate and 3−methylglutaconyl−CoA was hypothesized (Figure 113). This is 
the only “mevalonate shunt” per se15. It seems that the shunt is more active in tissue of 
ectodermal origin (e.g., skin, placental tissue) than in tissue of mesodermal origin13. 
Physiologic evidence that the mevalonate shunt or a related shunt is significant in humans, 
at least in renal tissue, has been provided16. More data are available for rats, in which the 
liver is the main organ of mevalonate shunting17. Investigations in 35 patients with Smith-
Lemli-Opitz syndrome (SLO, MIM 27400) showed a weak inverse correlation between low 
plasma cholesterol, its elevated precursor 7- dehydrocholesterol, and elevated plasma 
3−MGA12. SLO patients with very low plasma cholesterol (< 200 μg/ml; seven of 35 
patients) generally had plasma 3−MGA levels above the + 2 standard deviation (SD) range 
for age (five of seven patients; range 400– 5,000 nmol/l). The rise in cholesterol precursors 
(isoprenoids), which cannot be metabolized to cholesterol in patients with SLO, leads to 
overflow via the mevalonate shunt and a consequential increase in 3−MGA (Figure 1). The 
authors also hypothesized another mechanism. Low plasma cholesterol can induce 
HMG−CoA synthase, leading to increased HMG−CoA levels and an increased flux through 
the cholesterol biosynthesis pathway18 . The HMG−CoA is then dehydrated to 3−MGA 
through 3−MGH (Figure 112). The urine of some patients also contained high amounts of 
3−MGA but no increased 3−HIVA levels, which is characteristic for 3−MGA−uria type I, 
suggesting that the 3−MGA does not originate from leucine catabolism. Still, the described 
shunt does not explain how mitochondrial dysfunction relates to excessive 3−MGA 
excretion. Several enzymes involved in leucine degradation as well as sterol biosynthesis 
are nicotinamide adenine dinucleotide phosphate (NADP)- NADP, reduced (NADPH) 
dependent. One could hypothesize that oxidative phosphorylation system (OXPHOS) 
dysfunction influences NADP-NADPH-dependent enzymes, such as the 3−MGA-hydratase 
by a disturbed NADP/NADPH ratio. However, excretion seems unrelated to clinical severity 
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or disease course. At the moment, 3- MGA is a biochemical marker for mitochondrial 
dysfunction of still unknown origin.  
 
 
Figure 2. [1H]-nuclear magnetic resonance (NMR) spectra of patients with 
3−methylglutaconic aciduria (3−MGA−uria) types I and IV. One-dimensional [1H]- NMR 
spectra (500 MHz) of urine measured at pH 2.5. The region between 2.2. and 1.9 ppm is 
shown. A) 2:1 cis:trans ratio in the urine of a patient with 3- MGA-uria type I. B) 1:1 cis:trans 
ratio in the urine of a patient with 3−MGA−uria type IV. 
 
Measuring 3−MGA by gas chromatography/mass spectrometry (GC−MS) and one-
dimensional [1H]-NMR spectroscopy 
As part of the routine metabolic screening in our lab, urinary organic acid analysis is per-
formed by gas chromatography/ mass spectrometry (GC–MS) after extraction of the urine 
sample with ethyl acetate and derivatization with N,N-bis(trimethylsilyl)trifluoroacetamide 
containing 1% trimethylchlorosilane. The concentration of 3−MGA is quantified by com-
paring the signals obtained with calibration curves of the pure compound, using a CP-Sil 8 
CB column (Varian, Middelburg, The Netherlands) on a high performance (HP) 6890 Gas 
Chromatograph (Agilent, Amstelveen, The Netherlands). For research purposes, we 
additionally perform one-dimensional [1H]-nuclear magnetic resonance (NMR) 
spectroscopy of different body fluids (Figure 219). Body fluid samples are measured at 500 
MHz on a Bruker DRX 500 spectrometer with a triple-resonance inverse (TXI) 1H {15N, 13C} 
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probe head equipped with X,Y,Z gradient coils. 1H spectra are acquired as 128 transients in 
32-K data points with a spectral width of 6,002 Hz. The water (H2O) resonance is 
presaturated by single-frequency irradiation during a relaxation delay of 10 s; a pulse width 
of 7 μs is used (corresponding to a 90° excitation pulse). 
 
3−MGA−uria type I (MIM 250950) 
For a long time, 3−MGA−uria type I was thought to be a classic organic aciduria. It is a rare 
autosomal recessive disorder of leucine catabolism characterized by markedly increased 
urinary excretion of 3−MGA and mildly elevated urinary 3−MG and 3−HIVA. The underlying 
cause of 3- MGA-uria type I is deficiency of 3−MGH, the enzyme that catalyzes the fifth 
step of leucine catabolism, the conversion of 3−methylglutaconyl−CoA to HMG−CoA 
(Figure 1). Murine 3−MGH is highly expressed in kidney, skeletal muscle, heart, and brain 
and was shown to be located in the mitochondria20. The activity of 3−MGH can be 
determined in fibroblasts or lymphocytes by use of an overall enzyme assay measuring 
three steps of leucine degradation, from 3−methylcrotonyl−CoA to acetoacetate21, 22. 
3−MGH is encoded by the AUH gene, which was mapped to chromosome 9 and 
encompasses ten exons encoding for a protein with 339 amino acids22, 23. The ratio of cis 
and trans isoforms of 3−MGA in urine of 3−MGA−uria type I patients is 2:1, whereas in 
cerebrospinal fluid (CSF), only the cis isoform is detectable19. In the other 3−MGA−uria 
types, the urinary cis:trans ratio is approximately 1:1 (Figure 2; repetitive measurements in 
patients with 3−MGA−uria type I (n=5), II (n=5), III (n=6), and IV (n>80)11). 
It is known that 3−methylcrotonyl−CoA carboxylase specifically forms the trans form of 
3−methylglutaconyl−CoA24. The metabolic origin of cis−3−methylglutaconyl−CoA remains 
as yet unknown. Spontaneous cis/trans interconversion may play a role. A brainspecific 
isoform of 3−MGH or an enzyme converting the trans form into the cis form, thus taking 
care of local production of the cis form in the brain, may be an explanation19. 
3−MGA−uria was thought to present in childhood with nonspecific symptoms such as 
mental retardation or seizures. It was even speculated to be a nondisease25. Recently, we 
reported that it is, in fact, a slowly progressive leukoencephalopathy clinically presenting in 
adulthood26. Function abolishing mutations were reported in seven children with various 
nonspecific symptoms, such as mental retardation, seizures, hepatopathy22, 23, 27, 28. 
Recently, our group reported the biochemical details of the first patient with an adult onset 
of the disease, a Dutch woman19, 26. She presented with a progressive bilateral visual 
decline and optic atrophy at the age of 35 years. Over the following 16 years, dysarthria 
and mild limb ataxia with severe gait ataxia were observed. One additional late-presenting 
patient was reported with dementia and spasticity by a Japanese group29. Both had a 
slowly progressive leukoencephalopathy. The same clinical signs and symptoms and 
disease course was observed in a third adult patient who came to our attention26. This 
British man first presented at the age of 30 years with mild cerebellar ataxia and slowly 
worsened over 29 years, showing spastic paraparesis, nystagmus, and dementia. Magnetic 
resonance imaging (MRI) of our adult patients showed extensive and diffusively distributed 
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white-matter lesions restricted to the supratentorial region not affecting the cerebellum or 
the corpus callosum (for MRI/MR spectrometry (MRS), see19). 
The Japanese patient also showed cerebellar involvement29. This led us to perform an MRI 
in a pediatric 3−MGA−uria type I patient who was detected upon metabolic screening for 
recurrent febrile seizures (in total, 15 up to age 7 years) at the age of four years27. He is ten 
years old at this writing and has developed completely normally. His MRI showed mild 
signal abnormalities in deep frontal white matter with sparing of the U-fibers. We propose 
that these abnormalities represent the earliest stages of the slowly progressive neuro-
degenerative disorder mainly affecting the white matter observed in the adult patients. 
Metabolite accumulation may contribute to the clinical signs and symptoms of this disease. 
A toxic effect of 3−MGA on the cerebral cortex has been demonstrated in rats30. There have 
also been speculations about the neurotoxicity of 3−HIVA31. The obvious accumulation of 
3−HIVA in CSF and brain observed by MRS in the Dutch woman may be indicative for a 
central role of 3−HIVA accumulation in the natural course of brain damage in this disease19. 
As in other organic acidurias, accumulation of toxic metabolites may give rise to slow-
onset excitotoxicity with cellular dysfunction and eventually cell death. If the natural-
course scenario that we propose can be confirmed in a larger series of patients, leucine-
restricted diet as a therapeutic approach from childhood onward must be reconsidered. 
 
3−MGA−uria type II (Barth syndrome, MIM 302060) 
The 3−MGA−uria type II or Barth syndrome is an X-linked recessive cardiomyopathy with 
(cyclic) neutropenia, skeletal myopathy, and mitochondrial respiratory chain dysfunction 
first described in a large Dutch family some 30 years ago32, 33. Ten years later, the 
3−MGA−uria and decreased plasma cholesterol were added as consistent disease features7. 
Sudden unexpected death in early life has been reported34. The progression of 
cardiomyopathy (CM) is variable, sometimes slowly improving over the years, but mostly 
progressive and ending up at a point where heart transplantation is the only treatment 
option8, 35, 36. Cyclic neutropenia, ranging from mild to severe, is frequently seen; and fatal 
bacterial infections can occur in the neonatal period. Neutropenia and CM can develop 
simultaneously or in isolation. Onset ranges between birth and 49 years and peaks around 
puberty37. Chronic aphthous ulceration due to Candida infections is a common sequela. 
Treatment with granulocyte colony-stimulating factor (GCSF) seems to be successful and 
safe 38, 38. Most patients show a degree of growth deficiency with height following the −2 
SD percentile37. There is evidence that patients share distinct facial features (tall and broad 
forehead, round face with prominent chin and full cheeks, large ears, and deep-set eyes), 
which are most evident in infancy39. In early studies, normal mental functioning and 
intelligence is reported. Recent studies suggest a higher incidence of cognitive difficulties 
with regard to mathematics, visual spatial tasks, and short-term memory. Language ability 
is spared. In combination with the excess fatigue often seen in these patients, this should 
be given special attention40.  
Chapter 1 
 
20 
The excretion of 3−MGA in urine can be highly variable, even within 24 h, and is often 
intermittent3, 8. The 3−MGA−uria is seemingly unrelated to the clinical course or severity of 
metabolic derangement. Even patients without 3−MGA−uria have been described10. Other 
characteristic findings in the urine are increased levels of 3−MG and 2-ethylhydracrylic acid, 
the latter a consequence of the isoleucine breakdown. Neither prolonged fasting nor leucin 
loading tests leads to changes in 3−MGA excretion, suggesting an alternative source of 
3−MGA in affected patients7, 8. Moderately decreased plasma total cholesterol, mostly 
belonging to the low-density lipoprotein (LDL) pool, is a consistent finding 7. This led to the 
hypothesis that 3−MGA results from overflow via the mevalonate shunt (Figure 17, 12). Cells 
from patients with Barth syndrome show a characteristic abnormal cardiolipin profile, 
which is the basis for the diagnosis (for review, see41).  
Total cardiolipin levels are lower, especially of the tetralineoyl subclasses, and the acyl 
chain composition is shifted toward less unsaturated species with markedly elevated 
monolysocardiolipin42. Cardiolipin is primarily found in the inner mitochondrial membrane 
and to a lesser extent in the outer mitochondrial membrane. Several proteins of the res-
piratory chain have been reported to bind to cardiolipin or require cardiolipin for optimal 
activity (as reviewed in43). Furthermore, cardiolipin is reported to function in the stabiliza-
tion of the individual respiratory chain complexes in a larger so-called supercomplex, en-
abling efficient channelling of electrons through the complexes. Barth syndrome is caused 
by mutations in the TAZ gene located at Xq28, encoding the protein tafazzin, named after 
the masochistic comic character from an Italian TV sport show44. The function of this 
mitochondrial cardiolipin transacylase and its different splice variants (129–292 amino 
acids long) in the remodelling of cardiolipin remains elusive. A role in apoptosis has been 
suggested, but how this causes CM and neutropenia is unknown43. 
 
3−MGA−uria type III (Costeff syndrome, MIM 258501) 
The 3−MGA−uria type III, or Costeff syndrome, is an autosomal recessive disorder with 
infantile bilateral optic atrophy, extrapyramidal signs, spasticity, ataxia, dysarthria, and 
cognitive deficit in decreasing order of frequency. It was first described in 19 Israeli patients 
in 198945. The excretion of 3−MGA and 3−MG is, as in the other 3−MGA−uria types, quite 
variable1. All patients of Iraqi Jewish origin are homozygous for a splice site founder muta-
tion in OPA3 (mapped to 19q13.2-q13.346). Several patients have been reported since then, 
almost exclusively of Iraqi Jewish origin, with the exception of one Turkish Kurdish and one 
Indian patient harboring different mutations47-49. Two other OPA3 mutations result in a 
rare dominant disorder (ADOAC; MIM 165300) involving optic atrophy, cataracts, and 
extrapyramidal signs without 3−MGA−uria50, 51. The OPA3 gene was first thought to consist 
of two exons; recently, it was proven to compromise three exons, resulting in two gene 
transcripts—OPA3A and OPA3B46, 52. Both transcripts contain exon 1, which is spliced to 
exon 2 in OPA3A (179 amino acids) and exon 3 in OPA3B (180 amino acids). OPA3A is 
expressed and conserved from fungi to primates, whereas OPA3B is uniquely found in 
mammals. In contrast to OPA3A, OPA3B is not identified in the proteomic database and is 
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considerably less frequently expressed in wild-type cells52. Recently, the prediction of a 
mitochondrial localization of the OPA3A protein could be confirmed. It is an integral 
protein of the mitochondrial outer membrane. The authors also reported an integral role 
for OPA3A in mitochondrial fission and apoptosis53. Very recently, a zebrafish model of 
Costeff syndrome has been described. Herein mitochondrial OPA3 is shown to protect the 
electron transport chain against inhibitory compounds54. 
 
3−MGA−uria type IV (MIM 250951) 
Although about 100 patients with 3−MGA−uria not being classified as type I, II, III, or V have 
been described, OMIM refers to only one case report from 1992 for 3−MGA−uria type IV. 
This was a young man with severe psychomotor retardation, poor growth, subvalvular 
aortic stenosis, and CM. He later developed seizures, spasticity, and sensorineural hearing 
loss 9. Since then, the spectrum has expanded rapidly. The underlying etiology has not 
been elucidated as yet but is certainly heterogeneous 55. 
The majority of patients described so far presented with CM56-62. A subgroup presented 
with a severe early-onset phenotype with hypertrophic CM, and the unique features of 
early cataract, hypotonia/developmental delay, and lactic acidosis63. Recently, the 
underlying genetic defect in a subgroup of patients of Gypsy origin presenting with 
hypertrophic CM, hypotonia, hepatomegaly, facial dysmorphism, and microcephaly was 
found. Mutations in TMEM70 encoding a mitochondrial protein proposed to be an ancillary 
factor involved in the biosynthesis and assembly of adenosine triphosphate (ATP) synthase 
(complex V of the respiratory chain) cause an isolated deficiency of ATP synthase. Half of 
the patients died, mostly within the first weeks of life; survivors showed psychomotor and 
various degrees of mental retardation56, 61, 64, 65. Interestingly, ATP synthase deficiency has 
been reported twice more in association with 3−MGA−uria. Recently, a young woman with 
mild mental retardation and peripheral neuropathy was described. She harbored a 
mutation in the ATP5E gene encoding the F1 epsilon subunit of the ATP synthase. This 
subunit is supposed to be involved in the incorporation of subunit c to the rotor structure of 
mammalian ATP synthase66. Some time ago, a girl with a syndromic phenotype mimicking 
cerebrooculo-facio-skeletal syndrome (but without microphthalmia/cataracts) was 
reported. She had hypoplastic kidneys, dysgenesis of the corpus callosum, and progressive 
brain atrophy involving the basal ganglia. She died aged 14 months after a course with 
intercurrent infections and seizures. She was found to have a mutation in the ATP12 gene, 
which encodes an ATP synthase assembly factor67. How these nuclear-encoded 
mitochondrial disorders involved in ATP synthesis or ATP synthase assembly lead to 
3−MGA−uria remains elusive. 
 In 2006, we reported four patients with a distinct clinical phenotype called MEGDEL 
association68. These patients presented with neuroradiological evidence of Leigh disease, 
sensorineural hearing loss, recurrent lactic academia, severe neonatal infections, and 
hypoglycemia. The 3−MGA in urine was moderately elevated, and all patients had complex 
I deficiency. In the mean time, we found three additional patients from other countries. 
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Genetic investigations are pending. Furthermore, patients with mitochondrial DNA 
(mtDNA) depletion or deletion syndromes, and m.3243A>G mutation, have been described 
in literature (POLG1 mutations69; unspecified mtDNA depletion70, 71; Pearson syndrome72-74; 
m.3243A>G60). Recently, we presented a diagnostic strategy that enabled us to elucidate 
the underlying genetic defect in 11 out of 18 children with 3- MGA type IV by delineating 
patient groups (encephalomyopathic: SUCLA2; hepatocerebral: POLG1, cardiomyopathic: 
TMEM70, myopathic: RYR1) on clinical and biochemical grounds (for details, see11). 
The 3−MGA−uria type IV is definitely the most intriguing type of the 3−MGA−urias, with a 
rapidly broadening spectrum. In contrast to the well-defined, distinct phenotypes 
3−MGA−uria I, II, III and V, 3−MGA−uria type IV is most frequently associated with 
progressive neurological impairment, variable organ dysfunction, and biochemical features 
of a dysfunctional OXPHOS. Urinary 3−MGA seems to be a biochemical marker for 
mitochondrial dysfunction.  
 
Clinical feature in the patient 
with 3−MGA−uria 
Type Next diagnostic step Genetic 
confirmationb 
Leukoencephalopathy I UOA: 3−MGA cis:trans isoforms (2:1), no ↑3−HIVA 
3−MGH activity in leucocytes/fibroblasts 
AUH 
 
Optic atrophy I UOA: 3−MGA cis:trans isoforms (2:1), no ↑3−HIVA 
3−MGH activity in leucocytes/fibroblasts 
AUH 
 III + Iraqi Jewish origin: proceed to genetic testing OPA3 
Ataxia/spasticity I UOA: 3−MGA cis:trans isoforms (2:1), no ↑3−HIVA 
3−MGH activity in leucocytes/fibroblasts 
AUH 
 III + Optic atrophy: proceed to genetic testing OPA3 
Sensorineural deafness IV OXPHOS measurements in muscle/fibroblastsa SUCLA2 
Encephalopathy (epilepsy, 
psychosis, depression) 
IV OXPHOS measurements in muscle/fibroblastsa  POLG1, 
SUCLA2 
Cardiomyopathy (± 
cataracts) 
II Cardiolipin profile 
+ Neutropenia: proceed to genetic testing 
TAZ 
 IV OXPHOS measurements in muscle/fibroblastsa 
 
m.3243A>G 
 IV + Gypsy origin: proceed to genetic testing TMEM70 
 V + Canadian-Hutterite origin: proceed to genetic 
testing  
DNAJC19 
Liver failure IV OXPHOS measurements in muscle/fibroblastsa 
Typical case of Alpers syndrome: proceed to genetic 
testing 
POLG1 
 
Bone marrow failure, 
exocrine pancreas 
insufficiency 
IV Proceed to genetic testing mtDNA 
deletions 
Table 1. A diagnostic approach to the patient with 3-MGA-uria. 3−MGA = 3−methylglutaconic 
acid, 3−MGA−uria = 3−methylglutaconic aciduria, 3−MGH = 3−methylglutaconyl−CoA 
hydratase, OXPHOS = oxidative phosphorylation system, UOA = urine organic acid analysis. 
aIn case of suspicion of a mitochondrial disorder (e.g., combined with lactic acidosis, elevated 
alanine, clinical or biochemical signs, and symptoms of multisystem disease), bCurrent 
knowledge, the underlying genetic defect is not always known. 
 
3−MGA−uria type V (MIM 610198) 
The 3−MGA−uria type V, or dilated cardiomyopathy with ataxia (DCMA) syndrome, is a 
novel autosomal recessive condition with early-onset dilated CM with conduction defects 
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and nonprogressive cerebellar ataxia in 18 patients of the Canadian Dariusleut Hutterite 
population, further characterized by testicular dysgenesis and growth failure75. Affected 
patients consistently showed five- to tenfold increases in both plasma and urine 3−MGA 
and 3−MG. Homozygosity mapping revealed the underlying splice-site mutation in the 
DNAJC19 gene. Proteins containing a DNAJ domain are typically involved in molecular 
chaperone systems. Based upon the predicted tertiary structure of DNAJ19 it could be 
located in the inner mitochondrial membrane. Because of the similarity with the yeast 
Tim14 protein, a defect of protein import via the inner mitochondrial membrane, as seen in 
Mohr-Tranebjaerg syndrome, is suggested76. 
 
Other causes of 3−MGA−uria 
Elevated urinary excretion of 3−MGA, parallel with increased excretion of 3−HIVA, 3−MG, 
3−methylglutarylcarnitin, and 3- hydroxy-3−methylglutaconic acid, can be found in 
patients with HMG−CoA lyase deficiency (MIM 246450, 77).This mitochondrial enzyme 
catalyses the last step of leucine breakdown (Figure 1) but is also required for ketogenesis. 
Patients present with a Reye-like picture with hypoketotic acidosis, metabolic acidosis, and 
liver failure. The prognosis is good if no damage from the initial presentation remains. The 
excretion pattern of HMG−CoA lyase deficiency is characteristic and distinguishes it from 
the other 3−MGA−uria types. Two patients with the late-onset form of multiple acyl-CoA 
dehydrogenase deficiency (MADD, or glutaric aciduria II, MIM 231680) also excreted 
3−MGA78. Deficient electron transfer from the flavin adenine dinucleotide (FAD)-
dependent dehydrogenases to the respiratory chain due to genetic defects of electron 
transfer flavoproteins (ETF) not only affects fatty acid oxidation but also dehydrogenases 
involved in the metabolism of amino acids (e.g., leucine), which could explain the 
3−MGA−uria. The diagnosis is difficult to establish but worth elucidating, as treatment with 
riboflavin or coenzyme Q10 shows dramatic improvement in some patients. 
The 3−MGA−uria can occur secondarily in patients with SLO because of abnormal 
isoprenoid/cholesterol biosynthesis, as well as in patients with glycogen storage disease Ib 
(MIM 232220) and IX (MIM306000), where it is speculated that an imbalance between 
gluconeogenesis and de novo cholesterol synthesis result in secondarily increased 3−MGA 
excretion (12, 79; Wortmann et al. unpublished data). These patients may present with 
elevated lactate levels and hypoglycemia. However, the clinical picture is distinct enough 
to allow correct diagnosis. 
In the 1990s a letter to the Lancet suggested that 3−MGA−uria seen in pregnant mothers 
could be indicative for a metabolic disorder or in general a congenital defect in the 
offspring80. Investigations in a larger cohort of pregnant women revealed that 3−MGA−uria 
is frequently seen in healthy pregnant women (13/18 patients reported by81, and no 
correlation to an underlying disease in the mother or child could be established81. It is 
speculated that the 3−MGA−uria occurs due to increased flux via the mevalonate shunt, as 
this is possible in tissue of ectodermal origin such as the placenta15. Interestingly, patients 
with congenital adrenal hyperplasia and thereby elevated production of sterol precursors 
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do not show 3−MGA−uria. The authors concluded that this is due to increased steroid flux 
occurring in the adrenal cortex, which is of mesodermal origin and where the mevalonate 
shunt is not supposed to function15. 
 
Gene  Type Protein Predicted function in patientsa 
AUH I  3−methylglutaconyl−CoA hydratase Leucine catabolism 10 
TAZ II Tafazzin, a mitochondrial cardiolipin 
transacylase 
Cardiolipin remodelling >100 
OPA3 III OPA3A and OPA3B protein Mitochondrial (mt) fisson, 
apoptosis 
>36 
TMEM70 IV Transmembrane protein 70 Biosynthesis and assembly of 
ATP synthase 
53 
ATP5E IV ATP synthase, epsilon subunit Biosynthesis and assembly of 
ATP synthase 
1 
ATP12 IV ATP 12 protein Biosynthesis and assembly of 
ATP synthase 
1 
POLG1 IV Polymerase gamma mtDNA replication 3 
m.3243A>G IV tRNA leucine mtDNA translation 1 
mtDNA 
deletions 
IV Not applicable mtDNA replication and 
translation 
6 
mtDNA 
depletion 
IV Not applicable mtDNA replication and 
translation 
5 
SUCLA2 IV Succinate-CoA ligase Tricarboxylic acid cycle 3 
RYR1 IV Ryanodine receptor  Calcium channel of 
sarcoplasmatic reticulum 
1 
DNAJC19 V Translocase of inner mitochondrial 
membrane 14 
Mitochondrial protein import 16 
Table 2. Genes, their translational products, and predicted function associated with 
3−MGA−uria. ATP = adenosine triphosphate. Mt = mitochondrial. aGenetically confirmed, in 
association with 3−MGA−uria. 
 
Conclusion and approach to the patient with unexplained 3−MGA−uria 
In this review, we present to the reader the fascinating spectrum of the 3−MGA−uria syn-
dromes. 3−MGA−uria is an important biochemical marker that should stimulate the 
physician to proceed with investigations. Therefore, we would end our review by providing 
an approach to the patient with unexplained 3−MGA−uria. 3−MGA−uria can be seen in two 
conditions: as a consistent feature in the well-defined 3−MGA−uria subtypes I, II, III, V, and 
as a marker for mitochondrial dysfunction. It is often necessary to repeat (but certainly 
worth doing so) the urine organic acid analysis, as the 3−MGA−uria can occur 
intermittently. Table 1 gives an overview of which diagnostic steps should be taken in 
patients with 3- MGA-uria and unexplained signs and symptoms, such as optic atrophy or 
CM. Table 2 provides an overview of all known genes and their translational products that 
are involved in the 3−MGA−urias. 
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Abstract 
 
Objective: 3−methylglutaconic aciduria type I is a rare inborn error of leucine catabolism. It 
is thought to present in childhood with nonspecific symptoms; it was even speculated to be 
a nondisease. The natural course of disease is unknown. Methods: This is a study on ten 
patients with 3−methylglutaconic aciduria type I. We present the clinical, neuroradiologic, 
biochemical, and genetic details on 2 new adult-onset patients and follow-up data on two 
patients from the literature. Results: Two unrelated patients with the characteristic 
biochemical findings of 3−methylglutaconic aciduria type I presented in adulthood with 
progressive ataxia. One patient additionally had optic atrophy, the other spasticity and 
dementia. Three novel mutations were found in conserved regions of the AUH gene. In 
both patients, MRI revealed extensive white matter disease. Follow-up MRI in a ten-year-
old boy, who presented earlier with isolated febrile seizures, showed mild abnormalities in 
deep white matter. Conclusion: We define 3−methylglutaconic aciduria type I as an inborn 
error of metabolism with slowly progressive leukoencephalopathy clinically presenting in 
adulthood. In contrast to the nonspecific findings in pediatric cases, the clinical and 
neuroradiologic pattern in adult patients is highly characteristic. White matter 
abnormalities may already develop in the first decades of life. The variable features found 
in affected children may be coincidental. Long-term follow-up in children is essential to 
learn more about the natural course of this presumably slowly progressive disease. Dietary 
treatment with leucine restriction may be considered. 
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Introduction 
 
3−methylglutaconic aciduria type I (3−MGA−uria I; MIM 250950) is a rare autosomal 
recessive disorder of leucine catabolism, characterized by markedly increased urinary 
excretion of 3−methylglutaconic acid (3−MGA), and mildly elevated urinary 
3−methylglutaric acid (3−MG) and 3−hydroxyisovaleric acid (3−HIVA). This disorder is 
caused by a deficiency of 3−methylglutaconyl−CoA hydratase (3−MGH), which catalyzes 
the conversion of 3−methylglutaconyl−CoA to 3-hydroxy-3-methylglutaryl-CoA. 3−MGH is 
encoded by AUH and function-abolishing mutations were reported in 7 children with 
various unspecific symptoms (Table 1)22, 23, 27, 28. There is no firm evidence that 3−MGA−uria 
I causes clinical signs and symptoms in early childhood. Recently our group reported the 
biochemical details on the first patient with an adult onset of the disease19. One additional 
late-presenting patient was reported29. Both had a slowly progressive leukoencephalo-
pathy with ataxia. Additionally, optic atrophy occurred in one patient while the other had 
dementia and spasticity. 
Here we present the clinical, neuroradiologic, biochemical, and genetic details of two 
patients with adult presentation of 3−MGA−uria I. The clinical findings are compared with 
the spectrum seen in the eight patients reported in literature. Our data shed new light on 
the natural course of the disease. 3−MGA−uria I may remain asymptomatic in childhood 
but seems to present with a slowly progressive leukoencephalopathy in adulthood. 
 
Methods and results 
Patient characteristics 
Detailed patient characteristics are available in appendix e-1 and summarized in Table 1. 
Patient 1, a Dutch woman, had experienced a progressive visual decline with bilateral optic 
atrophy from 35 years of age. Over the following 16 years, dysarthria and mild limb ataxia 
with severe gait ataxia were observed. Patient 2, a British man, first presented at the age of 
30 years with mild cerebellar ataxia. Over 29 years, the condition slowly worsened, and 
spastic paraparesis, nystagmus, and dementia occurred. 
To study the natural course of the disorder, follow-up on two patients was obtained (Table 
1; patients 4 and 8).  
 
MRI characteristics 
Extensive, confluent white matter signal abnormalities (high on T2-weighted images) were 
seen in patients 1 and 2 (Figure 1, A–D). The lesions were restricted to the supratentorial 
region with predominant involvement of the deep and subcortical white matter. Notably, 
the cerebellum and the corpus callosum were spared. In patient 1 (at age 61 years), a 
periventricular rim was clearly spared. In patient 2 (at age 50 years), the subcortical U-
fibers were less extensively involved, while there was a smaller periventricular rim with 
normal signal intensities in the parietooc cipital regions. Magnetic resonance spectroscopy 
in patient 1 was suggestive of 3−HIVA accumulation in brain19. 
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Biochemical and genetic characteristics 
See appendix e-1 and Figure e-1 for details. Urine proton nuclear magnetic resonance 
spectroscopy in both patients revealed markedly elevated 3−MGA and mildly elevated 
3−MG and 3−HIVA (Table e-1). As described pathognomic for 3−MGA−uria I, both patients 
presented cis and trans isoforms of 3−MGA in the characteristic 2:1 ratio in urine, and only 
cis isoform in CSF19. In both, 3−MGH activity was virtually undetectable in fibroblasts and 
lymphocytes. 
Sequence analysis of AUH on genomic DNA identified compound heterozygosity for 
c.559G_A (G187S) and c.650 G_A (G217D) mutations in patient 1, which are predicted to 
abolish the enzymatic activity by altering trimer formation and catalytic activity. Patient 2 
harbors a novel homozygous c.991A_T (K331X) mutation, which leads to the production of 
an aberrant protein, in which only eight terminal amino acid residues are missing. As 
crystal structure analysis suggests that the terminal part of the protein is not only a 
constituent of the active-site pocket, but is also necessary for subunit interaction and 
trimer stabilization, this could well explain the complete deficiency of 3−MGH activity in 
our patient (Figure e-1). 
 
 
Figure 1: Neuroradiologic findings in patients with 3−methylglutaconic aciduria type I 
(3−MGA−uria I). Cerebral MRI (T2-weighted) in three patients with 3−MGA−uria I. Images of 
patient 1 at age 61 years (A, B) and patient 2 at age 50 years (C, D) show extensive, confluent 
white matter lesions, almost completely sparing the corpus callosum as well as a 
periventricular rim especially in patient 1. The lesions spread until the U-fibers in patient 1 and 
to a lesser extent also in patient 2. Images of patient 8 (E, F) at age 10 years show mild 
abnormalities in deep frontalwhite matter sparing the corpus callosum and the U-fibers. 
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Follow-up of pediatric patients from the literature 
A summary of all reported patients is shown in Table 1. Patient 4, son of Lebanese 
consanguineous parents, was diagnosed by newborn screening (elevated C5- OH-carnitine: 
2.5 μmol/L, normal 1.5 μmol/L)23. He had the characteristic 3−MGA−uria I urine profile 
while 3−HIVA was normal. 3−MGH deficiency was confirmed in fibroblasts; mutation 
analysis revealed a homozygous c.80delG mutation in AUH. He is now nine years of age, 
has developed normally, and formal neuropsychological testing showed functioning within 
the normal range. The patient’s sister, now aged 6.5 years, had similar findings on newborn 
screening (no genetic testing). She also developed age appropriately and does well at 
school. So far, no cerebral imaging has been undertaken in the patients; physical 
examination was unremarkable. 
Patient 8, a son of German nonconsanguineous parents, was diagnosed upon metabolic 
screening for recurrent febrile seizures (in total 15 up to age seven) at the age of four 
years27. Now he is ten years old and has developed normally. He attends regular school but 
exhibits attention-deficit/hyperactivity disorder. Physical examination was unrevealing. A 
recent MRI (Figure 1, E and F) showed mild signal abnormalities in deep frontal white 
matter with sparing of the U-fibers. 
 
Discussion 
Currently, eight patients from seven families have been reported with AUH mutations and 
3−MGA−uria I (Table 1)19, 22, 23, 27-29. We identified three novel missense mutations in two 
patients presenting in adulthood. The homozygous mutation in patient 4 is predicted not 
to leave any residual enzyme activity. In spite of this, the patient and his sister (not shown 
in Table 1) are both healthy at the age of nine and 6.5 years23. The adult patient 3 with late-
onset ataxia, dementia, and spasticity has the same homozygous mutation as the pediatric 
patient 6 with motor and speech delay22, 29. Comparing all patients, there seems to be no 
genotype–phenotype correlation. Only four pediatric patients (5, 6, 9, 10) share one 
particular symptom: the common and nonspecific finding of psychomotor retardation. In 
contrast, the adult patients show a distinct clinical pattern with adult onset of ataxia and 
spasticity29. 
In the pediatric group, findings on cerebral imaging have been reported in only three 
patients (patient 5: MRI with basal ganglia lesions and cerebral atrophy; patient 6: normal 
MRI; patient 7: normal CT; ages at imaging not reported)5, 28, 82. The MRI of the adult 
patients 1–3 showed extensive and diffusively distributed white matter lesions restricted to 
the supratentorial region not affecting the cerebellum or the corpus callosum (Figure 1). 
Patient 3 also showed cerebellar involvement29. This led us to perform an MRI in the 
pediatric patient 8 (aged ten) which showed mild abnormalities in deep supratentorial 
white matter. We propose that these abnormalities represent the earliest stages of the 
slowly progressive neurodegenerative disorder mainly affecting the white matter observed 
in the adult patients. 
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3−MGA, 3−MG, and 3−HIVA accumulate in the body fluids of patients with 3−MGA−uria I. 
Metabolite accumulation may contribute to the clinical signs and symptoms of the disease. 
A toxic effect of 3−MGA on the cerebral cortex has been demonstrated in rats30. The same 
is speculated for 3−HIVA31. The obvious accumulation of 3−HIVA in CSF and brain (as 
detected by MRS in patient 1) provides further evidence for the potentially toxic effects of 
this metabolite on the brain19. As in other organic acidurias, accumulating toxic 
metabolites may give rise to slow onset excitotoxicity with cellular dysfunction and 
eventually cell death. Patients may have a normal life expectancy, and the ultimate 
phenotype of the disease may turn out to be a progressive leukoencephalopathy with 
incapacitating neurologic deficits. In view of the healthy boy found by newborn screening 
and the mild and nonspecific phenotypes in other published pediatric patients with 
3−MGA−uria I, it has been suggested that complete absence of 3−MGH causes clinical 
problems in childhood only in association with other, as yet undefined genetic or external 
factors23, 27. Ascertainment bias seems unlikely, owing to the rarity of this condition found 
in newborn screening83. At least three of the seven reported pediatric patients have 
consanguineous parents (patients 4, 6, and 7); the four other children harbor homozygous 
mutations (patients 5, 8–10), which may hint toward unknown or unreported consanguinity 
or a genetic founder effect. Such consanguinity could explain the high incidence of a 
second “genetic hit” which leads to the reported nonspecific symptoms in children that in 
fact are unrelated to 3−MGA−uria I (Table 1, Figure e-1). 
Urinary organic acid analysis should be carried out in adult patients with unexplained 
slowly progressive leukoencephalopathy, as the diagnosis may be easily overlooked. We 
further advise performing regular MRIs of affected patients in the first decades of life to 
learn more about the natural course in these early stages of the disease. If the natural 
course scenario that we propose can be confirmed in a larger series of patients, leucine-
restricted diet as a therapeutic approach from childhood onwards must be reconsidered. 
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Supplementary data 
 
Appendix e-1 
Supplementary patient characteristics 
Patient 1, a Dutch woman, daughter of non-consanguineous parents, had experienced a 
progressive visual decline from 35 years of age, in the beginning with recurrent episodes of 
rapid deterioration and subsequent improvement. Initial ophthalmological examinations, 
two years later, revealed a best corrected visual acuity of 0.6 (20/33) in the right eye and 0.8 
(20/25) in the left. Examination of the ocular fundus showed bilateral optic disc pallor and 
atrophy. Visual evoked potentials (with bilateral absence of occipital response) and color 
vision tests (with bilateral dichromatic red-green defect) indicated optic neuropathy of 
both eyes. Electroretinography indicated normal cone function and subnormal rod 
function. Over the years, her visual acuity gradually deteriorated with fluctuations. 
Repeated Goldmann perimetry showed progressive concentric constriction of the visual 
fields. Ophthalmological evaluation at age 61, revealed best corrected visual acuity of 0.05 
(20/400) in the right eye and 0.02 (20/1000) in the left eye, bilateral optic disc atrophy, and 
pendular nystagmus. At initial neurological evaluation aged 37 years slight gait and limb 
ataxia and bilateral extensor responses of the toes were seen. Ataxia and pyramidal 
abnormalities increased slightly, while orobucal dyskinesia was noted three years later. By 
the age of 61 years, minimal dysarthria, mild limb ataxia with severe gait ataxia and 
frequent falls despite preserved ambulation were observed. Increased tendon reflexes with 
absent ankle tendon reflexes and extensor responses of the toes were seen. Nerve 
conduction studies at that age remained normal. Biochemical details on this patient have 
been reported previously.19 
Patient 2, a British male, son of consanguineous parents, first presented to neurology 
services at the age of 30 years, complaining of progressive unsteadiness on walking. 
Examination showed a mild cerebellar ataxia with a spastic increase in tone of both legs, 
brisk reflexes throughout, and bilateral extensor plantar responses. The previous medical 
history was unremarkable except for “pigeon-toed” walking and clumsiness at school sport 
with plain lumbar radiographs showing a spina bifida occulta. No definite diagnosis was 
made. He re-presented to neurology at the age of 45 complaining of worsening 
unsteadiness. Examination showed similar findings as before, with a marked spastic 
paraparesis and mild/moderate cerebellar ataxia. Eye movement examination showed 
broken pursuit movements in all directions of gaze and bilateral first degree horizontal 
nystagmus in lateral gaze. At age 50 his best corrected visual acuity was 6/6 (20/20) 
bilaterally with normal appearing optic discs. Visual evoked potentials showed no 
abnormalities. The P100 latency on the right was at the upper limit of normal but overall 
there was no evidence of optic nerve demyelination. 
At the age of 52 years, his wife complained that her husband’s thinking was slowing down;  
this lead to definite concern about his performance at work. Cognitive assessment showed 
moderate global impairment and he was subsequently retired on medical grounds. 
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Physical examination showed a spastic ataxic paraparesis as before. At the most recent 
presentation (59 years) he had also developed a sleep disorder with excessive daytime 
sleepiness and involuntary jerky leg movements at night. Polysomnography was 
unremarkable. 
 
Supplemental Table e-1. Biochemical findings in patients with 3−MGA−uria I. Biochemical 
details of our patients detected in different body fluids by proton NMR spectroscopy with a 
500 MHz Bruker spectrometer. Ref. = Reference range19. 
 
Supplementary biochemical and genetic characteristics 
In both patients reported here routine blood clinical chemistry analysis was normal, both 
showed slight increases of plasma C5-hydroxy-carnitine (patient 1: 0.10 μmol/L; patient 2: 
0.09 μmol/L; N: < 0.06 μmol/L). CSF cell count, lactate, glucose and total protein, were 
normal. No intrathecal immunoglobulin synthesis nor abnormal IgG bands were detected. 
3−MGH-activity was virtually undetectable in both patients (reference values fibroblasts 2.1 
± 0.7 nmol/min/mg protein, lymphocytes 1.8 ± 0.2 nmol/min/mg protein)84. 3−MGA−uria 
type III was excluded in patient 1 by sequence analysis of the OPA3 gene46. Both patients 
were not suspected of 3−MGA−uria type IV, which is known to be associated with 
mitochondrial dysfunction, as they both had normal lactate and alanine and low 
mitochochondrial disease scores11, 85. 
Sequence analysis of the AUH gene on genomic DNA identified compound heterozygosity 
for c.559G>A (G187S) and c.650G>A (G217D) missense mutations in patient 1 (Figure e-1). 
These mutations predict the substitution of the neutral amino acid glycine for a polar 
residue (serine or aspartic acid). Both glycine residues are conserved between different 
species, including Mus musculus (mouse), Rattus norvegicus (rat), Bos taurus (cow), Canis 
lupus familiaris (dog), Pan troglodytes (chimpanzee), Caenorhabditis elegans (nematode), 
Drosophila melanogaster (fruitfly) and Danio rerio (zebra fish). This suggests that these 
glycines are critical for enzyme function. Hydration of an enoyl-CoA substrate by 3−MGH 
proceeds through an intermediate which is stabilized via hydrogen bond interactions with 
two peptide NH-groups86. These amino groups are positioned in two distinct, but 
conserved regions that are an intrinsic part of the active site pocket. Glycine 187 of 3−MGH 
is located in one of these regions. Mutagenesis studies of this region in human short-chain 
enoyl-CoA hydratase revealed that substitution of glycine with proline resulted in a 106-
fold decrease in hydratase activity, whereas the overall protein production of this mutant 
 Urine (Pmol/mmol creatinine) CSF (Pmol/L) 
 Pat. 1 Pat. 2 Reference Pat. 1 Pat. 2 Ref. 
3−methylglutaconic 
acid (total) 
94-141 78 1.0-6.5 125 122 <10 
- cis isoform 62-90 54 1.0-6.5 125 122 <10 
- trans isoform 32-51 24 <10 <10 
3−methylglutaric 
acid 
12-15 <10 0.3-0.7 <10 <10 <10 
3−hydroxyisovaleric 
acid 
61-63 58 <15 172 122 <10 
Chapter 2 
 
36 
remained unaffected87. The three-dimensional structure of 3−methylglutaconyl−CoA 
hydratase is a dimer of trimers88. Glycine 217 is located in a short flexible region (seven 
nucleotides) which is surrounded by two α-helices; one helix contains a catalytic glutamate 
residue, whereas the other is involved in subunit interactions to form the trimers.  
Both the catalytic activity and trimer formation depend on hydrogen bond interactions. 
Substitution of glycine 217 with the charged amino acid residue aspartate could alter the 
conformation of the flexible region thereby disrupting the distance required for optimal 
hydrogen bond interaction. As a result, trimer formation and catalytic activity could be 
hindered which may abolish the enzymatic activity. 
 
 
Mutation 
(DNA level) 
Mutation 
(amino acid 
level) 
Effect Observed 
in patient 
c.80delG S27fs Frameshift and truncated protein after 7 amino acids 4 
IVS1-2A>G - Skipping of exon 2 5 
c.559G>A G187S Predicted to affect the active site pocket 1 
c.589C>T R197X Truncated protein 9, 10 
c.613_614insA M205fs Frameshift and truncated protein after four amino 
acids. 
7 
c.650G>A G217D Predicted to alter protein conformation 1 
c.719C>T A240V Not investigated 7 
IVS8-1G>A - Skipping of exon 9 3, 6 
IVS9-2A>G - Expected to delete exon 9* 8 
c.991A>T K331X Truncated protein with last 8 amino acids missing, 
predicted to disrupt the active site pocket and alter 
protein conformation 
2 
Supplementary Figure e-1: Overview of mutations in the AUH gene and functional 
consequences. Schematic representation of the AUH gene, including all mutations known 
from literature and from the current paper. Note that mutations found in pediatric patients are 
shown in the upper part and mutations found in the adult patients are shown in the lower 
part. The table gives an overview of all reported mutations on c.DNA and protein level and 
their (predicted) effects. * personal communication Prof. J. Zschocke, Innsbruck, Austria. 
 
In patient 2 a novel homozygous c.991A>T (K331X) mutation (Figure e-1), consistent with 
parental consanguinity, was identified. This nonsense mutation leads to the production of 
an aberrant protein, if any, in which only eight terminal amino acid residues are missing. 
Crystal structure analysis suggests that the terminal part of the protein is a constituent of 
the active-site pocket, but is also necessary for subunit interaction and trimer stabilization. 
Indeed, the importance of the terminal part of the mature protein is illustrated by the 
complete deficiency of 3−methylglutaconyl−CoA hydratase activity in our patient. The 
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mutations identified were not found in the NCBI single nucleotide polymorphism (SNP) 
database (www.ncbi.nlm.nih.gov/SNP/) and were not present in 50 Caucasian control 
alleles. 
 
Supplementary details of patients reported in literature (see Figure e-1) 
Currently eight patients from seven families are reported with AUH mutations and 
3−MGA−uria I.5, 19, 21-23, 25, 27-29, 82, 89, 90 Several patients are reported more than once. In the 
main text we only cite the articles in which the mutation and the neuroradiological details 
are reported. For more details: patient 528, 89, patient 6 (patient 1 in22, patient 4 in5, 23), 
patient 7 (patient 5 in23, patient 1 in82, patient EVR in25), patient 9 (patient 2 in23, patient 2 
in21, patient 2 in90) and patient 10 (patient 2 in22, patient 3 in23 patient 1 in21, patient 1 in90). 
All patient details are summarized in Table 1. 
Seven different mutations were found in patients diagnosed in the first decade of life 
(patients 4-10): three splice site mutations (patients 3, 5, 6, 8), one deletion (patient 4), one 
insertion and two missense mutations (patient 7, 9, 10). Three mutations lead to a 
premature stop codon (patients 4, 7, 9, 10). We identified three novel missense mutations 
in two patients presenting in adulthood. Nine patients were homozygous for the reported 
mutations (patients 2-6, 8-10) while consanguinity was reported in four patients (patients 
2, 4, 6, 7).  
The homozygous mutation in patient 4 is of particular interest as it leads to seven 
abnormal aminoacids from serine 27 onwards and hereafter the protein is truncated. This 
mutation is therefore unlikely to leave any residual enzymatic activity. This patient was 
identified by newborn screening. In spite of the severe homozygous truncating mutation 
he and his sister (not shown in Table 1; no genetic testing but identical newborn screening 
result), who presumably share the same defect, are both healthy at the age of nine and 6.5 
years.  
Interestingly patient 3 with the late-onset presentation with ataxia, dementia and 
spasticity has the same homozygous mutation as the pediatric patient 6 with motor and 
speech delay.29 Comparing all patients, there seems no genotype-phenotype correlation. 
The pediatric patients presented between the day of newborn screening and before seven 
years of age with diverse symptoms such as quadriplegia, athetoid movements, vomiting, 
hepatomegaly, self mutilation, febrile seizures or shortened attention span and fasting 
hypoglycemia (see Table 1 for details). Only four patients (patients 5, 6, 9, 10) share one 
particular symptom: the common and nonspecific finding of psychomotor retardation. In 
contrast, the adult patients show a distinct clinical pattern with late presentation of ataxia 
and spasticity, two also had dementia.29 Patient 1 had optic atrophy as the presenting 
symptom and was misdiagnosed for a long time as having multiple sclerosis, OPA3 
mutations were excluded. 
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Abstract 
 
The heterogeneous group of 3−methylglutaconic aciduria type IV consists of patients with 
various organ involvement and mostly progressive neurological impairment in combination 
with 3-methyl-glutaconic aciduria and biochemical features of dysfunctional oxidative 
phosphorylation. Here we describe the clinical and biochemical phenotype in 18 children 
and define four clinical subgroups (encephalomyopathic, hepatocerebral, 
cardiomyopathic, myopathic). In the encephalomyopathic group with neurodegenerative 
symptoms and respiratory chain complex I deficiency, two of the children, presenting with 
mild Methylmalonic aciduria, Leigh-like encephalomyopathy, dystonia and deafness, 
harboured SUCLA2 mutations. In children with a hepatocerebral phenotype most patients 
presented with complex I deficiency and mtDNA-depletion, three of which carried POLG1-
mutations. In the cardiomyopathic subgroup most patients had complex V deficiency and 
an overlapping phenotype with that previously described in isolated complex V deficiency, 
in three patients a TMEM70 mutation was confirmed. In one male with a pure myopathic 
form and severe combined respiratory chain disorder, based on the pathogenomic 
histology of central core disease, RYR1 mutations were detected. In our patient group the 
presence of the biochemical marker 3−methylglutaconic acid was indicative for nuclear 
coded respiratory chain disorders. By delineating patient-groups we elucidated the genetic 
defect in 10 out of 18 children. Depending on the clinical and biochemical phenotype we 
suggest POLG1, SUCLA2, TMEM70 and RYR1 sequence analysis and mtDNA-depletion 
studies in children with 3−methylglutaconic aciduria type IV. 
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Introduction 
 
The heterogeneous group of 3−methylglutaconic aciduria (3−MGA−uria) syndromes 
includes several different inborn errors biochemically characterized by increased urinary 
excretion of 3-methyl-glutaconic acid (3−MGA) and 3−methylglutaric acid. At the present 
time five distinct types have been recognized. 3−MGA−uria type I (MIM 250950) is an 
inborn error of leucine catabolism with either an acute, life threatening presentation or a 
late onset form, caused by the deficiency of 3-methylglutaconyl- CoA hydratase (3−MGH; 
EC 4.2.1.18). The additional four types of 3−MGA−uria all affect mitochondrial function 
through different pathomechanisms. Type II (Barth syndrome; MIM 302060) occurs due to 
mutations of the TAZ gene and abnormal cardiolipin metabolism, presenting in males with 
cardiomyopathy (CM), cyclic neutropenia, muscle hypotonia, and (in the classical form) 
with normal cognitive function. In type III (Costeff syndrome, MIM 258501) patients present 
with bilateral optic atrophy and progressive extrapyramidal symptoms. The underlying 
mutations are in the mitochondrial OPA3 gene, whose function is not fully understood. 
3−MGA−uria type V (MIM 610198)75 is a novel autosomal recessive condition with early 
onset dilated CM with conduction defects and non-progressive cerebellar ataxia (DCMA) in 
the Canadian Dariusleut Hutterite population, further characterized by testicular 
dysgenesis and growth failure. It is speculated that the underlying mutation in the 
DNAJC19 gene leads to a defective mitochondrial protein import. 
The diagnosis of 3−MGA−uria type IV (‘unspecified’ MIM 250951) is based on the exclusion 
of the other, well-defined clinical subtypes. The underlying aetiology is not yet elucidated 
but certainly heterogeneous55. 3−MGA−uria can occur secondarily in patients with Smith-
Lemli-Opitz syndrome, a defect of cholesterol biosynthesis, because of abnormal 
isoprenoid/cholesterol biosynthesis12 as well as in patients with glycogen storage disease 
Ib79, where it is speculated that imbalanced gluconeogenesis and de novo cholesterol 
synthesis result in secondarily increased 3−MGA excretion. 
However, 3−MGA−uria type IV is frequently associated with progressive neurological 
impairment, variable organ dysfunction and the common finding of biochemical features 
of a dysfunctional oxidative phosphorylation (OXPHOS). In some 3−MGA type IV patients 
the underlying genetic defect has been elucidated, mostly in patients with multiple 
complex deficiencies, like in mitochondrial DNA depletion syndromes69-71, mitochondrial 
DNA deletion syndromes72-74 or MELAS syndrome60. Furthermore there are several reports 
about patients with CM, mitochondrial dysfunction and 3−MGA−uria type IV57-59, 61-63. Di 
Rosa et al. described five patients presenting with a severe early-onset phenotype with 
hypertrophic cardiomyopathy (HCM), cataract,hypotonia/developmental delay and lactic 
acidosis63. Another distinct phenotype has been defined in 14 cases with an isolated 
deficiency of the mitochondrial complex V of nuclear genetic origin presenting with HCM, 
hypotonia, hepatomegaly, facial dysmorphism and microcephaly. Half of the patients died, 
mostly within the first weeks of live; the survivors showed psychomotor and various 
degrees of mental retardation61. 
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Recently we performed biochemical and genetic investigations in four children with 
3−MGA−uria presenting with neuro-radiological evidence of Leigh disease, hearing loss, 
recurrent lactic academia and hypoglycemia, and defined a new mitochondrial phenotype 
within 3−MGA−uria type IV (MEGDEL association: 3−MGA−uria with sensori-neural 
deafness, encephalopathy and Leigh-like syndrome)68. 
In this study we evaluated 18 children sequentially diagnosed with 3−MGA−uria type IV to 
assess the occurrence of associated symptoms, malformations, minor anomalies and 
biochemical features in order to define distinct phenotypes and elucidate the underlying 
genetic etiology in 3−MGA−uria type IV syndrome. 
 
Methods 
 
We evaluated the clinical data, collected by the same clinical investigator, of 17 out of 262 
children evaluated by muscle biopsy in the period of 2002–2006 at our centre who were 
consecutively diagnosed with a mitochondrial disorder and 3−MGA−uria. We additionally 
included one child related to the index patients with overlapping clinical features, who 
underwent a skin biopsy. All children were referred under suspicion of an OXPHOS disorder 
and underwent a standard diagnostic protocol including organ function, imaging and 
laboratory studies91. 
 
Urine organic acid analysis/in vitro NMR spectroscopy 
Organic acids in urine were analysed by gas chromatography/mass spectrometry (GC−MS) 
after extraction of the urine sample with ethylacetate and derivatization with N,N 
bis(trimethylsilyl)-trifluoracetamide containing 1% trimethylchlorosilane. The 
concentration of 3−MGA was quantified by comparing the signals obtained with calibration 
curves of the pure compound, using a CP-Sil 8 CB column (Varian, Middelburg, The 
Netherlands) on a HP 6890 Gas Chromatograph (Agilent, Amstelveen, The Netherlands). 
An 8000 Top Gas Chromatograph and Trace Mass Spectrometer Plus (InterSciences, 
Breda, The Netherlands) was used to verify the identity of both 3−methylglutaconic 
isoforms. Body fluid NMR spectroscopy and quantification of the cis and trans forms of 
3−MGA were performed essentially as described elsewhere92. 
 
Biochemical and histological analysis in muscle and fibroblast samples 
A surgical muscle biopsy was performed as well as a skin biopsy in all cases using standard 
methods. The samples were used for histological, histochemical and detailed biochemical 
investigations. Measurement of the 3−methylglutaconyl−CoA hydratase activity and 
Cardiolipin analysis were performed in blood or fibroblasts by standard methods42. 
Oxidative phosphorylation was evaluated in muscle and fibroblasts, including ATP 
production measurement from pyruvate oxidation in muscle, and complex I–V activity in 
both tissues93. 
 
Biochemical and genetic analysis of 3- methylglutaconic aciduria type IV: a diagnostic strategy 
 
43 
Complex V assembly and activity/ ANT1 evaluation 
BN-PAGE, blotting and complex V in-gel activity was performed as described94, loading 60 
mg of protein of OXPHOS complexes isolated from a mitoplast fraction of the patient and 
control cybrids and muscle homogenates. For Western blotting, monoclonal antibodies 
against mitochondrial ATP synthase subunit alpha and CoII-70 kDa (complex II) (Invitrogen, 
Breda, The Netherlands) were used. For the complex V in-gel activity assay the gel was 
incubated overnight at room temperature with the following solution: 35mM Tris, 270mM 
glycine, 14mM MgSO4, 0.2% Pb(NO3)2 and 8mM ATP, pH 7.894. ANT1 evaluation was 
performed by Western blot analysis62. 
 
Genetic analysis 
PCR amplification of both exons and their flanking intronic DNA sequences of the OPA1 
and OPA3 genes were performed as described46 in all patients. Mitochondrial depletion 
studies were performed in patients 1, 3, 7–9, 11, 12 and 19 as described95. Mitochondrial 
DNA mutations were evaluated using a standard mitochip analysis (GeneChip© Human 
Mitochondrial Resequencing Array 2.0, Affymetrix, Inc.). Deletions were analysed by long 
template PCR. Sequencing of the nuclear coded structural complex I genes and RYR1 
mutation analysis was performed on an ABI 3730 DNA analyser using BigDye terminator 
chemistry (Applied biosystems, Lekkerkerk a/d IJssel, The Netherlands). 
Molecular investigations included sequence analysis of the structural genes of the oxidative 
phosphorylation complex I (NDUFS1, NDUFS2, NDUFS4, NDUFS7, NDUFS8, NDUFV1), and 
of the POLG1, DGUOK and SUCLA2 genes depending on the biochemical results from the 
muscle biopsy and fibroblasts91. In the three patients with complex V deficiency, highly 
overlapping clinical phenotype and consanguinity we performed genome-wide 
homozygosity mapping using the 10K and 250K Affymetrix Single Nucleotide 
Polymorphisms arrays96. Homozygous areas were found on the chromosomes 2, 4, 8, 10 
and 14. Upon the overlapping clinical and biochemical features with the patients described 
by 97 we checked the TMEM70 gene for disease causing mutations. 
 
Results 
 
Clinical patient characteristics 
Based on the clinical phenotype we divided the patients into the following four distinctive 
sub-groups: encephalomyopathic form (CNS and muscle involvement without liver 
involvement), hepatocerebral form (encephalomyopathy and liver dysfunction), 
cardiomyopathic form (motor developmental delay with CM, no or mild encephalopathy) 
and myopathic form (skeletal muscle involvement, no central nervous system 
involvement). We describe eight new patients, the other ten patients (1–6, 8, 15, 16, 18) 
have already been published as case reports, we therefore refer to the original papers. The 
essential clinical findings are summarized in Table 1. 
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Encephalomyopathic form 
Patients 1 and 2 (patients 11 and 12)95: Both patients initially presented with muscular 
hypotonia, poor suck and failure to thrive (FTT). In patient 1 later hearing loss, 
kyphoscoliosis and developmental delay as well as severe regression occurred. Patient 2 
developed extrapyramidal symptoms and myoclonic seizures in the first year of life. 
Hearing evaluation revealed a sensorineural deafness followed by chochlear implant. 
Patients 3–5: These patients were recently reported as MEGDEL association by our group 
(patients 1, 2 and 4)68. The three children presented with severe infections in the neonatal 
period, hypoglycemia and lactic acidemia were seen. Feeding problems and FTT made 
tube feeding necessary in two cases. All but one child had a delayed motor development 
and muscle hypotonia. One patient did not develop at all, the other patient showed 
psychomotor regression, one had epilepsy and all were mentally retarded. The patients 
developed severe spasticity, combined with extrapyramidal symptoms. One patient 
showed behavioural problems with constant laughing. Two patients died at the age of 
three and 16 years, respectively. No cardiologic alteration was noted. The MRI of the brain 
revealed characteristic bilateral hyper-dense lesions of the basal ganglia and diffuse 
cerebellar and/or cerebral atrophy in all patients. Visual evoked potential analysis was 
bilaterally delayed in two patients, however, no optic atrophy was noted. The BAEP studies 
showed severe sensori-neural hearing loss in all patients, making hearing devices 
necessary. 
 
 
Figure 2. A) One of the patients with SUCLA2 mutation with myopathic face by rigid dystonia. 
B) Patient 8 with a POLG1 mutation demonstrating the mask-like face due to facial dystonia, 
note the tube feeding. C) Patient 16 at the age of 8 months with extreme hypotonia. (D) 
Patient 18, note the myopathic face. E) Cerebral MRI of a patient with SUCLA2 mutation: 
Leigh disease and hyperintensities on T2-weighed images in both thalami. F) Cerebral MRI of 
Patient 7 with a POLG1 mutation: hyperintensities in all basal ganglia with sparing of the 
putamina in T2-weighed images. G) Transverse light microscopic serial sections of quadriceps 
muscle of Patient 15, note the myosin ATP-ase staining (bar 50 mm) and fibre type 
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dysproportion. H) Transverse light microscopic serial sections of quadriceps muscle of Patient 
18, Areas devoid of oxidative activity (cores), as well as predominance of type I fibers with the 
presence of centrally located nuclei or of rods comparable to central core disease (NADH TR 
staining).  
 
Hepatocerebral form 
Patient 6 (patient 3)69: The male patient had an older brother with a similar clinical 
phenotype. At the age of eight months FTT, hypotonia, mental retardation and myoclonic 
seizures became obvious. He died at the age of 17 months following intractable seizures 
and a progressive synthetic and cytotoxic liver failure. 
Patient 7: The female patient presented at the age of 16 years with a progressive 
neurological dysfunction of the left hemisphere (headache, hemi-anopsia, latent left-sided 
paresis and aphasia). Up to then, the medical history was negative, as was the family 
history. She was diagnosed with, and treated for acute disseminated encephalomyelitis. 
She suffered from an organic psychosyndrome and epilepsy, treated with valproic acid. 
After a brief period of clinical improvement she presented with a relapse in combination 
with gastrointestinal symptoms, and showed a neurological regression with apathy, 
agitation, anorexia and liver failure (synthetic/ cytotoxic) and deceased in a multi-organ 
failure due to a gram-negative sepsis. Autopsy revealed spongiosis in thalamus and nucleus 
caudatus, suggestive of Morbus Alpers-Huttenlocher. 
Patient 8 (patient 5)69: From the age of four months the male patient was followed for FTT, 
muscular hypotonia and delayed psychomotor development, later also regression. The 
EEG showed a burst suppression pattern and he had severe epilepsy. Hepatomegaly and 
elevated liver-function tests were noted as well. At the age of 13 months he died due to 
cardiorespiratory insufficiency after multi-drug treatment (without Valproic acid) during 
status epilepticus. 
Patient 9: The female patient was born prematurely by 31 weeks gestation after a 
pregnancy complicated by severe hyperemesis. Two other pregnancies, in which solely 
intrauterine growth retardation (IUGR) was noted, ended with a stillbirth. The neonatal 
period was uncomplicated, the cerebral ultrasound showed a right sided subepidermal 
hemorrhage and bilateral mild periventricular leucomalacia. At the age of 3.5 months she 
was diagnosed with epilepsy, muscle hypertonia and psychomotor development delay. 
From the age of two years on she suffered from unexplained encephalopathic periods with 
atonia, apneas and stupor. These episodes of deep coma (Glasgow coma scale 3), lasted for 
about 72 h and then she became conscious again spontaneously and quickly. Continuous 
EEG-registration then showed a bizarre pattern of burst suppression changing with hours 
nearly without any cortical activity. MRI showed mild periventricular leucomalacia, 
irregularly widened ventricles, gracile corpus callosum and a partial pachygyria. Repetitive 
drug-screening in blood and urine was negative. She received a gastrostomy due to severe 
FTT and gastro-esophageal reflux after malrotation correction. Transient elevations of 
transaminases were noted. At age three years she died due to cardio-respiratory failure in 
an encephalopathic state. 
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Patient 10: The male patient was born at 26 weeks of gestation, with intrauterine growth 
retardation. No family history is available. He had an infantile encephalopathy with 
epilepsy and a delayed psychomotor development. He was noted to have episodes with 
hypo- and hyperthermia, extraordinary resistance to pain and severe FTT. At the age of 9 
years he was admitted with a stroke-like episode with hemiplegia after valproic acid use for 
seizures. The MRI suggested a hemi-encephalitis. After a multiorgan failure with liver 
dysfunction and synthesis-failure, pancreatitis and a long-time depressed consciousness, 
his residual hemiparesis and speech problems are improving over time. 
Patient 11: The pregnancy with this female patient was complicated by an early growth 
retardation and microcephaly, and she was born at term by caesarean section. Genetic and 
metabolic analysis was initiated at the age of three months due to severe microcephaly, 
dysmorphic features comparable to Brachmann-de Lange syndrome, psychomotor 
retardation, no development (could not sit or roll over, and made no contact), muscle 
hypotonia, epilepsy, severe FTT, feeding difficulties and tracheomalacia. She received tube 
feeding. She suffered from recurrent episodes of hyperthermia, liver dysfunction and 
intractable seizures and died at the ageof 2.5 years. 
 
Cardiomyopathic form 
Patient 12–14: These three female patients from a large Roma family descent from a 
possible inbred community. There are several additional siblings known with an 
overlapping phenotype. Patient 12, the index patient presented with severe FTT, arterial 
hypertension, CM and Wolf-Parkinson-White syndrome at the age of three years. Patient 
13, a maternal cousin of patient 12 had HCM in combination with an aorta stenosis, 
pulmonary valve stenosis and occasional extrasystoles. Patient 14 presented with feeding 
problems leading to FTT and was evaluated from the age of 8 months onwards four times 
for periods of encephalopathy with extremely elevated lactate (11 mmol/l, N<52.1 mmol/l), 
alanine and glutamine/glutamate levels by normal liver enzyme and intermittently high 
ammonia concentrations. She had a normal motor development, only slight mental 
retardation and suffered from myoclonic episodes. Besides a HCM, an aortic valve stenosis 
was detected with rhythm disturbances (occasional extrasystoles). None of the patients 
had hypotonia. At the age of three, five and nine years, respectively, they have a nearly 
normal psychomotor development, short stature, FTT, but no neurological or other organ 
involvement. They all shared dysmorphic facial features including high forehead, curved 
eyebrows, flat midface, long philtrum, low implanted ears and thin lips. 
Patient 15 and 16 (Cases 1, 2)62: patient 15 was evaluated for severe muscle hypotonia with 
hyporeflexia, delayed motor development and a severe, stable HCM with mild left 
ventricular outflow obstruction. His sister, patient 16, had a lactic acidosis at birth, no 
hypotonia. An echocardiogram detected HCM without an obstructive component. Both 
children developed early bilateral cataracts. Cranial MRI showed delayed myelinization for 
patient 15, in patient 16 it was normal. At the age of 11 and seven years, respectively, they 
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have a normal psychomotor development and severe exercise intolerance, both receive 
speech therapy. 
Patient 17: The male patient was noted to have a severe muscle hypotonia from the age of 
five months, swallowing problems, recurrent infections and loss of motor skills. By ten 
months of age a non-obstructive CM was detected with mitral valve insufficiency, a 
tricuspidal aortic valve and pericardial effusion. Due to severe FTT and swallowing 
problems he got a gastrostomy. He received a lipid enriched diet. Physical examination 
revealed mild hepatomegaly, with transient elevation of the liver function tests. At the age 
of 4 years he is developing impressively, walks independently and communicates on an 
approximate age appropriate level. 
 
Myopathic form 
Patient 18 (patient 5)98: In this male patient generalized hypotonia, multiple contractures, 
swallowing problems and a lack of facial expression were apparent at birth. In spite of 
several severe infections he never needed artificial ventilation. He had FTT and his multiple 
episodes of hypoglycaemia were successfully treated with raw cornstarch. Besides a severe 
generalized muscle disease, he is unable to crawl or walk and therefore wheelchair 
dependant, he has no other organ involvement. By the age of ten years the patient attends 
a regular school. 
 
Biochemical patient characteristics 
As shown in Table 1, urine organic acid analysis with GC−MS and in vitro NMR 
spectroscopy showed an increased urinary excretion of 3−MGA in all patients in at least one 
sample. The excretion of 3−MGA in the children ranged between 4 and 200 mmol/mmol 
creat (control <20), with a strict 1 : 1 ratio of the cis and trans isoforms of 3−MGA (Figure 1). 
The excretion of 3−hydroxyisovaleric acid (3−HIVA) in the samples was within the normal 
range (data not shown). Hence, we conclude that our patients show 3−MGA−uria. 
3−MGA−uria types I, II (Barth syndrome) and III (Costeff syndrome) were excluded in all 
patients as the activity of 3−methylglutaconyl−CoA hydratase, the cardiolipin levels and 
molecular analysis of the OPA3 gene, respectively, showed no abnormalities (data not 
shown). Smith-Lemli-Opitz-syndrome and glycogen storage disorder were ruled out as 
well. 
As all our patients scored above three points on the clinical diagnostic scoring system for 
mitochondrial disorders (MDC, see Table 1)91 the possibility of a respiratory chain defect 
was further explored. Indeed, as shown in Table 2, the biochemical analysis of 
mitochondrial function in the fresh muscle biopsy and/or fibroblast cell lines showed 
disturbed oxidative phosphorylation in all 18 patients with an ATP production from 
pyruvate oxidation ranging between 0.9 and 37 nmol ATP/ h/mU CS (control range 42–81 
nmol/h/mU/CS). 
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Figure 1. NMR spectroscopy demonstrating two resonances of the cis and trans forms of 
3−methylglutaconic acid (urine sample of Patient 5). 
 
In the subgroup of children with the encephalomyopathic form (patients 1–5), including the 
patients 3–5 with the MEGDEL association, all children had (when measured) a decreased 
ATP production from pyruvate oxidation (24–37 nmol ATP/h/mU CS) in fresh muscle 
biopsy. Four patients demonstrated complex I deficiency (either in muscle or fibroblasts), 
and one patient with SUCLA2 defect had additional complex IV deficiency. The activities in 
fibroblasts were normal, with exception of a complex I deficiency in patient 5. The 3−MGA 
excretion levels were mildly to moderately and intermittently increased in the MEGDEL 
patients (16–141 mmol/mmol creat) and mildly elevated (20– 25 mmol/mmol/creat) in the 
other patients. 
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In the subgroup of children with the hepatocerebral form (patients 6–11) all children had 
moderately to severe decreased ATP-production (13–34 nmol ATP/h/mU CS). All but 
patient 7 had a decreased activity of complex I, two had additional complex III deficiency, 
patient 8 demonstrated multiple enzyme deficiencies. The enzyme measurements in 
fibroblasts were normal in all children. Patient 11 additionally underwent a liver biopsy 
which revealed a complex I and IV deficiency. The 3−MGA−uria was intermittent in most of 
the children with normal results alternating with mildly elevated excretion (23–38 
mmol/mmol creat). 
The patients 12–17 with the cardiomyopathic form show very low ATP production from 
pyruvate oxidation; 0.9–5.5 nmol ATP/h/mU CS. Patients 12–14 have similar biochemical 
features as described by Sperl et al.61 with severe complex V deficiency (0.4–4.9% of lowest 
controls). In patient 13, due to a positive family history, only a skin biopsy was performed, 
showing mild complex I (63%) and severe complex V deficiency (5%). In patients 12 and 14 
mild complex I (80–97%) and severe complex V deficiency (20–37%) were found in 
fibroblasts. The two patients with Sengers-like syndrome (patients 15 and 16) had severe 
combined multi-complex deficiency (complexes I, III and IV). The 3−MGA−uria was 
moderate in patients 12, 13 and 14 (44–121 mmol/mmol creat), intermittently very high in 
patient 17 (up to 200 mmol/mmol creat) and mildly to moderately elevated (13–60 
mmol/mmol creat) in the other patients. 
Patient 18 with the myopathic form had a multiple complex deficiency (complex I activity 
83%, complex II 93%, complex III 33% and complex IV activity 24% of lowest controls, 
respectively) and a very low ATP production from pyruvate oxidation of 4.0 mmol ATP 
h/mU CS. No abnormalities were detected in fibroblasts. 3−MGA-excretion in urine was 
mild (9–38 mmol/mmol creat). 
 
Histology/electron microscopy 
Alterations were found on histology by light microscopy in the majority of patients, 
ranging from fibre type disproportion in patients 3, 6, 11, 15 and 16, critical illness 
myopathy in patient 7 to increased percentage of lipid vacuoles, suggesting lipid myopathy 
in patient 17 (Table 2). In patient 15 necrotizing regions were detected and severely 
decreased COX-activity, SDH-staining was diffusely increased in several type I fibres 
(Figure 2). The histology and histochemistry of patient 16, with the identical clinical 
phenotype, was normal. Significant histological alterations were also found in patient 18 
(Figure 2) with the myopathic subtype. Areas devoid of oxidative activity (cores) were 
observed in the skeletal muscle biopsies, as well as predominance of type I fibres with the 
presence of centrally located nuclei or of rods comparable to central core disease. 
Electron microscopy showed abnormal structure of mitochondria in patient 2, absent 
cristae in patient 8 and zones with absent mitochondria in patient 18. In patient 15 many 
mitochondrial aggregations and an increased number of lipid droplets were found in many 
fibres. The mitochondria were abnormal with a severe loss of christae, also ring-shaped 
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mitochondrial were seen. These alterations were also seen in patient 16, but less 
impressive. 
 
Genetic studies 
Molecular analysis of the mitochondrial DNA detected no mutation in any of the patients. 
Additional sequencing of the nuclear coded structural genes of the oxidative 
phosphorylation complex I (NDUFS1, NDUFS2, NDUFS4, NDUFS7, NDUFS8, NDUFV1) 
showed no disease causing mutations. 
 
Figure 3. One-dimensional Blue Native-PAGE showing severely reduced expression of holo-
complex V in fibroblasts of two patients from the cardiomyopathic subgroup. Complex V was 
detected by an antibody against ATP-synthase subunit alpha. As a loading control complex II 
levels were visualized using an antibody against the 70 kDa FP subunit. P = patient, C = 
control. 
 
Mitochondrial depletion analysis was performed in eight children, and mitochondrial 
depletion was confirmed in patients 1, 2, 6, 7, 8, 11, but not in patients 10 and 1869, 95. No 
associated mitochondrial DNA deletions were found. Mutations in the DGUOK and POLG1 
genes were evaluated in all patients, TK2, SUCLA2, P53R2, MPV17 were analysed 
appropriate to the phenotype. Patients 1 and 2 (patients 13 and 11, respectively)95 
harboured homozygous SUCLA2 mutations (c.534 + 1G4A). POLG1 mutations were 
detected in the patients 6 (G2869C/G1399A; Patients 3 in69), 7 (G1399A/G1399A) and 8 
(G680C/G1399A, patient 5 in69). In the three Patients 12–14 with complex V deficiency we 
performed genome-wide homozygosity mapping revealing several homozygous regions 
that were shared by all three patients tested. No homozygosity was found in any of the 
previously described nuclear encoded structural assembly genes. Upon the finding of a 
homozygous region on chromosome eight and the overlapping clinical and biochemical 
phenotype with 97, we performed mutation analysis of the TMEM70 gene. This revealed a 
homozygous substitution c.317-2A4G in Patients 12–14 identical with those recently 
described97. Western blotting with monoclonal antibodies against mitochondrial ATP 
synthase subunit alpha and CoII-70 kDa (complex II) showed a severely reduced amount of 
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holo-complex V in the fibroblasts of these patients (Figure 3). In Patient 18 RYR1 mutations 
(c14804-1G4T/c.10616G4A; Patient 5 in98) were detected. 
 
Discussion 
Until now, several distinct metabolic disorders have been described demonstrating 
3−MGA−uria, affecting the leucine degradation pathway or mitochondrial function in 
variable degree and severity. Besides these clinically and biochemically well-defined forms, 
the highly heterogeneous diagnostic category of 3−MGA−uria type IV encompasses 
patients with progressive neurologic impairment, variable organ involvement and 
OXPHOS dysfunction99. During our study within a 5-year period in the group of patients 
undergoing muscle biopsy based on standard clinical criteria, we detected a high number 
of children (18 out of 262) with 3−MGA−uria and oxidative phosphorylation complex 
deficiencies; almost 7% of the patients were diagnosed with 3−MGA−uria type IV. In nine 
children we confirmed a nuclear coded mutation underlying the disease, in one patient 
only mitochondrial depletion was found. One child, who is not included in the current study 
was additionally diagnosed with Barth syndrome. No OPA1 mutations were elucidated in 
any of the patients. In spite of the presence of mitochondrial depletion in a high 
percentage of the mutation positive patients none of the children were diagnosed with 
mitochondrial mutations and no mitochondrial DNA deletion was confirmed in muscle 
tissue. Based on our findings we confirm the previous observation that 3−MGA−uria is an 
important diagnostic marker and could be used for screening in the diagnostic workup of a 
suspected dysfunction in the oxidative phosphorylation. 
3−MGA−uria has been described as an associated finding in various mitochondrial DNA 
depletion syndromes 70, 71, however the finding of this organic aciduria is highly variable and 
frequently intermittent. In our patient group diagnosed with POLG1 mutations, 
3−MGA−uria was present in only three out of ten patients and in a large cohort of children 
with SUCLA2 defect only 5 out of 16 showed 3−MGA−uria during their disease course (U. 
Steuerwald 2008, personal communications). The majority of these patients have normal 
concentration of 3−MGA in the urine95. This suggests that the metabolic marker could be 
indicative for mitochondrial depletion, but not directly related to the disease, even in the 
presence of the same mutation. One should interpret the presence of mild 3−MGA−uria 
very cautiously, the same level of excretion can be detected in children with primary and 
secondary liver disease, including glycogen storage disorder type I79 and type IX (E. 
Morava: personal communication) or cholesterol synthesis defects12 as a marker of lipid 
mobilization and upregulated cholesterol synthesis. These patients might present with 
elevated lactate levels and hypoglycaemia, still the clinical picture is distinct enough to be 
able to find the correct diagnosis. 
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Figure 4. Excretion levels of 3−MGA in urine in the different subtypes of 3−MGA−uria. 
 
In nearly all of our patients the finding of 3−MGA−uria was intermittent. Even the children 
carrying POLG1 mutations had periods during the course of their disease without 
3−MGA−uria. No correlation was found with either possible episodes of infection or the 
nutritional state in our patients. Since the underlying mechanism leading to 3−MGA−uria is 
still undiscovered, we have no appropriate explanation for this phenomenon. Interestingly 
variable excretion, even within 24 h 3, of 3−MGA was reported in several patients with Barth 
and Costeff syndrome (own experience;1, 8) seemingly unrelated to the clinical course or 
the severity of metabolic derangement (Figure 4). 
By far the most patients described so far with 3−MGA−uria type IV dysfunction present 
with HCM57, 58 59, 61, 63. The most striking biochemical feature in the patients described by 
Sperl et al., is a severe complex V deficiency, measured in muscle in fibroblasts and 
associated with a mild complex I deficiency61. This characteristic pattern has been 
described so far only in children with gypsy ethnicity originating from highly 
consanguineous families, in combination with normal mental development and 
characteristic facial features. These patients were recently diagnosed with a novel nuclear 
genetic defect leading to abnormal biogenesis of the respiratory chain complex V 97. We 
have identified three patients (Patients 12–14) with the same TMEM70 mutation, sharing 
the same ethnic background. 
Interestingly all of our patients (Patients 12–17) with HCM had no regression and an only 
somewhat delayed or normal psychomotor development. Only in Patient 17 there is a 
moderate psychomotor retardation, but the patient is improving impressingly over time. 
Besides the slowly progressive HCM some of the children suffered from rhythm 
disturbances or congenital valve anomalies. Still one should emphasize the absence of 
associated neurological symptoms in this patient group. In both children diagnosed with 
Sengers like syndrome (Patients 15 and 16) infantile cataract was diagnosed at an early 
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stage of the disease. Cataract seldomly occurs at such a young age in children with a 
respiratory chain disease, and mostly presents in association with mtDNA deletions100, 
mtDNA depletion101 or in the classical Sengers syndrome (MIM 212350)102. Cataract has 
been observed several times in combination with 3−MGA−uria type IV in combination with 
HCM63. This unique symptom therefore might lead the clinician early on to the correct 
diagnosis. Based on the strong correlation of CM, 3−MGA−uria, complex V deficiency and 
cataract we strongly advice detailed cardiological and ophthalmological evaluation in all 
patients with 3−MGA−uria and a suspected OXPHOS disorder. 
Patients with a diagnosis of 3−MGA−uria type IV present with an extremely variable clinical 
phenotype. NMR-spectroscopy of the urine in 3−MGA−uria type I19 showed a 2 : 1 ratio for 
cis and trans isoforms of 3−MGA in all patients. Interestingly in the CSF only the cis 
stereoisomer was found. Additional to other biochemical features, these findings helped to 
differentiate patients with type I from the other 3−MGA types. In our study we expected to 
be able to delineate further patient groups upon the cis and trans ratios of 3−MGA in urine. 
Unfortunately the ratio was 1 : 1 in all patients and therefore NMR spectroscopy revealed 
no additional information compared to standard organic acid analysis. 
Assigning clinical subgroups within the large patients group of 3−MGA−uria could however 
effectively facilitate the molecular diagnostic workup. There is a long ongoing discussion 
between clinical geneticists and molecular/biochemical geneticists regarding ‘splitting or 
lumping’ phenotypic groups in clinical syndromes; either based on biochemical and 
phenotypic patterns, to define relatively homogeneous groups for further genetic analysis 
or to be able to form larger groups for follow up and counselling. In the current study we 
tried to approach our patient group with ‘splitting’, leading to the discovery of the genetic 
aetiology in many children. Although forming smaller, but characteristic groups might lead 
to even more complex descriptions of an individual patient, it might also help in better 
prognosis assessment and optimal follow up in this unique patient group. By delineating 
patient groups we elucidated the genetic defect in ten out of 18 children. Depending on the 
phenotype, the presence of complex V deficiency and the finding of additional biochemical 
markers we recommend POLG1, SUCLA2, TMEM70 and RYR1 sequence analysis and 
mtDNA-depletion studies in children with 3−MGA−uria type IV. 
In the patient group with encephalopathic presentation we found SUCLA2 mutations in 
patients demonstrating an associated methylmalonic aciduria. Both patients came from 
the Faroer islands due to a founder effect. In the other children with progressive dystonia, 
Leigh like syndrome and deafness, a ‘classical mitochondrial’ presentation, no 
mitochondrial DNA deletion or mutation, no alteration in the OPA1, POLG1 or DGUOK 
genes were discovered. Homozygosity mapping might reveal the underlying suspected 
nuclear gene defect in these consanguinous cases. 
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Figure 5. Diagnostic flowchart. MDC= Mitochondrial disease criteria91. 
 
Most patients with 3−MGA−uria type IV present with either neurodegenerative symptoms, 
or encephalopathy in combination with other organ involvement. In our patient cohort, but 
also in most of the so far published cases only a minority of children diagnosed with type IV 
have an isolated muscle disorder. Due to the distinct, syndromic presentation and the 
characteristic association of biochemical and clinical markers we suggest a practical 
evaluation protocol to facilitate an effective diagnostic route and optimalize counselling 
(Figure 5). Solving the genetic defect and assigning a syndrome diagnosis to a child with 
‘the unclassified’ type IV 3−MGA−uria, finally ‘excludes’ the patient from this unclassified 
group. 
Obviously in case of a classic syndromic presentation in a child with 3−MGA−uria and a 
suspected mitochondrial dysfunction, invasive diagnostics, such as muscle biopsy or skin 
biopsy should be avoided, if possible. By using the diagnostic flowchart we elucidated the 
underlying genetic defect in two additional patients with 3−MGA−uria. One male patient 
from the Faroer islands with MMA-uria, hypotonia and deafness, in whom a SUCLA2 
mutation could be confirmed, and a gipsy female with typical facial features and HCM, 
where we confirmed a TMEM70 mutation. Both mutations were confirmed in blood, hence 
we spared the children undergoing muscle biopsy. 
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We read with interest the article ‘Dysmorpholgy on Barth syndrome’39 in this journal. Barth 
syndrome, also called 3−methylglutaconic aciduria (3−MGA−uria) type II, is an X-linked 
disorder of cardiomyopathy, neutropenia, mild cognitive impairment, and myopathy (MIM 
302060). Hastings et al.39 added a distinct facial appearance to the diagnostic features of 
the classic phenotype (Figure 1a). 
Barth syndrome is one of the subtypes of the rapidly expanding group of genetic disorders 
associated with an elevated urinary excretion of 3−methylglutaconic acid (as reviewed in 
103for summary see Table 1). Four additional subtypes have been described so far. Of these 
four subtypes, three syndromes are well-defined multisystem disorders with clear-cut 
diagnostic features. 
 
3−MGA−uria 
type 
Involved gene (mode 
of inheritance) 
Main features beside 3−MGA−uria 
I AUH (ar) Slowly progressive leukoencephalopathy, adult onset of 
symptoms, ataxia, spasticity, dementia, no facial features  
II (Barth 
syndrome) 
TAZ (X-linked) X-linked, cardiomyopathy, congenital neutropenia, mild 
cognitive impairment, myopathy, distinct facial features  
III (Costeff 
syndrome) 
OPA3 (ar) Infantile bilateral optic atrophy, extrapyramidal symptoms  
IV ‘unclassified’ Heterogeneous, 
examples below 
Progressive neurological course of disease, clinical, biochemical, 
and radiological signs of mitochondrial encephalomyopathy, 
secondary facial dysmorphism  
 SUCLA2 (ar) Mild methylmalonic aciduria, dystonia, deafness, secondary facial 
dysmorphism  
 TMEM 70 (ar) ATP synthase deficiency, cardiomyopathy, myopathy, cognitive 
impairment, distinct facial features  
 POLG (ar) PMR, intractable epilepsy and early fulminant liver failure (Alpers 
syndrome)  
 MEGDEL syndromea Leigh-like MRI, dystonia, deafness, secondary facial 
dysmorphism  
V (DCMA 
syndrome) 
DNAJC19 (ar) Canadese Dariusleut-Hutterite, dilative cardiomyopathy, 
nonprogressive cerebellar ataxia, dysmorphic features not 
reported 
Table 1. Overview of the different types of 3−methylglutaconic aciduria. ar = autosomal 
recessive; DCMA = dilated cardiomyopathy with ataxia; 3−MGA−uria = 3−methylglutaconic 
aciduria. aGenetic defect unknown. 
 
3−MGA−uria type I (MIM 250950) is a rare disorder of leucine catabolism, which we have 
currently redefined as a syndrome with slowly progressive leukoencephalopathy 
presenting in adulthood26. The other known subtypes are biochemically and genetically 
diverse, but all have an effect on mitochondrial function through different 
pathomechanisms. In type III or Costeff syndrome (MIM 258501), patients show infantile 
bilateral optic atrophy and extrapyramidal symptoms. Facial dysmorphism has not been 
reported so far. Recently, a Canadese Dariusleut–Hutterite family with dilative 
cardiomyopathy and nonprogressive cerebellar ataxia has been reported as dilated 
cardiomyopathy with ataxia (DCMA) syndrome or 3−MGA−uria type V (MIM 610198). No 
dysmorphic features were noted. 
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Figure 1: Facial appearance in patients with 3−methylglutaconic aciduria (3−MGA−uria) types 
II and IV. A) A three-year-old boy with Barth syndrome (3−MGA−uria type II). Note the tall and 
broad forehead, the round face with the curved eyebrows, the prominent chin, and full cheeks. 
The ears are large and deep set. B-D) Patients with 3−MGA−uria type IV. Note the large and 
deep-set ears and the long philtrum in these patients, as well as the curved eyebrows in 
patients (B, C), and the full and broad forehead in patients (C, D). Patient (B) is a five-year-old 
patient with SUCLA2 mutation; note the mask-like appearance and the small mouth. Patient 
(C) is a one-year-old boy with POLG mutation. Patient (D) is a patient with MEGDEL 
association, aged four years. 
 
3−MGA−uria type IV (MIM 250951) has been defined by 9, based on the exclusion of the 
other well-defined 3−MGA−uria subtypes. He described one offspring of consanguineous 
Italian origin with severe psychomotor retardation and cerebellar dysgenesis. Since then 
the spectrum of patients not fitting into the known genetic subtypes, 3−MGA−uria type I, II, 
III, or V, has expanded rapidly. More than 100 patients have been described so far, 
classified as having 3−MGA−uria type IV, based on ruling out the other four syndromes.  
But is 3−MGA−uria type IV a distinct genetic syndrome? Are there diagnostic criteria 
regarding organ involvementand dysmorphology? The clinical and genetic spectrum is 
certainly heterogenous, but within the spectrum there are several distinctive disorders. For 
example, one group of patients with mutations in SUCLA2 (Figure 1b, MIM 603921104) 
leading to a distinct phenotype with mild 3−MGA−uria, mild methylmalonic aciduria, and 
severe mitochondrial encephalomyopathy with sensorineural deafness and dystonia. In 
addition, patients with the typicial trias of psychomotor retardation, intractable epilepsy, 
and early fulminant liver failure due to POLG mutations (Alpers syndrome, MIM 20370011) 
are described with 3−MGA−uria (Figure 1c). 
Another rapidly growing group of children, mostly of gipsy origin, harbor mutations in 
TMEM7064. Their phenotype encompasses 3−MGA−uria, severe deficiency of the 
mitochondrial ATP synthase (complex V of the respiratory chain), cardiomyopathy, distinct 
facial appearance, and mild cognitive impairment. In a third group of patients with the 
unique syndromic presentation of 3−MGA−uria, sensorineural deafness and dystonia 
combined with a deficiency of the complex I of the respiratory chain (Figure 1d; MEGDEL 
association68); the genetic defect has not yet been elucidated.  
Dysmorphic features are commonly present in 3−MGA−uria type IV (Figure 1b–d). Most of 
these appear during the course of disease, secondary to basal ganglia involvement 
(mask−like facial features), muscle wasting of the facial musculature, and hypotonia, 
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leading to an elongation of the face and long prominent ears. Some of these facial features 
are comparable with that described in patients with Barth syndrome (broad and tall 
forehead, curved eyebrows; Figure 1).  
In addition to the well-recognized Barth syndrome, we want to draw attention for the 
rapidly growing group of 3−MGA−uria type IV. We define 3−MGA−uria type IVas a group of 
inborn errors with primary mitochondrial dysfunction, leading to a multisystem disease 
often with a distinctive syndromic appearance. 3−MGA−uria can easily be detected upon 
routine urinary organic acid analysis. This acid, in combination with other Biochemical, 
neuroradiological, and especially clinical signs and symptoms can guide the physician to 
the right diagnosis11.  
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Abstract 
 
In this paper, we describe a distinct clinical subtype of 3−methylglutaconic aciduria. 3-
Methyl-glutaconic aciduria is a group of different  metabolic disorders biochemically 
characterized by increased urinary excretion of 3−methylglutaconic acid. We performed 
biochemical and genetic investigations, including urine organic acid analysis, NMR 
spectroscopy, measurement of 3-methyl-glutaconyl-CoA hydratase activity, cardiolipin 
levels, OPA3 gene analysis and measurement of the oxidative phosphorylation in four 
female patients with 3−methylglutaconic aciduria. 3−methylglutaconic aciduria type I, 
Barth syndrome, and Costeff syndrome were excluded as the activity of 3- 
methylglutaconyl-CoA hydratase, the cardiolipin levels, and molecular analysis of the 
OPA3 gene, respectively, showed no abnormalities. The children presented with 
characteristic association of hearing loss and the neuro-radiological evidence of Leigh 
disease. They also had neonatal hypotonia, recurrent lactic acidemia, episodes with 
hypoglycemia and severe recurrent infections, feeding difficulties, failure to thrive, 
developmental delay, and progressive spasticity with extrapyramidal symptoms. Our 
patients were further biochemically characterized by a mitochondrial dysfunction and 
persistent urinary excretion of 3−methylglutaconic acid.  
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Introduction 
 
3−methylglutaconic aciduria is a group of metabolic disorders biochemically characterized 
by increased urinary excretion of 3−methylglutaconic acid (3−MGA) and 3−methylglutaric 
acid. At the present time, four distinct forms have been recognized. 3−methylglutaconic 
aciduria type I (OMIM 250950) is an inborn error of leucine catabolism and is caused by the 
isolated defciency of 3−methylglutaconyl−CoA hydratase (3MGH; EC 4.2.1.18)21, 22, 90. 
These pediatric patients display a range of clinical manifestations varying from progressive 
neurologic deterioration to mild speech delay. Three additional forms of 3−MGA−uria have 
been documented—type II (Barth syndrome, OMIM 302060); type III (Costeff syndrome, 
OMIM 258501); type IV (“unspecified,” OMIM 250951)—all characterized by normal 
hydratase activities and mildly elevated urinary levels of 3−MGA. The precise etiology of 
the increased 3−MGA excretion in these latter subtypes has not been elucidated yet. 
Among the four types, patients with 3−MGA−uria type 1 excrete the highest levels of 
3−MGA.  
Barth syndrome is a X-linked disorder presenting in males with cardiomyopathy, cyclic 
neutropenia, muscle hypotonia, and a normal cognitive function32, 37. The disorder is caused 
by mutations of the Tafazzin gene (TAZ)44. Patients with Barth syndrome demonstrate 
decreased levels of total cardiolipins and cardiolipin subclasses, especially tetralineoyl-
cardiolipin42, 105. A skewed X-inactivation has been reported in obligate carriers, and no 
female patients have been reported yet44, 106. 
Costeff syndrome is a progressive, late onset disease with bilateral optic atrophy, 
extrapyramidal symptoms with choreiform movements, ataxia, and spasticity45, 47. Patients 
carry an autosomal dominant mutation in the OPA3 gene underlying the neuro-ophthalmic 
presentation46. No mitochondrial dysfunction has been reported in Costeff syndrome 
patients so far. 
The diagnosis of 3−MGA−uria type IV is based on the exclusion of the other, well-defined 
clinical subtypes9, 23, 44, 46, 55, 107. This type of mild, non-syndromic 3−MGA−uria is frequently 
associated with progressive neurological impairment and variable organ dysfunction107. 
Symptoms often present during the first year of life. In some patients clinical and 
biochemical features of a dysfunctional oxidative phosphorylation have been observed73, 
108. It is very likely, that this heterogeneous group of patients can be further subdivided into 
different genetic disorders55. 
We performed biochemical and genetic investigations, including urine organic acid 
analysis, NMR spectroscopy, measurement of 3−methylglutaconyl−CoA hydratase activity, 
cardiolipin levels, OPA3 gene analysis, and measurement of the oxidative phosphorylation, 
in four children with 3−MGA−uria, presenting with neuroradiological evidence of Leigh 
disease, hearing loss, recurrent lactic acidemia and hypoglycemia, and other clinical 
features comparable with a mitochondrial disorder. 
As part of the regular work-up for a suspected disorder in the oxidative phosphorylation we 
applied the diagnostic criteria for mitochondrial disease85 based on clinical symptoms, 
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metabolic alterations, and abnormal neuroimaging findings. Serum lactic acid (multiple 
measurements), pyruvic acid levels, blood gas, serum acylcarnitine, amino acid, and urine 
organic acid profiles were analyzed in all children. 
 
Patients and methods 
Patients 
Patients Patient 1 ♀ Patient 2 ♀ Patient 3a♀ Patient4b♀ 
Consanguinity + - + + 
Bilateral sensory hearing loss + + - + 
MRI: bilateral hyperdensity of basal 
ganglia 
+ + + + 
MRI: bilateral atrophy of the 
cerebrum 
+ + + + 
MRI: bilateral atrophy of the 
cerebellum 
+ - + + 
Neonatal features of “sepsis” + + + + 
Recurrent infections + + + + 
Failure to thrive + + + + 
Feeding problems + + + + 
Delayed motor development + + + - 
Loss of motor skills + + + + 
Mental retardation + + + + 
Muscle hypotonia, progressive 
spasticity 
+ + + + 
Extrapyramidal symptoms + + + + 
Epilepsy - + - - 
Abnormal behaviour - - + + 
3−MGA−uria mean level  
(Excretion range)* 
53,5 
(31–76) 
47,2 
(16–68) 
132,5 
(102-196) 
125,0 
(97-141) 
Lactic aciduria + + + + 
Hypoglycemia + + + + 
Lactic acidemia (controls <2,1 
mmol/L) 
2,9–3,8 1,8–26 2,0–8,2 0,95–2,3 
Clinical diagnostic scorec 85 8 8 9 8 
Table 1. Clinical and biochemical features in our patients. aConstant laughing; bConstant 
laughing, auto-mutilation; cScore 8–12: definite mitochondrial disorder;* (μmol/mmol 
creatinine, control <20). 
 
Cerebral spinal fluid investigations have been successfully performed in three patients 
(patients 1, 2, and 4). The children also underwent a diagnostic protocol of multiple 
investigations including ECG, chest X-ray, EEG, visual evoked potentials (VEP), acoustic 
evoked potentials (BAEP), sensory evoked potentials (SEP), and a cranial MRI. Based on 
the diagnostic score85, an open muscle biopsy was performed under general anaesthesia in 
all four children. Molecular genetic analysis for Rett syndrome was requested in patients 3 
and 4. The clinical features of the patients are described in Table 1.  
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All patients were born from an uneventful pregnancy by spontaneous delivery. In two cases 
decreased child movements were reported. Three couples of the parents were 
consanguineous and of Turkish origin (Table 1). One child had non-consanguineous Dutch 
parents. All children presented with severe infections in the neonatal period: two with 
CMV-infection, one with GBS-sepsis and one without a known causative agent. Except for 
patient 3 the children had neonatal hypoglycemia, patients 2 and 3 had later recurrent 
episodes of hypoglycemia, and all four patients had recurrent lactic acidemia from the first 
weeks of life. No lactic acid elevations were detected in patient 2 and 4 in blood after 
puberty, however, lactate levels remained repeatedly, significantly increased in the CSF. 
Feeding problems were present from the neonatal period, making tube feeding necessary 
in two cases, leading to failure to thrive. The children suffered from recurrent upper 
respiratory infections without proven alterations of the humoral or cellular immune 
system. All children (except for patient 4) had a delayed motor development and muscle 
hypotonia. In patient 1 there was no development at all, patient 4 had a developmental 
regression from the age of six years and in two of the cases further motor skills were lost 
during the early childhood (patients 2 and 3). The patients developed severe spasticity, 
combined with extrapyramidal symptoms. Mental retardation was present in all children. 
Two of the patients showed behavioural problems with constant laughing, and/or auto-
mutilation (Table 1). Patient 1 died at the age of three and patient 2 at the age of 16 years. 
The EEG showed no signs of epilepsy in any of the patients, except for a multifocal epilepsy 
in patient 2. No cardiologic alteration was noted. The MRI of the brain revealed 
characteristic bilateral hyper-dense lesions of the basal ganglia in all children.Diffuse 
cerebellar and cerebral atrophy was also observed in three out of the four patients. Visual 
evoked potential analysis was bilaterally delayed in two patients (patients 1 and 4), 
however, no optic atrophy was noted. The BAEP studies showed severe sensori-neural 
hearing loss in three patients, making hearing devices necessary. A severity assessment 
(Table 1) was applied based on the clinical, metabolic, and neurological (neuro-imaging) 
alterations. Using the mitochondrial diagnostic score85 all children scored above 8 points 
(mitochondrial score 8–12; definite mitochondrial disorder) comparable with the clinical 
diagnosis of a respiratory chain disorder.  
 
Mutation analysis 
PCR amplification of both exons and their flanking intronic DNA sequences of the OPA3 
gene (GenBank Accession No. BC047316) was performed by using the oligonucleotide 
primers for exon 1-F1(5’-CGTACATACGTACTGACGCA-3’), R1(5’-TAAGCAACCACCT-
GACAGG-3’), and for exon 2-F2 (5’-TCCCAGAGCGCAGCCTGAC-3’), R2 (5’-
GCCAAGTTGCATCAAGATCCT-3’)46. The PCR products were electrophoresed on a 1 % 
agarose gel, extracted from the gel (Qiaquick Gel Extraction, Qiagen, Valencia, CA) and 
directly sequenced. Automated sequencing was performed on a Beckman CEQ 2000, by 
the CEQ Dye Terminator Cycle Sequencing kit, according to the manufacturer’s protocol 
(Beckman Coulter). 
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Screening for the common mitochondrial point mutations was carried out using Pyro-
sequencing™ according to the protocol of the manufacturer. Deletions were analyzed by 
long template PCR. Additional sequence analysis of the mitochondrial ND genes and 
sequencing of the nuclear coded structural complex I genes was performed (in patients 1 
and 3) on an ABI 3730 DNA analyzer using BigDye terminator chemistry (Applied 
biosystems, Lekkerkerk a/d IJssel, The Netherlands).  
 
In vitro NMR spectroscopy 
Body fluid NMR spectroscopy and quantification of the cis and trans forms of 3−MGA were 
performed essentially as described elsewhere19, 92. 
 
Sample preparation 
The urine samples were centrifuged before analysis. An aliquot (70 μL for urine) of 20.2 mM 
trimethylsilyl-2,2,3,3-tetradeuteropropionic acid (TSP, sodium salt; Aldrich) in D2O was 
added to 700 μL of the urine, providing a chemical shift reference (δ = 0.00), a 
concentration reference and a deuterium lock signal. The pH of the urine was adjusted to 
2.50 ± 0.05 with concentrated HCl. Finally, 650 μL of the sample was placed in a 5 mm NMR 
tube (Wilmad Royal Imperial).  
 
One-dimensional 1H NMR spectroscopy 
Urine samples were measured at 500 MHz on a Bruker DRX 500 spectrometer equipped 
with a triple-resonance inverse (TXI) 1H{15N, 13C} probehead and equipped with x, y, z 
gradient coils. 1H spectra were acquired as 128 transients in 32K data points with a spectral 
width of 6002 Hz. Sample temperature was 298 K and the H2O resonance was presaturated 
by single-frequency irradiation during a relaxation delay of 10 s, and a 90° excitation pulse 
was used. Shimming of the sample was performed automatically on the deuterium signal. 
To improve the spectral resolution, the samples were spun (7 Hz) during the 
measurements. The resonance linewidths for TSP and metabolites were <1 Hz. A π/2-
shifted sine-bell window function was applied to the FID. Fourier transformation was 
performed after zero-filling to 64K data points. The phase and the baseline were corrected 
manually. The cis 3−MGA and trans 3−MGA resonances and the TSP singlet were fitted 
semi-automatically with Lorentzian line shapes. The concentration of cis 3−MGA and trans 
3−MGA were calculated from the relative integrals of the fitted line-shapes using the 
known concentration of TSP92. 
 
Cardiolipin analysis 
Cardiolipin concentrations were measured in blood samples or in cultured skin fibroblasts. 
High−performance liquid chromatography−electrospray mass spectrometry was applied to 
quantify total cardiolipin and subclasses of cardiolipin molecular species, foremost 
tetralineoyl-cardiolipin42. 
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Biochemical analysis in muscle and fibroblast samples 
Parallel with routine immune-histological analysis and electronmicroscopy, the ATP 
production from pyruvate oxidation and the activity of the mitochondrial complexes I–V in 
our patients were measured in a fresh muscle biopsy sample and in cultured fibroblasts as 
described elsewhere93, 109. 
 
Results 
 
As shown in Table 1, urine organic acid analysis and in vitro NMR spectroscopy showed an 
increased urinary excretion of 3−MGA, with a strict 1:1 ratio of the cis and trans isoforms of 
3−MGA. The excretion of 3−MGA in the children was consecutively the following: patient 1 
(62, 45, 76, and 31 ;mean 53.5); patient 2 (31, 68, 54, and 16; mean 47.2); patient 3 (107, 196, 
115, and 102; mean 132.5); patient 4 (141, 97, 106, and 116; 125.0) μmol/mmol creatinine, 
respectively (controls: <20 μmol/mmol creatinine). The excretion of 3−hydroxyisovaleric 
acid in the most recent samples were 46, 10, 16, and 33 μmol/mmol creatinine, 
respectively; controls: <42 μmol/mmol creatinine. Hence, we conclude that our patients 
suffer from 3−MGA−uria. 
3−MGA−uria type I, Barth syndrome, and Costeff syndrome were excluded as the activity 
of 3methylglutaconyl-CoA hydratase, the cardiolipin levels, and molecular analysis of the 
OPA3 gene, respectively, showed no abnormalities.  
 
Biochemical measurements in muscle P 1 P 2 P 3 P 4 
ATP production from pyruvate oxidation  
(nmol ATP/h/mU CS) 
Control range 42–81 nmol/h/mU/CS, N: 22 
37 24 43 26 
Complex I activity (mU/mU/CS) 
Control range (70–251 mU/mU/CS), N: 24 
65 180 63 112 
Complex III activity (mU/mU/CS) 
Control range (2200–6610mU/mU/CS), N: 22 
2422 ND 2994 3040 
Complex IV activity (mU/mU/CS) 
Control range (650–2810mU/mU/CS) 
971 1092 1079 1590 
Enzyme measurements in fibroblasts  
Complex I activity (mU/mU/CS) 
Control range (100–310mU/mU/CS) 
160 ND 16 ND 
Complex III activity (mU/mU/CS) 
Control range (1320–2610mU/mU/CS) 
1810 ND 1487 ND 
Complex IV activity (mU/mU/CS) 
Control range (680–1190mU/mU/CS) 
709 ND 571 ND 
Table 2. Biochemical analysis of the mitochondrial function in the muscle biopsy sample and 
fibroblast lines of the patients. Decreased results in bold. ND = not determined, P= patient. 
 
The clinical symptoms of our patients are demonstrated in Table 1. As all our patients 
scored above 8 points on the clinical diagnostic scoring system for mitochondrial disorders 
a respiratory chain defect was suspected. Indeed, the biochemical analysis of 
mitochondrial function in the fresh muscle biopsy and/of that of fibroblasts showed 
reduced oxidative phosphorylation in all four patients. Patient 1 had a slight decrease in the 
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ATP production from pyruvate oxidation with a decreased activity of the mitochondrial 
enzyme complex I, but no alterations in fibroblasts. Patients 2 and 4 had a more 
pronounced decrease in the ATP production, but no alteration in the enzyme complex 
activities. Patient 3 had normal ATP production, however the activity of complex I in 
muscle and that of complex I and III in fibroblasts were decreased (Table 2). 
Mutation analysis of the MELAS 3243A>G, MERRF  8344A>G and Leigh/NARP 8993T>C 
point mutations and long template PCR analysis for mitochondrial deletions were normal 
in all children. Sequence analysis of the mtDNA for mutations in the genes ND1, ND2, ND3, 
ND4, tRNA Leu (uur), tRNA Lys and sequencing the mRNA of the nuclear coded NDUFS1, 
NDUFS2, NDUFS4, NDUFS7, and NDUFS8 genes detected no mutations in patients 1 and 3. 
 
Discussion 
 
Until now, four types of 3−MGA−uria have been described, three of which have a distinct 
genetic background. Patients diagnosed with unclassified 3−MGA−uria, or type IV, present 
with mild increased urinary levels of 3−MGA. Although this type of non-syndromic 
3−MGA−uria is frequently associated with progressive neurological impairment and 
variable organ dysfunction55, some patients have been reported with variable features of 
mitochondrial dysfunction, or the biochemical finding of disturbed oxidative 
phosphorylation 61, 107, 108, 110. Therefore it is very likely that this heterogenous group of 
patients could be further subdivided into different genetic disorders55. 
Indeed, here we describe a distinct clinical subtype of 3−MGA−uria. All of our patients are 
biochemically characterized by a mitochondrial dysfunction and a recurrent mild urinary 
elevation of 3−MGA. The level of 3−MGA excretion, confirmed by the in vitro NMR analysis, 
was comparable to that previously described in type IV 3MGA-uria (Table 1). It is also 
important to note the equal presence of cis and trans isoforms (“no stereospecifcity”) of 
3−MGA in the urine of the children. 
Engelke et al.19 described recently a 2:1 cis/trans 3−MGA isoform ratio in 3−MG CoA 
hydratase deficiency (3−MGA−uria type I), and in a second disorder of leucine metabolism; 
3-OH-3-methylglutaryl-CoA lyase deficiency, as well. Stereo-specificity has been already 
observed for 3-methylcrotonyl CoA carboxylase, another enzyme in leucine metabolism. 
Non-enzymatic isomerization of cis and trans 3-methylglutaconyl CoA has been also 
described under alkaline conditions. Further investigations are required to find the 
background of the different cis/trans ratios in the different types of 3−MGA−urias. The lack 
of stereospecificity in these four patients with mitochondrial dysfunction and 3−MGA−uria 
further supports the biochemical homogeneity of our clinical group. 
3-Methylglutaconyl CoA hydratase deficiency and Barth syndrome were excluded in our 
patients. Although the children have many features in common with that of Costeff 
syndrome, except for the optic atrophy, recent studies reported the presence of OPA3 
mutations in patients without the development of optic atrophy48. However, sequence 
MEGDEL association in four patients with a disorder of the oxidative phosphorylation 
 
73 
analysis of the OPA3 gene revealed no mutations in our cases. Moreover, no mitochondrial 
dysfunction has been reported in patients with Costeff syndrome. 
The finding of the neuro-radiological evidence of Leigh(-like) disease is rather specific for 
oxidative phosphorylation disorders. The combination of Leigh syndrome and hearing loss 
has been previously described in association with both mitochondrial and nuclear coded 
mutations. Hypotonia, lactic acidemia, hypoglycemia, feeding difficulties, failure to thrive, 
developmental delay, progressive spasticity, and extrapyramidal symptoms are less 
specific, but common features of mitochondrial dysfunction. 3−MGA−uria, however is not a 
common finding in respiratory chain defects.  
Biochemical evaluation confirmed a deficient oxidative phosphorylation in the muscle 
biopsy and/or in fibroblasts of the four children. Previous reports on mitochondrial 
dysfunction in association with 3−MGA−uria, however showed a very different clinical 
presentation in patients61, 73, 108, 110, suggesting genetic heterogeneity. There are only a few 
reports on clinically comparable patients with 3−MGA−uria. One patient described by 
Broide et al.111 showed clinical signs of sepsis at the age of three days, without a proven 
underlying infective agent. Hepato-splenomegaly and hepatic dysfunction, later on severe 
feeding difficulties and failure to thrive occurred. Hypotonia of the trunk and hypertonia of 
the extremities, neurosensory hearing loss and the neuro-radiological picture of Leigh 
syndrome with bilateral symmetric changes in basal nuclei region have been noted. The 
mitochondrial respiratory chain enzyme activity in muscle biopsy was reduced by 50 %111. 
In addition al Aqeel et al.112 described patients with 3−MGA−uria with neonatal acidosis and 
hypoglycemia. In one case the clinical features were very similar to that of our patients, 
including a possible sepsis, myoclonus epilepsy, and deafness. Brain imaging showed 
global cerebral/cerebellar atrophy, loss of the cerebral white matter, and bilateral 
putaminal necrosis, suggestive for Leigh-like syndrome. One of the patients died at three 
years of age. Unfortunately, no data concerning oxidative phosphorylation were given.  
So far, no underlying mutation has been discovered in our patients. The presence of 
consanguinity in three out of four cases could be comparable with an autosomal recessive 
inheritance. We have not found the etiology of the mitochondrial dysfunction associated 
increased 3−MGA excretion either. In the lack of a proven inborn error in the leucine 
metabolism one might hypothesize that the metabolic abnormalities occur due to an 
interaction between different epigenetic factors and the primary disease causing gene 
defect. 
Based on the association of the clinical features and biochemical abnormalities we suggest 
that our patients form a distinct clinical subgroup of deficient oxidative phosphorylation 
and 3−MGA−uria; with deafness, encephalopathy, and neuro-radiological evidence of 
Leigh-like disease (MEGDEL association). Further genetic mapping studies might be 
helpful for the elucidation of the etiology within the heterogeneous group of 3−MGA−uria 
type IV.  
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Abstract 
 
Using exome sequencing, we identify SERAC1 mutations as the cause of MEGDEL 
syndrome, a recessive disorder of dystonia and deafness with Leigh-like syndrome, 
impaired oxidative phosphorylation and 3−methylglutaconic aciduria. We localized 
SERAC1 at the interface between the mitochondria and the endoplasmic reticulum in the 
mitochondria-associated membrane fraction that is essential for phospholipid exchange. A 
phospholipid analysis in patient fibroblasts showed elevated concentrations of 
phosphatidylglycerol-34:1 (where the species nomenclature denotes the number of carbon 
atoms in the two acyl chains:number of double bonds in the two acyl groups) and 
decreased concentrations of phosphatidylglycerol-36:1 species, resulting in an altered 
cardiolipin subspecies composition. We also detected low concentrations of bis(monoacyl-
glycerol)-phosphate, leading to the accumulation of free cholesterol, as shown by 
abnormal filipin staining. Complementation of patient fibroblasts with wild-type human 
SERAC1 by lentiviral infection led to a decrease and partial normalization of the mean ratio 
of phosphatidylglycerol-34:1 to phosphatidylglycerol-36:1. Our data identify SERAC1 as a 
key player in the phosphatidylglycerol remodeling that is essential for both mitochondrial 
function and intracellular cholesterol trafficking. 
SERAC1, a phospholipid remodeler at the crossroads of mitochondrial function and cholesterol trafficking 
 
77 
The lipid bilayer surrounding cells and organelles consists mainly of phospholipids, such as 
the common phospholipids phosphatidylcholine and phosphatidylethanolamine and also 
the less abundant specialized phospholipids cardiolipin and 
bis(monoacylglycerol)phosphate (Figure 1). 
 
 
Figure 1. Structural formula of key phospholipids. 
 
Bis(monoacylglycerol)phosphate and cardiolipin are both synthesized from 
phosphatidylglycerol, which is made de novo in mitochondria113, 114. Bis(monoacylglycerol)-
phosphate is an anionic phospholipid that is necessary for intracellular cholesterol 
trafficking115. Cardiolipin is essential for the stability and catalytic activity of mitochondrial 
membrane proteins and is key for apoptosis116, 117. Abnormal cardiolipin acyl chain 
composition and accumulation of monolysocardiolipins results in Barth syndrome (MIM# 
302060)41, a 3−methylglutaconic aciduria (3−MGA−uria) with (cardio)myopathy, 
neutropenia and oxidative phosphorylation (OXPHOS) dysfunction 32, 103. Barth syndrome 
is caused by mutations in TAZ, which encodes tafazzin, a transacylase that is required for 
cardiolipin remodelling44. Here we identify the causative genetic defect in 15 individuals 
with MEGDEL syndrome (Supplementary Note), which we have previously defined as 
3−MGA−uria with impaired OXPHOS, deafness, encephalopathy, Leigh-like magnetic 
resonance imaging (MRI), progressive spasticity and dystonia11, 68. 
MEGDEL syndrome was predicted to be an autosomal recessive disorder based on its 
occurrence in one large pedigree with two affected siblings (patients 6 and 7) and an 
affected first cousin (patient 3) and in several individuals from consanguineous families 
(Supplementary Table 1). To find the underlying genetic cause of the syndrome, we 
sequenced the exomes (~21,000 genes) of two affected individuals using the SureSelect 50 
Mb human exome kit and a multiplexed sequence analysis on a SOLiD 4 system. For this 
analysis, we selected the affected cousin (patient 3) and an unrelated subject (patient 5), 
who is the affected child of a consanguineous marriage. We applied several filtering steps 
in which we excluded all nongenic, intronic and synonymous variants, other than those 
occurring at canonical splice sites, and focused on variants not reported in dbSNP or found 
in in-house–sequenced exomes under the assumption of an autosomal recessive 
inheritance pattern118. Only a single gene, SERAC1 (NM_032861.3), contained homozygous 
variants in both affected individuals (Supplementary Table 2). For patient 3, 73 of 74 (99%) 
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reads showed a C>T transition at chromosome 6 (hg19):g.158,567,859 indicating a 
homozygous r.442C>U transition at the mRNA level that is predicted to result in a 
premature stop codon (p.Arg148X; Supplementary Figure 1). Similarly, for patient 5, 50 of 
52 (96%) reads showed a G>C substitution at chromosome 6 (hg19):g.158,538,758 in the 
canonical donor splice site of exon 13. Of note, both mutations were located in 
homozygous regions of size 5.8 Mb and 9.7 Mb, respectively, as shown by homozygosity 
mapping using 250K arrays (Supplementary Table 3). Conventional Sanger sequencing 
confirmed the presence of these mutations as well as their homozygous state in patients 3 
and 5 and in the two cousins of patient 3. We identified neither of these two mutations in 
369 healthy ethnically matched controls. 
 
Figure 2. Schemetic representation of human SERAC1 showing the positions of all mutations 
identified. The black box represents the lipase/ esterase domain. Del =  deletion.  
 
An analysis of the protein coding sequence of SERAC1 in 11 additional unrelated individuals 
clinically diagnosed with MEGDEL syndrome identified 12 additional homozygous and 
compound heterozygous mutations that were absent in 369 healthy ethnically matched 
controls. In total, we identified 14 different mutations in 15 affected individuals from 13 
families, including three nonsense, three canonical splice site, four frameshift and three 
missense mutations and one in-frame deletion of a single amino acid (Table 1, Figure 2, 
Supplementary Table 4 and Supplementary Note). We found the two canonical splice site 
mutations in exons 13 and 16 and the missense mutation in exon 14 (c.1493G>C) in two, 
three and two unrelated subjects, respectively, indicating common ancestry, which was 
confirmed by their matching haplotypes (Supplementary Figure 2 and Supplementary 
Note). In addition, an mRNA transcript analysis showed that the exon 13 splice site 
mutations resulted in skipping of this exon (Supplementary Figure 3). Eight mutations 
resulted in a premature termination codon more than 55 nt before the last exon-exon 
boundary and, hence, should give rise to nonsense-mediated decay of the SERAC1 mRNA. 
Indeed, a quantitative PCR analysis of SERAC1 mRNA levels in fibroblasts from patients 3 
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and 5 showed 12% (P < 0.0001) and 40% (P < 0.029) of the SERAC1 levels in control 
fibroblasts, respectively (Supplementary Figure 4 and Supplementary Note).
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SERAC1 (serine active site containing 1) encodes a protein with a serine-lipase domain that 
is a member of the PGAP-like protein domain family (PFAM PF07819). Nothing is known 
about the function of this protein, although the presence of a conserved lipase domain 
containing the consensus lipase motif GXSXG119 strongly suggests a function in lipid 
metabolism. SERAC1 is present in all eukaryotes and is highly conserved, especially its 
lipase domain (Supplementary Table 5 and Supplementary Figure 5). The three amino 
acids (Gly401, Gly404 and Ser498) affected by the missense mutations and Leu479, which 
was deleted in one affected individual, are all located within this lipase domain and are fully 
conserved down to the fruit fly (Figure 2 and Supplementary Figure 5). Both the SIFT and 
PolyPhen-2 programs120, 121 predict these changes to be detrimental to protein function. 
Moreover, Ser498 is the serine of the consensus lipase motif GXSXG (Supplementary 
Figure 5)119, 120. 
Barth and MEGDEL syndromes share 3−MGA−uria and mitochondrial dysfunction. This, in 
combination with the presence of a lipase domain in SERAC1, formed the rationale for our 
phospholipid analysis in MEGDEL fibroblasts (Figure 3). The concentrations and acyl chain 
compositions of the major phospholipid classes (phosphatedylcholine, 
phosphatidylethanolamine, phosphatidylserine and phosphatidyl-inositol; data not shown) 
were normal. However, we found higher concentrations of phosphatidylglycerol-34:1 and 
lower concentrations of phosphatidylglycerol-36:1 species in all five affected individuals 
analyzed as compared to ten control fibroblast cell lines (Figure 3 a,b). A more detailed 
analysis of the mass spectrometry fragmentation spectra of phosphatidylglycerol-34:1 and 
phosphatidylglycerol-36:1 showed that the most abundant species of these 
phosphatidylglycerol molecules corresponded to 1-palmitoyl(16:0)-2-oleoyl(18:1) 
phosphatidylglycerol and 1-stearoyl(18:0)-2-oleoyl(18:1) phosphatidylglycerol 
(Supplementary Figure 6a). The median phosphatidylglycerol-34:1 concentration in patient 
fibroblasts was 220% of that in control fibroblasts, whereas the median 
phosphatidylglycerol-36:1 concentration in patient cells was 20% of that in control 
fibroblasts, resulting in a mean ratio of phosphatidylglycerol-34:1 to phosphatidylglycerol-
36:1 of 8.4 in patient fibroblasts as compared to 0.7 in control fibroblasts, justifying this 
ratio as a clinically relevant diagnostic marker (Figure 3b). 
In contrast to individuals with Barth syndrome, the total concentrations of cardiolipin were 
unaltered in fibroblasts from patients with MEGDEL syndrome (Figure 3b). However, there 
were differences in cardiolipin species composition in the patient fibroblasts compared to 
the control fibroblasts. Patients with MEGDEL syndrome had significantly higher 
concentrations of cardiolipin-66:3, cardiolipin-66:4, cardiolipin-68:3, cardiolipin-68:4 and 
cardiolipin-68:5 (Figure 3), which are derived from phosphatidylglycerol-34:1, than control 
individuals, whereas other cardiolipin species were the same between the two groups 
(Supplementary Figure 7). The inability to convert phosphatidylglycerol-34:1 to 
phosphatidylglycerol-36:1 leads to the accumulation of phosphatidylglycerol-34:1 and 
subsequent incorporation into cardiolipin.  
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Figure 3 A, B. SERAC1 and its role in phosphatidylglycerol remodeling. A) Representative 
high-performance liquid chromatography (HPLC) tandem mass spectrometry spectra of 
bis(monoacylglycerol)phosphate (BMP) and phosphatidylglycerol (PG) in fibroblasts. In 
patients with MEGDEL syndrome, phosphatidylglycerol-34:1 accumulates, 
phosphatidylglycerol-36:1 is deficient and bis(monoacylglycerol)phosphate concentrations are 
low. B) Box and whisker plots (minimum and maximum) of phosphatidylglycerol-34:1 and 
phosphatidylglycerol-36:1 concentrations, the ratio of phosphatidylglycerol-34:1 to 
phosphatidylglycerol-36:1, total concentrations of bis(monoacylglycerol)phosphate and total 
concentrations of cardiolipin (CL) in controls (C, n = 10) and patients (P, n = 5). 
 
In Barth syndrome, it is firmly established that cardiolipin alterations lead to OXPHOS 
dysfunction through different mechanisms, for example, by affecting the stability and 
assembly of inner mitochondrial membrane respiratory chain complexes41. Therefore, the 
alteration in the concentrations of cardiolipin species is probably directly related to the 
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OXPHOS dysfunction present in different tissues of patients with MEGDEL syndrome 
(Supplementary Tables 1 and 6). It is of note that the OXPHOS abnormalities in MEGDEL 
syndrome seem less pronounced than those in Barth syndrome, which may relate to the 
substantial differences in total cardiolipin content between the two diseases and the fact 
that monolysocardiolipins accumulate in Barth syndrome but are normal in patients with 
MEGDEL syndrome. Morphologically, however, we found an aggregation of degrading 
mitochondria in the muscle of patients with MEGDEL syndrome using electron microscopy 
(Supplementary Figure 8). We evaluated autophagy and mitophagy under basal conditions 
and under induced cellular stress in fibroblasts by analyzing the concentrations of 
mitochondrial marker proteins (GRP75 and MTCO2) and autophagy and mitophagy marker 
proteins (LC3, Mfn2, P62 and Parkin) and found no differences between patients and 
controls (Supplementary Figure 9 and Supplementary Note). Mitochondrial fusion and 
fission were also normal in patients with MEGDEL syndrome, as evidenced by 
semiquantitative immunohistochemistry and a quantitative PCR analysis of the fusion and 
fission protein markers Fis1, Drp1, Opa1 and Mfn1 (Supplementary Figure 10 and 
Supplementary Note). 
 
 
 
Figure 4. Cardiolipin species composition in patients and controls. Box and whisker plots 
(minimum and maximum) showing the concentrations of the cardiolipin (CL) species 
cardiolipin-66:3, cardiolipin-66:4, cardiolipin-68:3, cardiolipin-68:4 and cardiolipin-68:5 in 
control (C, n = 10) and patient (P, n = 5) fibroblasts. These specific cardiolipin species are 
significantly more abundant in patients than in controls. No significant differences were found 
in the other cardiolipin species: cardiolipin-70:7 through cardiolipin-70:5, cardiolipin-72:8 
through cardiolipin-72:5 and cardiolipin-74:8 through cardiolipin-74:6. 
 
Besides changes in phosphatidylglycerol and cardiolipin species composition, the median 
bis(monoacylglycerol)phosphate concentration in patients was 40% of that in controls 
(Figure 3 B). The four most abundant bis(monoacylglycerol)phosphate species (34:1, 36:2, 
40:7 and 44:12) had identical acyl chain composition in patients and controls 
(Supplementary Figure 6 B). Low bis(monoacylglycerol)phosphate concentrations are 
known to lead to free cholesterol accumulation in late endosomes122. We assessed the 
accumulation of unesterified cholesterol in patient and control fibroblasts. For comparison, 
we used Niemann-Pick type C (NPC) fibroblasts, which are known to accumulate 
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unesterified cholesterol123. All three patients with MEGDEL syndrome tested clearly had 
more filipin staining than the control (Figure 5).  
 
Figure 5. Filipin staining of fibroblasts from patients with MEGDEL syndrome, a patient with 
Niemann-Pick disease type C (NPC) as positive control and a healthy control showing 
background fluorescence. Scale bar, 5 μm. 
 
 
Figure 6 A,B,C. Subcellular localization of SERAC1. A,B) Immunodetection of SERAC1 in total 
cell lysate (TC), cytoplasmic fraction (CF), crude mitochondrial fraction (CMF) and ER of HeLa 
(A) or HEK293 (B) cells showing SERAC1 enrichment in the CMF and ER. Calnexin (MAM-ER 
marker), NDUFS3 and COXII (inner mitochondrial membrane markers) and creatine kinase-B 
(CK-B; cytoplasmic marker) were used for comparison. C) Immunodetection of SERAC1 in 
CMFs subjected to no or mild digitonin treatment and incubated with or without proteinase K 
(Prot K) in the absence or presence of Triton X-100 showing SERAC1 association with the 
mitochondria, ER and MAMs of HEK293 cells. Calnexin, TOM20 (mitochondrial outer 
membrane marker) and NDUFS3 were used for comparison. 
 
In general, the localization of the fluorescent signal seemed more prominent in the 
perinuclear region of the MEGDEL fibroblasts as compared to the NPC fibroblasts, which 
showed an abundance of small aggregates with positive fluorescence throughout the cell. 
These results suggest an accumulation of unesterified cholesterol in patients with MEGDEL 
syndrome. This conclusion is supported by the lipid storage found in the muscle of patients 
with MEGDEL syndrome (Supplementary Figure 8). Because intracellular accumulation of 
cholesterol may lead to lower blood cholesterol concentrations, we reinvestigated all 
subjects with mutations in SERAC1. Notably, 4 of 11 patients with MEGDEL syndrome in 
whom cholesterol was measured had a cholesterol concentration below the lower 
reference range limit, but for the total group of 11 patients in this study, the serum 
cholesterol concentrations were not statistically different from controls (Supplementary 
NPC MEGDEL P3 MEGDEL P4 MEGDEL P5 Healthy control 
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Table 1). SERAC1 is ubiquitously expressed, with markedly high expression in fetal muscle 
and in adult brain (Supplementary Figure 11 and Supplementary Note). Prediction of the 
subcellular localization of SERAC1 by PSORT II suggested a mitochondrial localization (a 
43.5% chance of mitochondrial localization compared to a 30.4% chance of cholesterol 
may lead to lower blood cholesterol concentrations, we reinvestigated all subjects with 
mutations in SERAC1. Notably, four of 11 patients with MEGDEL syndrome in whom 
cholesterol was measured had a cholesterol concentration below the lower reference 
range limit, but for the total group of 11 patients in this study, the serum cholesterol 
concentrations were not statistically different from controls (Supplementary Table 1). 
 
Figure 7 A, B. Subcellular localization of SERAC1. A) Partial colocalization of SERAC1 with 
the mitochondrial matrix marker MRPL12 in control fibroblasts showing SERAC1 in close 
proximity to mitochondria. Scale bar, upper two rows, 5 μm; bottom row, 2.5 μm. The bottom 
row shows the images at the highest magnification. B) Ratio of phosphatidylglycerol (PG)-
34:1 to phosphatidylglycerol-36:1 in the CMF of patient (P, n = 3) and control fibroblasts (C, n = 
3). 
 
We postulate that phosphatidyl-glycerol-34:1 is the primary precursor of 
bis(monoacylglycerol)phosphate species and that the inability to produce 
phosphatidylglycerol-36:1 from phosphatidylglycerol-34:1 causes 
bis(monoacylglycerol)phosphate deficiency (Figure 8).  
 
 
Figure 8. The role of SERAC1 in phosphatidylglycerol remodeling. CLS = cardiolipin synthase; 
IS = internal standard; TAZ =  tafazzin. 
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SERAC1 is ubiquitously expressed, with markedly high expression in fetal muscle and in 
adult brain (Supplementary Figure 11 and Supplementary Note). Prediction of the 
subcellular localization of SERAC1 by PSORT II suggested a mitochondrial localization (a 
43.5% chance of mitochondrial localization compared to a 30.4% chance of cytosolic 
localization and an 8.7% chance of nuclear localization). Accordingly, a western blot 
analysis showed that SERAC1 was absent from the cytosol (Figure 6 A) but was enriched in 
the crude mitochondrial and endoplasmic reticulum (ER) fractions compared to total cell 
lysates (Figure 6 A, B and Supplementary Note). Subsequent treatment of crude 
mitochondrial fractions with proteinase K showed that the amount of SERAC1 decreased, 
whereas the outer mitochondrial membrane protein marker TOM20 was fully degraded 
(Figure 6 C). However, calnexin, an ER marker protein that is enriched in the mitochondria-
associated membranes (MAMs)124 that co-purify with the crude mitochondrial fraction125, 
showed a similarly confined protection pattern as SERAC1 after proteinase K treatment.  
This finding, together with the SERAC1 enrichment in the ER (Figure 6 B), suggests that 
SERAC1 localizes at the ER and at the ER-mitochondria interface. This is supported by 
immunohistological studies in which SERAC1 was found in close proximity to the 
mitochondria but only partially colocalized with the mitochondrial matrix protein MRPL12 
(Figure 7 A). In addition, the difference in the mean ratio of phosphatidylglycerol-34:1 to 
phosphatidylglycerol-36:1 between patients and controls was more evident in the crude 
mitochondrial fraction compared to in the total fibroblasts (19.3 compared to 8.4, 
respectively; Figure 7 B). This indicates that phosphatidylglycerol remodeling probably 
occurs in this fraction, which is in line with the proposed intracellular localization of 
SERAC1 at the interface of the two compartments and the fact that the exchange of 
phospholipids has been shown to be a key function of the MAM126.  
The localization of SERAC1 at the contact sites between the ER and mitochondria, the low 
concentrations of phosphatidylglycerol-36:1 and the accumulation of 
phosphatidylglycerol-34:1 in MEGDEL fibroblasts indicate that SERAC1 catalyzes the 
remodeling of phosphatidylglycerol and is involved in the transacylation-acylation reaction 
to produce phosphatidylglycerol-36:1. The altered acyl chain composition of the affected 
phosphatidylglycerol molecules suggests that SERAC1 catalyzes the transfer of stearic acid 
(18:0) from an as yet unknown donor to 1-palmitoyl(16:0)-2-oleoyl(18:1) 
phosphatidylglycerol to produce 1-stearoyl(18:0)-2-oleoyl(18:1) phosphatidylglycerol and, 
thus, effectively exchanges palmitic acid (16:0) on the sn-1 position of 
phosphatidylglycerol-34:1 for stearic acid (18:0).  
To support this role of SERAC1 in phosphatidylglycerol remodeling, we successfully 
complemented two patient fibroblast lines with wild-type human SERAC1 by lentiviral 
infection, which led to a decrease and partial normalization of the mean ratio of 
phosphatidylglycerol-34:1 to phosphatidylglycerol-36:1 from 8.6 to 4.0 (Figure 9), directly 
linking mutations in SERAC1 to compromised phosphatidylglycerol remodeling. We found 
no differences in the concentrations and subspecies distribution of other phospholipids 
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(phosphatidylcholine, phosphatidylethanolamine and phosphatidylserine; Supplementary 
Figure 12). 
 
 
 
Figure 9. The ratio of phosphatidylglycerol (PG)-34:1 to phosphatidylglycerol-36:1 in patient 
fibroblasts complemented with wild-type SERAC1. Fibroblasts from patients were infected 
with a mock vector (n = 4) or an expression vector containing wild-type SERAC1 (+SERAC1, n = 
4). Complementation of SERAC1 (for western blot see Supplementary Figure 13) restores the 
ratio of phosphatidylglycerol-34:1) to phosphatidylglycerol-36:1. 
 
In conclusion, mutations in SERAC1 cause a clinically recognizable progressive neurological 
deafness dystonia syndrome (MEGDEL). MEGDEL syndrome is a phospholipid remodeling 
disorder, but it also classifies as a defect in intracellular cholesterol trafficking. Our data 
identify SERAC1, a protein located at the contact sites between mitochondria and the ER, 
as a key player in the remodeling of phosphatidylglycerol, particularly of those species 
needed for the synthesis of bis(monoacylglycerol)phosphate. SERAC1 is crucial for both 
mitochondrial function and intracellular cholesterol trafficking. This study identifies 
SERAC1 as catalyzing the first enzymatic reaction in the as yet unknown 
bis(monoacylglycerol)phosphate biosynthetic pathway. 
 
Methods 
 
Library generation 
Exome enrichment required 3 μg of genomic DNA, and an AB SOLiD optimized SureSelect 
50 Mb human exome kit (Agilent) was used for enrichment, representing exonic sequences 
for ~21,000 genes (including >99% genes from the September 2009 version of CCDS and 
>95% of the RefSeq genes and transcripts from the June 2010 version of RefSeq, as 
specified by the company). The manufacturer’s instructions (version 1.5) for enrichment 
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were followed, with a minor modification being a reduction of the number of post-
hybridization ligation-mediated PCR cycles from 12 to 9. To allow for multiplexing libraries 
before sequencing, we used post-hybridization sample barcodes (Agilent) that were 
compliant with SOLiD sequencing technology. 
 
SOLiD sequencing 
Enriched exome libraries were equimolarly pooled in sets of four based on a combined 
library concentration of 0.7 pM. Subsequently, the obtained pool was used for emulsion 
PCR and bead preparation using the EZ Bead system according to the manufacturer’s 
instructions (version 05/2010; Life Technologies). For each pool of four exome libraries, a 
full sequencing slide was used on a SOLiD 4 System (Life Technologies), thereby 
anticipating that all four samples would be represented by 25% of the total beads 
sequenced on the slide. 
 
Mapping of variants 
Color space reads were mapped to the hg19 reference genome with the SOLiD bioscope 
software v1.3, which uses an iterative mapping approach. Single nucleotide variants were 
subsequently called by the diBayes algorithm 1 using high stringency settings and requiring 
calls on each strand. Small insertions and deletions (indels) were detected using the SOLiD 
Small InDel Tool. Variants and indels were selected using strict quality settings, which 
included the presence of at least five unique variant reads (different start sites), as well as 
the variant being present in at least 20% of all reads. All called variants and indels were 
combined and annotated using a custom analysis pipeline, resulting in HCDiff files for each 
patient. 
 
Custom bioinformatic analysis pipeline 
For the filtering steps, we excluded all nongenic, intronic (other than canonical splice sites) 
and synonymous variants, reducing the number of variants to an average of 5,363 per 
patient. Then, all known variants were excluded by comparison with data from dbSNPv132 
(>30 million variants) as well as with data from our in-house variant database.  
At the time of this study, this in-house database contained variants from 177 in-house–
performed exomes, contributing a further 332,849 unique variants. Of note, if the variant 
observed in a patient occurred at a genomic position that was known in dbSNPv132 but the 
change was different from that in dbSNP (for example, A>C in dbSNP but A>T in the 
patient), the variant was not excluded from analysis. The filtering step using these data 
further reduced the average number of variants to 227 per patient. Next, as a recessive 
disease model was expected and given the assumption of a common ancestral allele 
(based on parental consanguinity), we prioritized the variants according to the percentage 
of variant reads. To do this, we used the threshold of >70% variant reads as an indicator for 
homozygous variants. This prioritization resulted in an average of 19 variants per patient. 
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Homozygosity mapping 
Genomic DNA was extracted from peripheral blood lymphocytes using standard salting-
out procedures127. Genotyping was performed using the Affymetrix NspI 250K SNP array. 
All SNP array experiments were performed and analyzed according to the manufacturer’s 
protocols (Affymetrix). Homozygosity mapping was performed using PLINK v1.06 using a 
homozygous window of 50 SNPs and tolerating two heterozygous SNPs and ten missing 
SNPs per window.128 
 
Lipid analysis 
Fibroblast cell lines were harvested by centrifugation at 200g for 5 min at room 
temperature, washed once with PBS, pelleted by centri-fugation at 200g for 5 min at room 
temperature and snap frozen in liquid nitrogen. The concentrations of the following 
phospholipids were analyzed: phosphatidylglycerols, bis(monoacylglycerol)phosphate, 
phosphatidic acids, phosphatidylcholines, phosphatidylethanolamines, phosphatidyl-
serines, phosphatidylinositols, cardiolipins, sphingomyelines and their lyso-analog species. 
The relative abundances of the species in the sample extracts were determined by HPLC 
tandem mass spectrometry using a Surveyor HPLC system hyphenated to a TSQ Quantum 
AM tandem mass spectrometer (Thermo Finnigan Corporation). The mass spectrometer 
was operated alternating in the negative and positive ion electrospray ionization mode in 
consecutive runs, as described in detail previously129. The method was adjusted by adding 
two extra internal standards (C14:0-phosphatidylglycerols and C14:0-
bis(monoacylglycerol)phosphate, m/z 665.3) for more accurate quantification of the 
phosphatidylglycerols and bis(monoacylglycerol)phosphate. Acyl-chain compositions were 
determined by the product-ion scans of the respective quasi-molecular ions. 
 
Filipin staining of fibroblasts 
Fibroblasts were grown on coverslips and washed three times with PBS. The cells were 
fixed in 3% paraformaldehyde and 2% glutaraldehyde in PBS for 1 h in the dark. After three 
washes with PBS, the cells were incubated with filipin solution (5% in dimethylformamide 
and PBS, 1:50 (v/v)) for 1 h in the dark130. After washing three times in 0.5% bovine serum 
albumin in PBS, cells on the coverslips were washed once with ultrapure water and inserted 
into a drop of glycerin on a microscope glass slide. Digital images were captured with a Carl 
Zeiss Axioskop-20 (Carl Zeiss). 
 
Colocalization studies 
Fibroblasts on coverslips were washed 4× for 15 min in PBS, followed by incubation in 0.5% 
Triton X-100 (Sigma-Aldrich) in PBS for 30 min. After a short rinse in PBS, cells were 
incubated in 2% normal donkey serum (NDS) in PBS for 30 min, followed by an incubation 
in a mixture of primary antisera in 2% NDS in PBS for 16 h at room temperature. The fol-
lowing sera were used: polyclonal (rabbit) anti-SERAC1 (1:100; HPA025716; Sigma-Aldrich) 
and monoclonal (mouse) anti-MRPL12 (1:750; #ab58334; Abcam). After several washes in 
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PBS, a secondary antiserum cocktail consisting of Cy2-conjugated anti-mouse IgG (1:100) 
and Cy3-conjugated anti-rabbit IgG (1:100) (Jackson Immunoresearch Laboratories) were 
applied in blocking agent tyramide signal amplification (B/TSA) in PBS for 2.5 h at room 
temperature. After several rinses in PBS, cells were coverslipped with Fluorsave 
(Calbiochem) and studied with a Leica confocal laser scanning microscope (Leica 
Microsystems). 
 
Fluorescence semiquantitative immunohistochemistry 
For fluorescent immunohistochemistry, fibroblasts on culture glass were washed six times 
for 10 min at room temperature and incubated in 0.5% Triton X-100 in blocking buffer 
consisting of PBS and 2% NDS (Jackson Immunoresearch Laboratories) for 30 min. Then, 
sections were incubated for 16 h in affinity-purified primary anti-Drp1 (1:100; mouse; 
611112; BD Biosciences), anti-Fis1 (1:100; rabbit; IMG-5113A; Imgenex), anti-Mfn1 (1:75; 
chicken; NB110-58853; Novus Biologicals) and anti-OPA1 (1:25; mouse; 612607; BD 
Biosciences) in blocking buffer. After three 15-min washes in PBS, they were incubated in 
Cy3-conjugated donkey anti-rabbit IgG (for Fis1), Cy3-conjugated donkey anti-mouse IgG 
(for Drp1 and OPA1) and Cy3-conjugated donkey anti-chicken IgG (for Mfn1) in blocking 
buffer for 2 h, rinsed and coverslipped with antifade mounting medium (Vectashield Vector 
Laboratories). Digital images were taken at a resolution of 1,200 × 1,600 dpi using the Leica 
DMRBE system with a Leica digital camera (Leica Microsystems) connected to an IBM 
computer running Scion Image software (version 3.0b; NIH).  
The specific signal density in an individual fibroblast, corrected for background density, 
was measured for 20 random cells using Image J software version 1.37 (NIH) and expressed 
in arbitrary units. 
 
Lentiviral infections 
The pLenti6.2-SERAC1 construct (‘+SERAC’) or the control construct pLenti6.2V5-AcGFP 
(‘mock’) were transfected into 10-cm dishes containing 293FT cells together with a 
packaging mix consisting of the plasmids pLP1, pLP2 and pLP/VSVG using Lipofectamine 
2000 (Invitrogen). At 24 h after transfection, the medium was refreshed, and the 
supernatants containing the viral particles were harvested at 72 h after transfection. 
Subsequently, supernatants were cleared by centrifugation at 300g for 5 min, and the viral 
particles were stored at –80 °C before use. Infections were performed on fibroblasts in 75 
cm2 flasks with 2 ml of virus containing the supernatant in the presence of 6 μg/ml 
polybrene (Sigma-Aldrich). At 24 h after infection, the medium was refreshed, and after 48 
h, the selection medium was added (M199, 20% FCS (100U/ml) and penicillin and 
streptomycin (100 μg/ml)) and 2 μg/ml blasticidin (InvivoGen). Cells were selected for 14 d, 
in which time the mock-infected cells (without virus) died. Blasticidin-resistant cells were 
used for biochemical analysis within six passages after transduction. 
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Supplementary information 
 
Patients 
Patients were under treatment of one of the contributing clinicians (SW, PvH, IB, EP, SKU, 
KN, KS, ZK, JS, EM). Written informed consent was obtained from all patients and our 
research project was approved by the local ethics committee (Commissie Mensgebonden 
Onderzoek Regio Arnhem-Nijmegen) according to the World Medical Association Declaration 
of Helsinki. 
 
Haplotype analysis by using short tandem repeat (STR) markers 
Primers to amplify polymorphic short tandem repeat markers on 9q34.11 were designed by 
using the Primer3 program (http://frodo.wi.mit.edu/cgi-bin/primer3/primer3_www.cgi)131. 
An M13 tail was added to the 5’ and 3’-ends of the primers. Markers were amplified by 
using an M13 forward primer labeled with one of the fluorophores, FAM, VIC, NED and 
ROX, at the 5’-end and a M13 reverse primer with a 5’-gtttctt-3’ added to its 5’-end to 
reduce tailing132, 133. Primer sequences are shown in Supplementary Table 4 and PCR 
conditions are available upon request. Final PCR products were mixed with eight volumes 
of formamide and half a volume of GenescanTM 500(-250) LIZ size standard (Applied 
Biosystems, Foster City, USA), and analysed with the ABI PRISM 3730 DNA analyzer 
(Applied Biosystems, Foster City, USA). The results were evaluated by Genemapper 
(Applied Biosystems, Foster City, USA). 
 
Mutation analysis 
Primer sequences for amplification of all protein coding exons of SERAC1 (GenBank ID 
NM_032861.3) are shown in Supplementary Table 4. PCR conditions are available upon 
request. PCR products were sequenced using the ABI PRISM BigDye Terminator Cycle 
Sequencing V2.0 Ready Reaction Kit and analysed with the ABI PRISM 3730 DNA analyzer 
(Applied Biosystems, Foster City, USA). 
 
Cell culturing 
Different cell types were cultured under specific conditions for each experiment. Fibroblast 
cell lines for NMD inhibition and lipid analysis were cultured in RPMI 1640 medium (Gibco, 
Breda, The Netherlands) containing 10% (v/v) fetal calf serum (FCS; Sigma, Zwijndrecht, 
The Netherlands), 1% 10 U/μl Penicillin-10 μg/μl Streptomycin (Gibco, Breda, The 
Netherlands), and 1% GlutaMAX (Gibco, Breda, The Netherlands)134.  
Fibroblast that were used for the preparation of cell lysates, filipin staining, co-localization, 
and lentiviral infections were grown in E199 medium (Gibco, Breda, The Netherlands) 
supplemented with 10% FCS (Lonza, Breda, The Netherlands) and 1% 10 U/μl Penicillin-10 
μg/μl Streptomycin (Gibco, Breda, The Netherlands).  
Fibroblasts that were used for assessment of mitophagy and autophagy, and fusion and 
fission, were kept in high glucose Dulbecco’s Modified Eagle’s Medium supplemented with 
10% FCS (Lonza, Breda, The Netherlands) and 1% 10 U/μl Penicillin-10 μg/μl Streptomycin 
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(Gibco, Breda, The Netherlands). All fibroblasts were grown at 5% CO2 and a temperature 
of 37°C. HEK293 and HeLa cells were cultured in DMEM (Gibco, Breda, The Netherlands) 
supplemented with 10% FCS (Lonza, Breda, The Netherlands) and 1% 10 U/μl Penicillin-10 
μg/μl Streptomycin (Gibco, Breda, The Netherlands). All cells were grown at 5% CO2 and a 
temperature of 37°C. 
 
Nonsense-mediated decay (NMD) inhibition by cycloheximide 
Fibroblasts were cultured to a density of 0.5*106 cells/ml. Subsequently, 20 μl 
cycloheximide (concentration: 100 mg/ml DMSO) was added to the medium. After 
incubation for 4 hrs at 37°C, cells were harvested by centrifugation at 200xg for 5 min at 
room temperature, washed once with phosphate-buffered saline (PBS), pelleted by 
centrifugation at 200xg for 5 min at room temperature, and snap frozen in liquid nitrogen.  
 
First strand synthesis 
RNA was isolated from EBV-LCLs of patients and control individuals by using the 
NucleoSpin RNA II kit (Macherey-Nagel, Düren, Germany) according to the manufacturer’s 
protocols. The integrity of the RNA was assessed on 1.2% agarose gel, and the 
concentration and purity determined by optical densitometry. The OD260/OD230 and 
OD260/OD280 ratios were in between 1.8 and 2.0. Half a μg of total RNA was transcribed into 
cDNA by using the iScript cDNA synthesis kit (Bio-Rad Laboratories, Hercules, CA, USA) 
according to the manufacturer’s protocol. cDNA was purified by using the NucleoSpin 
extract II kit (Macherey-Nagel, Düren, Germany) according to the manufacturer’s protocol. 
In case of expression profiling, total RNA from different human adult and fetal tissues was 
ordered from Stratagene Europe (Amsterdam, The Netherlands). All fetal tissues are from 
20 or 21 weeks-old embryos after gestation, except for cochlear RNA that was isolated 
from an 8 weeks-old embryo by using the NucleoSpin RNA II kit (Macherey-Nagel, Düren, 
Germany) according to the manufacturer’s protocols. To remove residual traces of 
genomic DNA, the cochlear RNA was treated with DNase I (Invitrogen, Leek, The 
Netherlands) while bound to the RNA binding column. The integrity, concentration, and 
purity of the RNA were assessed as described above.  
Of all tissues, 5 μg of total RNA was transcribed into cDNA by using the iScript cDNA 
synthesis kit (Bio-Rad Laboratories, Hercules, CA, USA) according to the manufacturer’s 
protocol. cDNA was purified by using the NucleoSpin extract II kit (Macherey-Nagel, 
Düren, Germany) according to the manufacturer’s protocol. 
 
Quantitative PCR (QPCR) analysis 
SYBR Green-based real-time quantitative PCR (QPCR) expression analysis was performed 
on a 7500 Fast Real-Time PCR System (Applied Biosystems, Foster City, CA, USA) by using 
Power SYBR Green PCR Master Mix (Applied Biosystems, Foster City, CA, USA) according 
to the manufacturer´s instructions. Primers were designed by the primer3 program 
(http://frodo.wi.mit.edu/cgi-bin/primer3/primer3_www.cgi)131. Primer sequences are given 
SERAC1, a phospholipid remodeler at the crossroads of mitochondrial function and cholesterol trafficking 
 
93 
in Supplementary Table 4. PCR products encompassed at least one boundary between two 
exons. GUSB was used as reference gene134. RNA was isolated from fibroblasts of patients 
and control individuals by using the NucleoSpin RNA II kit (Macherey-Nagel, Düren, 
Germany) according to the manufacturer’s protocols. QPCR quantifications were 
performed in duplicate on the equivalent of 7.8 ng of total RNA from the first strand 
synthesis, and included a water control. Experimental threshold cycles (Ct) values were 
within the range of cDNA dilutions used to validate the primers. The melt curves of all PCR 
products showed a single PCR product. All water controls were negative. Differences in 
expression of a gene of interest between the individual samples of the patients and five 
controls were calculated by the comparative Ct or 2ΔΔCt method135, 136. The p-value was 
derived from the standard score (Z-value) calculated for each individual as compared to the 
normal distribution of the five controls. Since we assume a lower expression level as a 
result of nonsense-mediated mRNA decay (NMD), a one-sided test was enough to reject 
the null hypothesis, i.e., no statistically significant difference between the expression of 
SERAC1 in fibroblasts of a patient and that in fibroblasts of controls. We used an alpha level 
of 0.05, because only one gene was assessed. 
 
Tissue expression analysis 
QPCR quantifications were performed in duplicate on the equivalent of 12.5 ng total RNA 
input. Experimental threshold cycles (Ct) values were within the range of cDNA dilutions 
used to validate the primers. The melt curves of all PCR products showed a single PCR 
product. All water controls were negative. GUSB and PPIB were used as reference genes. 
Differences in expression of a gene of interest between two samples were calculated as 
described above. 
 
Preparation of cell lysates and cellular fractionation 
Fibroblasts, HEK293 cells, or HeLa cells were harvested by centrifugation at 200xg for 5 
min at room temperature and washed twice in PBS. Total cell lysates were obtained by 
resuspension of fresh cells in 50 μL PBS containing 2% (v/v) B-Laurylmaltoside. After ten 
minutes of incubation on ice, unbroken cells and nuclei were spun down. Protein 
concentrations in the supernatant were determined using a MicroBCA protein assay kit 
(Thermo Scientific, Etten-Leur, The Netherlands). To the supernatant an equal volume of 
Tricine sample buffer (Biorad laboratories, Ede, The Netherlands) containing 2% (v/v) 2-
mercaptoethanol was added and the mixture was kept at room temperature for 60 
minutes before further processing.  
To obtain cytoplasmic fraction, crude mitochondria and endoplasmic reticulum (ER), fresh 
cell pellets were resuspended in isotonic buffer (0.25 M sucrose, 5 mM Tris ⁄ HCl, pH 7.5, 
and 0.1 mM phenylmethylsulfonylfluoride(PMSF)) and pottered eight times at 2500 rpm to 
homogenize the cells. Unbroken cells and nuclei were removed by centrifugation at 600xg 
for 15 min. Supernatants were centrifuged at 10,000xg for 25 min to obtain crude 
mitochondria. The supernatant of this centrifugation step was either used as cytoplasmic 
Chapter 6 
 
94 
fraction or subjected to centrifugation at 100,000xg for 60 min to obtain ER. The crude 
mitochondrial pellet was washed twice with the isotonic buffer containing 1 mM EDTA.  
 
Proteinase K protection assay 
A Proteinase K protection assay was used to determine the SERAC1 localisation more 
precisely. Fresh crude mitochondrial fractions were prepared from HEK293 cells and 
resuspended in PBS. Half of the sample was used to generate a mitoplast by 
permeabilizing the outer membrane with digitonin (8μg/μl PBS; ~50% (TLC), Sigma–
Aldrich, Zwijndrecht, The Netherlands). Mitochondrial and mitoplast pellets were 
resuspended in PBS and the protein concentration was determined using a MicroBCA 
protein assay kit (Thermo Scientific, Etten-Leur, The Netherlands). The total volume was 
adjusted to a final protein concentration of 2 μg/ml. Mitochondria and mitoplasts were 
treated with proteinase K in different concentrations (1 or 10 μg/ml) in the absence or 
presence of 1% Triton X-100 for 15 min at 4°C. The reaction was terminated by the addition 
of 200 μM PMSF and an equal volume of Tricine sample buffer (Biorad laboratories, Ede, 
The Netherlands) containing 2% (v/v) 2-mercaptoethanol immediately followed by 
incubation of 5 minutes at 95°C.  
 
SDS PAGE and Immunodetection 
Equal amounts of protein of the obtained total cell lysates, crude mitochondria, ER, and 
cytosol were loaded and separated on a 10% polyacrylamide gel. Gels were blotted to 
nitrocellulose transfer membranes (Whatman, s’Hertogenbosch, the Netherlands).  
We used the following specific antibodies: rabbit anti-SERAC1 (1:500; HPA 025716; Sigma–
Aldrich, Zwijndrecht, The Netherlands); mouse anti-NDUFS3, (1:1,000; MS112; 
Mitosciences, Eugene, Oregon, USA); mouse anti-TOM20 (1:1,000; 612278; BD 
transduction laboratories, Breda, The Netherlands); rabbit anti-Calnexin (1:1,000; 2433S; 
Cell signaling technologies, Leiden, The Netherlands); Rabbit anti-Actin (1:500; NB600-533; 
novus biological, Cambridge, UK), mouse anti-COX II (1:10,000; A6404; Invitrogen, Leek, 
The Netherlands), and mouse anti-CK-B antibody (1:1,2000; 21E10)137. Secondary 
antibodies used for detection were goat anti-(rabbit Ig) Ig peroxidase (1:10,000; GARPO; 
Invitrogen, Leek, the Netherlands) and goat anti-(mouse Ig) Ig peroxidase (1:10,000; 
(GAMPO; Invitrogen, Leek, the Netherlands), and donkey anti-goat (1:10,000; sc-2020; 
Santa Cruz Biotechnology, Heidelberg, Germany). Signal was generated using the ECL 
Prime Western Blotting reagent (Amersham Biosciences, Roosendaal, the Netherlands). 
 
OXPHOS measurements 
OXPHOS measurements in different tissues were performed as reported earlier93, 138, 139. 
The measurement of the oxygen consumption rate in the presence of pyruvate and malate 
as mitochondrial respiration substrates was performed as described previously140. 
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Assessment of autophagy and mitophagy 
In all assays, fibroblast passage numbers (<10) were matched. To challenge cellular 
processes of mitophagy by increasing the amount of dysfunctional mitochondria, 
fibroblasts were treated with the potassium ionophore valinomycin (1μM for 1h, Sigma-
Aldrich, St. Louis, CA, USA)141. Proteins were extracted using RIPA buffer (50mM Tris-HCl 
pH7.6, 150mM NaCl, 1% DOC, 1% NP-40) containing 0.1% SDS. Cells were dissolved in the 
appropriate amount of buffer and incubated on ice for 30 min. Next, lysates were 
centrifuged at 16,000xg for 20min at 4oC. The supernatant was transferred into a new tube 
and used for Western blotting. Western blot analysis was performed as previously 
published142 using antibodies raised against β-actin (1:1000000, #A2228, Sigma-Aldrich, 
St. Louis, CA, USA), GRP75 (1:1000000, #ab2799, Abcam, Cambridge, UK), LC3 (1:1000, 
#4108, Cell Signaling Technology, Boston, MA, USA), Mfn2 (1:1000, #ab56889, Abcam, 
Cambridge, UK), MTCO2 (1:1000, #ab91317, Abcam, Cambridge, UK), P62 (1:1000000, 
#5114, Cell Signaling Technology, Boston, MA, USA) and Parkin (1:1000, #4211, Cell 
Signaling Technology, Boston, MA, USA).  
 
Assessment of fusion and fission 
QPCR was performed in a total volume of 25 μl buffer solution containing 5 μl of template 
cDNA, 12.5 μl 2× SYBR Green Master mix (Applied Biosystems, Foster City, CA, USA), 
1.5 μl DEPC-treated MQ water and 15 μM of each primer. Primers (see Supplementary 
Table 4) were designed in Vector PrimerExpress software (Applied Biosystems). The 
cycling protocol was 95°C for 10 min followed by 40 reaction cycles at 95°C for 15 sec and 
at 60°C for 1 min, using a 7500 GeneAmp PCR system (Applied Biosystems). For each 
reaction, the cycle threshold (Ct) was determined, i.e., the number of cycles needed to 
detect fluorescence above the arbitrary threshold (0.8). At this threshold, Ct values are 
within the exponential phase of the amplification. Standard curves were included in 
duplicate with cDNA concentrations ranging from 6.25 to 100 ng cDNA per sample. Using 
these curves, in which every Ct value corresponds to a certain amount of cDNA, the 
quantity of cDNA was calculated for each sample with Applied Bioscience 7500 System 
Software. All data were normalized to GAPDH expression. 
 
Cloning of human SERAC1  
The full length open reading frame of SERAC1 was amplified from full length cDNA clone 
HsCD00323657 (PlasmID, DF/HCC DNA Resource Core, Boston, MA, USA) using specific 
primers with Gateway AttB flanking sites with an inframe stop codon (Supplementary 
Table 4). PCR amplification was performed with Phusion® High-Fidelity DNA Polymerase 
(New England Biolabs, Ipswich, MA, USA) according to the manufacturer’s protocol using 
HF buffer and an annealing and extension temperature of 72°C. Next, the product was 
cloned into the pDONR201 vector using the Gateway BP Clonase II Enzyme Mix 
(Invitrogen, Leek, The Netherlands) according to the manufacturer’s instructions. The 
resulting entry clone was verified by sequence analysis and subsequently recombined with 
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the pLenti6.2V5-DEST destination vector (Invitrogen, Leek, The Netherlands) using the 
Gateway LR Clonase II Enzyme Mix (Invitrogen, Leek, The Netherlands) according to the 
manufacturer’s protocol. 
 
 
 
Supplementary Figure 1. SERAC1 exome sequencing. For patient 3 (right side), 73 of 74 (99%) 
reads showed a C to T transition at chr6(hg19):g.158567859, indicating a homozygous 
r.442C>U transition at mRNA level which is predicted to result in a premature stop codon, 
(p.Arg148X). For patient 5 (left side), 50 of 52 (96%) reads showed a G to C splice site 
substitution at chr6(hg19):g.158538758 in the canonical donor splice site of exon 13. 
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Supplementary Figure 2. Haplotype analysis. Haplotypes of patients with identical 
mutations on one or both alleles. Black bars represent the haplotype segregating with the 
mutation resulting in skipping of exon 13 (c.1403+1G>C). White bars indicate the haplotype 
carrying the p.Ser498Thr change (c.1493G>C). The question mark indicates that it is uncertain 
which haplotype actually segregates with the mutation. Phase could not be determined 
because parents were not available for analysis. Grey bars represent the haplotype carrying 
with the exon 16 retention change (c.1822_1828+10delinsACCAACAGG). SNPs, rs6929520, 
rs6929274, rs9356399, and rs2502604 are respectively within exon 4, exon 4, exon 5, and 
exon 15 of SERAC1. Mutations are given underneath the respective haplotypes. 
 
 
Supplementary Figure 3. Effect of the c.1403+1G>C mutation on SERAC1 mRNA transcript. 
Shown is the normal transcript length of SERAC1 in fibroblasts of controls (C1, C2: 520 bp) 
and the transcript without exon 13 in fibroblasts of patient 5 (425 bp). Fibroblasts of the 
patient have been treated by cycloheximide before harvesting to inhibit nonsense mediated 
decay (NMD). PCR primers are given in Supplementary Table 4 and PCR conditions are 
available upon request. 
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Supplementary Figure 4. Effect of different mutations on SERAC1 expression. Effect of the 
c.442C>T (p.Arg148X; 3), c.1435_1437del (p.Leu479del; 4), and c.1403+1G>C (exon 13 
skipping; 5) mutations on SERAC1 expression. Shown are mRNA expression levels in 
fibroblasts of the respective patients 3, 4, and 5 as compared to the average expression level 
of SERAC1 in five controls. 
 
Supplementary Figure 5. Cross-species alignment of the functional domains of SERAC1. A) 
Alignment of lipase/esterase domain from human (Homo sapiens; Q96JX3), mouse (Mus 
musculus; Q3U213), chicken (Gallus gallus; ENSGALT00000022317), zebrafish (Danio rerio; 
Q5SNQ7), and fruit fly (Drosophila melanogaster; CG5455/CG10383). The box indicates the 
region containing the consensus lipase motif GxSxG119, 143. The deleted amino acid residue, 
Leu479, and the amino acid residues that are affected by the missense mutations, Gly401, 
Gly404, and Ser498 are highlighted by black boxes and conserved in all five species. In case of 
the fruit fly orthologues CG10383 and CG5455, respectively amino acid residues 382-495 and 
436-458, are not given, since these have no resemblance to an amino acid sequence in the 
other animal species. B) Alignment of the first 60 amino acid residues on the N-terminus 
containing the predicted N-terminal signal sequence and/or transmembrane domain (see also 
Supplementary Table 5).  
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Supplementary Figure 7. Cardiolipin species in patients and controls. A) Box and whisker 
plots (minimum/maximum) of individual cardiolipin (CL) species levels in controls (n=10) and 
patients (n=5). Significantly higher levels of cardiolipin (66:3), cardiolipin(66:4), 
cardiolipin(68:3), cardiolipin(68:4), and cardiolipin(68:5) were found in patients (see also 
Figure 3) which are the cardiolipin species that can be synthesized from phosphatidylglycerol 
(34:1). B) Representative cardiolipin spectra from a patient and a control. Crosses indicate the 
selected species presented in the box and whisker plots.  
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Supplementary Figure 8. Electron microscopy of muscle tissue of MEGDEL patient and 
healthy control. Left panel: electron microscopy of m. quadriceps of patient 1 showing 
aggregates of degrading mitochondria in striated muscle cell: mitochondrial cristae (arrows), 
and lysosomes with neutral fat droplets (asterisks) and membranous remnants (arrowheads, 
bar = 0.2μm). Right panel: electron microscopy of same muscle of healthy control for 
comparison. 
 
 
Supplementary Figure 9. Expression of mitochondrial and mitophagy markers in patients 
and control fibroblasts. Fibroblasts from patients P3, P4 and P5 and three controls were 
cultured under basal conditions or treated with 1μM valinomycin for 1h and Western blotting 
was performed with antibodies against GRP75, LC3, Mfn2, MTCO2, P62, and Parkin. A) Under 
basal conditions, protein levels of the investigated mitochondrial (GRP75 and MTCO2) and 
auto-/mitophagy (LC3, Mfn2, P62 and Parkin) markers were comparable in patients and 
controls. B) After valinomycin stress, ubiquitinated forms of Mfn2 were detected in all samples 
indicating comparable accumulation of dysfunctional mitochondria. Furthermore, a similar 
shift of the LC3-II to LC3-I ratio toward LC3-II, in line with elevated numbers of 
autophagosomes in the cells, was observed in patient and control cells. Protein levels of 
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GRP75, MTCO2, P62 and Parkin were comparable in both groups. β-actin expression served as 
loading control. GRP75 = glucose-regulated protein 75 (mortalin); LC3 = microtubule-
associated protein 1A/1B-light chain 3; LC3-I = soluble form of LC3; LC3-II = membrane-bound 
form of LC3; Mfn2 = mitofusin 2; MTCO2 = mitochondrial cytochrome c oxidase subunit II; P62 
= sequestosome-1; Ub-Mfn2 = ubiquitinated mitofusin 2. 
 
 
 
Supplementary Figure 10. Assessment of fusion and fission in patient and control fibroblasts. 
Semi-quantitative immunohistochemistry (upper panel) and QPCR (lower panel) showed now 
difference in expression of fusion and fission markers between patients (black bars) and 
control fibroblasts (white bars). 
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Supplementary Figure 11: Expression of SERAC1 in different human tissues. Expression of 
SERAC1 by mRNA expression analysis in human fetal and adult tissues. Relative expression 
levels are given as the fold change in comparison to the tissue with the lowest expression 
level. 
 
 
Supplementary Figure 12. Phosphatidylserine, phosphatidylethanolamine, and 
phosphatidylcholine species ratios in patient fibroblasts complemented with wild type 
SERAC1. Fibroblasts from patients were infected with a mock vector (n=4) or an expression 
vector containing wild type SERAC1 (n=4). Complementation of SERAC1 (for Western blot see 
Supplementary Figure 13) does not affect the phosphatidylserine (PS) PS(34:1)/PS(36:1), 
phosphatidylethanolamine (PE) PE(34:1)/PE(36:1), and phosphatidylcholine (PC) 
PC(34:1)/PC(36:1) ratios. The phophatidylinositol (PI) PI(34:1)/PI(36:1) ratio could not be 
calculated since the amount of PI(34:1) is below the detection level in both mock and SERAC1-
infected cells. Total levels of these four phospholipids were unaffected as well (data not 
shown). 
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Supplementary Figure 13. SERAC1 expression in stably infected patient fibroblasts. Western 
blot analysis of patient fibroblasts stably infected with pLenti6.2-SERAC1 or the control 
construct pLenti6.2V5-AcGFP. Shown is the expression of SERAC1 and the loading control β-
actin. SERAC1 infected fibroblasts from patient 4 (lane 1,3) and 3 (lane 2,4) showed increased 
expression of SERAC1 (lane 1,2) as compared to the fibroblasts infected with GFP only (lane 
3,4). No SERAC1 was visible in GFP-infected fibroblast from patient 4 (lane 4) since the protein 
is shortened due to the truncating mutation and the SERAC1 antibody is directed against the 
C-terminal part of the protein that is not present anymore in this patient. 
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  Patient 5 Patient 3 
Total number of sequenced reads (×106) 124.46 133.81 
Total number of mapped reads (×106) 96.52 107.57 
Total number of bases mapped (Gb) 4.54 5.12 
Total bases mapping to targets (Gb) 3.89 4.33 
% targets with 10x coverage 82 80 
Mean target coverage (fold) 68 73 
Median target coverage (fold) 53 56 
QC filtering* 23,231 23,470 
After exclusion of nongenic, intronic & synonymous variants 5,405 5,320 
After exclusion of known variants 213 240 
Of which fit a recessive model of disease** 21 17 
Gene(s) with mutation in both patients 1 (SERAC1) 
Supplementary Table 2. Raw sequencing statistics and prioritization of variants. * >5 unique 
variant reads and >20% of all reads, **>70% variant reads 
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Start SNP End SNP Chr. Start 
position 
End 
position 
Size 
(Mb) 
% exons 
covered 
<10x 
Median 
coverage 
per exon 
Patient 3        
SNP_A-2200063 SNP_A-2151802 2 152,051,481 163,277,032 11.2 3.1 100 
SNP_A-2050760 SNP_A-1898944 7 46,239 9,744,833 9.6 36.4 52 
SNP_A-2186469 SNP_A-2109663 4 1,128,925 9,968,684 8.5 27.9 60 
SNP_A-2204105 SNP_A-1883568 11 12,072,213 20,006,336 7.9 9.2 71 
SNP_A-2077486 SNP_A-1937604 20 55,392,174 62,535,594 7.2 46.0 31 
SNP_A-2186392 SNP_A-2158961 4 23,757,800 30,390,253 6.6 6.7 84 
SNP_A-2058596 SNP_A-2241984 6 174,769 6,011,668 5.8 15.5 61 
SNP_A-2150721 SNP_A-2012220 6 154,074,079 160,018,988 5.8 7.8 78 
SNP_A-1835443 SNP_A-4237011 6 148,740,251 154,056,121 5.3 5.5 76 
        
Patient 4        
SNP_A-2028616 SNP_A-2107608 2 153,527,691 199,457,084 45.9   
SNP_A-1849616 SNP_A-2249544 8 78,593,899 122,515,531 43.8   
SNP_A-1908661 SNP_A-2290879 1 205,608,153 232,419,619 26.6   
SNP_A-2110513 SNP_A-1880093 9 82,562,184 107,751,593 25.0   
SNP_A-1980980 SNP_A-4232001 5 23,630,961 46,383,335 22.8   
SNP_A-2284739 SNP_A-2223106 1 142,569,068 163,772,455 20.5   
SNP_A-4230532 SNP_A-2137016 8 126,885,591 146,292,734 19.3   
SNP_A-1981478 SNP_A-1863137 5 49,560,859 68,720,419 19.2   
SNP_A-2035113 SNP_A-1886785 5 70,701,990 87,566,731 16.9   
SNP_A-2183027 SNP_A-1862731 2 110,285,766 124,754,515 14.8   
SNP_A-2118367 SNP_A-4223408 1 238,548,667 249,143,646 10.5   
SNP_A-1820584 SNP_A-1919785 6 156,850,664 165,588,607 8.6   
SNP_A-4225410 SNP_A-2078652 1 113,101,799 121,251,791 8.1   
SNP_A-4214375 SNP_A-2162165 15 80,902,266 86,758,895 5.9   
SNP_A-2091399 SNP_A-4197277 11 45,665,915 51,563,636 5.8   
SNP_A-4237484 SNP_A-1996154 9 14,244,413 19,925,073 5.7   
        
Patient 5        
SNP_A-2074590 SNP_A-1988005 6 130,217,785 146,960,353 16.7 4.3 102 
SNP_A-4239249 SNP_A-4240714 15 85,477,430 95,642,676 10.2 18.3 68 
SNP_A-1933498 SNP_A-1805304 6 150,367,320 160,154,099 9.7 6.3 87 
SNP_A-1793270 SNP_A-2262914 12 72,610,000 81,027,095 8.7 5.1 104 
SNP_A-1917086 SNP_A-4199152 2 224,951,090 233,227,833 8.3 7.4 96 
SNP_A-2280193 SNP_A-1806609 16 51,693,011 59,588,971 7.9 22.1 63 
SNP_A-2017397 SNP_A-2018641 21 29,385,244 36,789,212 7.4 9.1 84 
SNP_A-2234180 SNP_A-2298494 15 71,956,136 79,214,192 7.3 24.5 64 
SNP_A-1866954 SNP_A-4232940 15 79,264,037 85,175,750 5.9 14.5 73 
Supplementary Table 3. Homozygous regions (<5 Mb) in patients 3, 4, and 5 as determined 
by homozygosity mapping. The region containing SERAC1 on chromosome 6 is printed in bold. 
Positions are according to UCSC Human Genome Browser, Hg19. 
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 Forward primer (5’→3’) Reverse primer (5’→3’) 
 Sequencing 
Exon 2  tggaaagttttcttcgtagtcttg gggcctataaatttggggtg 
Exon 3 tgtgtgtttgtgtctaaggatagg ccaagagaaagcactcctcag 
Exon 4 cgatggctactcagtcactagg caggaacttggttttcacgg 
Exon 5 ttgaaacgttggagcatagtg ggcctgattaattttccatagc 
Exon 6 gagccacgattgtgtcactg tgaccttgtgatccaaccag 
Exon 7 ttgcacttgggaaattttgg atagaaggaacagcccctcc 
Exon 8 ctgggtgggtgactgttttc ttcatttacctgcctccctg 
Exon 9 cttgacgaggacacaggttg gccacatttagatgataggctg 
Exon 10 tccaaccaagagctaagcag tgaacatatcatgaggggtagag 
Exon 11 acttctccgccaaggacag caacctccaattcttttgtgg 
Exon 12 gttttcccagcaaacctgtg ccctaagggaaagaagaactg 
Exon 13 tggtaccacttcgagaccag ccactgcttattgacagcaaac 
Exon 14 ggggccaggagttcaataag gagaaaggaacagcatggaac 
Exon 15 ccctgtttgtaggcttgcac agcccaacccaaaatttcc 
Exon 16 cttagtggcttcttggcagg gcagggagaggtaatacccg 
Exon 17 tgcaatcaaacttcaggttcc tctgcaacacactccagacc 
 RT-PCR analysis 
RT-PCR ctcaggctgggtttccatc tccacaaaattcagcacctg 
 QPCR analysis 
GUSB (NM_000181.1) agagtggtgctgaggattgg ccctcatgctctagcgtgtc 
PPIB (NM_000942.4) cggaaagactgttccaaaaac gattacacgatggaatttgctg 
SERAC1 
(NM_032861.3) 
tctcctaccacctcctttgc ggtaaggaagccagcaactg 
DRP1 cgccgacatcatccagct tctccgggtgacaattccag 
FIS1 gtctgtggaggacctgctgaa ttgctccgcaccaggc 
MFN1 ccatcattggtgaggtgctatc acaacattgcattgataacagagct 
OPA1 tgtgaggtctgccagtctttagtg tgtccttaattggggtcgttg 
 STR markers analysis 
D6S415 gaccagatgggtgactacctg ggccaccagaagtaaagcag 
D6S1612 ccagtgaattaaggcctcgtc ccttggcgacagagtgaaac 
D6S1655 caggacatggacattcagacc agcagacctccaaaacaagc 
D6S95 tcggattagtttgctgtaccc gcttgggcaacaagagtaaaac 
D6S437 aatgatcactgctaggcttcc cattttccctgctgtggtg 
D6S1614 tcagaatgtttgtgcgtgtg ttctgcttggggcttattatg 
D6S969 gcatccattgaagtttcttcc aatccacaagtccatactgagg 
AFM291VC1 aggtgagcttccttgaccac tctgtcgacctggtcatttg 
 Cloning  
Forward primer ggggacaagtttgtacaaaaaagcaggcttcgaaggagatagaaccatgtccctggctgcttattgcgtcatc 
Reverse primer ggggaccactttgtacaagaaagctgggtcctagttttcaaggtctttggctaaagcttcacg 
Supplementary Table 4: Primer sequences . Primer sequences of primers used for direct DNA 
sequencing, RT-PCR, QPCR analysis and cloning of SERAC1 (NM_032861.3). Primers for STR 
marker analysis to determine the haplotypes in patients 5, and 10-15 are given without their 
M13 tails. 
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Organism Protein ID Gene ID Identity Lipase 
domain 
TM domain 
(HMMTOP)20 
TM domain 
(TMHMM)21 
Homo 
Sapiens 
NP_116250 SERAC1 100% 396-540 - -* 
Mus 
Musculus 
Q3U213 SERAC1 87% 396-540 - 32-54* 
Gallus Gallus ENSGALT0000
0022317 
SERAC1 64% 323-469 - -* 
Danio Rerio Q5SNQ7 SERAC1 61% 398-544 36-53 -* 
Droso-phila 
Melano-
gaster 
NP_609896 
NP_651481 
CG10383 
CG5455 
22% 
18% 
357-623 
411-582 
16-32 
625-644 
16-33* 
- 
Supplementary Table 5: Structure of SERAC1 in different vertebrates and the fruit fly. 
Structure of SERAC1 in different vertebrates and the fruit fly. Domains are given from first to 
last amino acid residue. The lipase domain is fully conserved from human to fruit fly. 
*TMHMM predicts a N-terminal signal sequence. 
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Abstract 
 
Elevated urinary excretion of 3−methylglutaconic acid is considered rare in patients 
suspected of a metabolic disorder. In 3−methylglutaconyl−CoA hydratase deficiency 
(mutations in AUH), it derives from leucine degradation. In all other disorders with 
3−methylglutaconic aciduria the origin is unknown, yet mitochondrial dysfunction is 
thought to be the common denominator. We investigate the biochemical, clinical and 
genetic data of 388 patients referred to our centre under suspicion of a metabolic disorder 
showing 3−methylglutaconic aciduria in routine metabolic screening. Furthermore, we 
investigate 591 patients with 50 different, genetically proven, mitochondrial disorders for 
the presence of 3−methylglutaconic aciduria. Three percent of all urine samples of the 
patients referred showed 3- methylglutaconic aciduria, often in correlation with disorders 
not reported earlier in association with 3−methylglutaconic aciduria (e.g. organic acidurias, 
urea cycle disorders, haematological and neuromuscular disorders). In the patient cohort 
with genetically proven mitochondrial disorders 11 % presented 3−methylglutaconic 
aciduria. It was more frequently seen in ATPase related disorders, with mitochondrial DNA 
depletion or deletion, but not in patients with single respiratory chain complex 
deficiencies. Besides, it was a consistent feature of patients with mutations in TAZ, 
SERAC1, OPA3, DNAJC19 and TMEM70 accounting for mitochondrial membrane related 
pathology. 3−methylglutaconic aciduria is found quite frequently in patients suspected of a 
metabolic disorder, and mitochondrial dysfunction is indeed a common denominator. It is 
only a discriminative feature of patients with mutations in AUH, TAZ, SERAC1, OPA3, 
DNAJC19 and TMEM70. These conditions should therefore be referred to as inborn errors of 
metabolism with 3−methylglutaconic aciduria as discriminative feature. 
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Introduction 
 
In the urine of healthy individuals the branched-chain organic acid 3−methylglutaconic acid 
(3−MGA) is found only in traces. Elevated urinary excretion of 3−MGA (3−MGA−uria) was 
First described in patients with 3−methylglutaconyl−CoA hydratase deficiency (former type 
I, AUH, MIM ID: #250950), a defect of leucin catabolism leading to a late onset 
leukoencephalopathy26. 
 
Figure 1 Shunting between Cholesterol biosynthesis and Leucine catabolism. AUH = 
3−methylglutaconyl−CoA hydratase (enzyme deficient in 3−MGA−uria type I). HMG−CoA = 3-
hydroxy-3-methylglutaryl CoA (adapted from103). 
 
Only in 3−methylglutaconyl−CoA hydratase deficiency the origin of 3−MGA is known, 
therefore it can be considered a “primary 3−MGA−uria”. This is in contrast to all other 
disorders in which 3−MGA−uria is seen, where the pathomechanismunderlying this 
biomarker is still not elucidated. However, 3−MGA−uria is the hallmark of several 
phenotypically heterogeneous but highly distinctive “3−MGA−urias” which were given 
Roman numbers randomly (Barth syndrome (former type II, TAZ, MIM ID: #302060), 
Costeff syndrome (former type III, OPA3, MIM ID: #258501) and DCMA syndrome (former 
type V, DNAJC19, MIM ID #610198)). Besides these well defined syndromes, there is a 
confusing and ever growing subgroup encompassing all “unclassified” patients, designated 
3−MGA−uria type IV (MIM ID 25951). 
Recently the underlying genetic defects of several of these disorders were elucidated 
allowing more insight into the underlying pathophysiology. Combined with the findings 
presented in this paper, we propose a proper pathomechanism based classification and 
new nomenclature of these “inborn errors of metabolism (IEM) with 3−MGA−uria as 
discriminative feature” which is presented in a separate article in this issue of JIMD 
(Wortmann et al JIMD 2013).To prevent confusion we will use the new nomenclature in this 
article as well. The old and new nomenclature are shown in parallel in Table 1. 
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 New nomenclature (affected gene) Old nomenclature 
Inborn errors with 3−MGA−uria as discriminative feature 3−MGA−uria 
Primary  
3−MGA−uria 
3−methylglutaconyl−CoA hydratase deficiency (AUH) 3−MGA−uria type I 
Secondary  
3−MGA−uria 
TAZ defect or Barth syndrome (TAZ) 3−MGA−uria type II 
OPA3 defect or Costeff syndrome (OPA3) 3−MGA−uria type III 
SERAC1 defect or MEGDEL syndrome (SERAC1) 3−MGA−uria type IV 
DNAJC19 defect or DCMA syndrome (DNAJC19) 3−MGA−uria type V 
TMEM70 defect (TMEM70) 3−MGA−uria type IV 
Not otherwise specified (NOS) 3−MGA−uria 3−MGA−uria type IV 
Table 1 . New and old nomenclature. 
 
After exclusion of the well-defined syndromes described above, each patient with elevated 
urinary 3−MGA has always been labelled as 3−MGA−uria type IV (MIM ID: 250951). This 
rapidly growing, clinically heterogeneous group challenges the physician in planning 
further diagnostic steps and does lead to serious confusion. Does 3−MGA−uria always 
indicate a mitochondrial disorder? Are there specific mitochondrial disorders one should 
search for in patients with 3−MGA−uria? Has every patient with an occasionally elevated 
urinary 3−MGA to be labelled 3−MGA−uria type IV? 
In this study we address these questions above with a bidirectional approach by evaluating 
977 patients. Group 1 patients (n=388) were referred to our hospital in the period 1992–
2010 and had increased urinary 3−MGA. We report the clinical, biochemical and genetic 
data on these patients, which will reflect the diversity of underlying causes of 3- MGA 
excretion. Group 2 consisted of 589 patients with a vast array of 50 genetically proven 
mitochondrial disorders in whom organic acid analysis in urine had been performed. The 
group was included to evaluate the occurrence of 3- MGA-uria in mitochondrial disorders. 
 
Material and methods 
 
Urinary organic acid analysis 
Urinary organic acid analysis was performed by gas chromatography/ mass spectrometry 
(GC−MS) on a HP 6890 Gas Chromatograph (Agilent, Amstelveen, The Netherlands). 
3−MGA was quantified on the basis of an in house synthesized 3−MGA model compound. 
For quantification purposes flame ionisation detection with standard calibration curve was 
used. The reference range for urinary 3−MGA was 0–20 mmol/mol creatinine and has been 
established on ahealthy subject population in our laboratory. In selected cases additionally 
1H-NMR spectroscopy on a Bruker DRX 500 spectrometer was performed19. 
 
Group 1: diagnoses and sampling circumstances in patients with 3−MGA−uria; inclusion and 
exclusion criteria  
The Radboud University Nijmegen Medical Centre (RUMC) is a tertiary academic referral 
centre in the Netherlands with afocus on mitochondrial disorders. The database of the 
Laboratory of Genetic, Endocrine and Metabolic Diseases (LGEM) at the RUMC was 
searched for all patients with elevated urinary 3−MGA excretion of > 20 mmol/mol 
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creatinine in the period 1992–2010. The charts of these patients were reviewed for the 
clinical circumstances at the time of sampling and for the diagnoses. Inclusion criteria: i) 
referral of the patient to RUMC under suspicion of a metabolic disorder (patients from 
whom only urine was received for analysis were not included), ii) routine metabolic 
screening completed (urinary organic acid analysis; serum lactate, amino acid and carnitine 
profile analysis, transferrin isoelectric focussing, and upon indication urine oligosaccharide 
analysis). Exclusion criteria: i) multi-organ-failure or ii) total parenteral nutrition at the 
moment of sampling.  
 
Group 2: patients with genetically proven mitochondrial disorders 
We aimed to investigate the excretion of 3−MGA in patients with genetically proven 
pathogenic mutations causing a mitochondrial disorder. As such we have considered 
patients with pathogenic mutations in nuclear or mitochondrial genes involved in the 
biogenesis and assembly of oxidative phosphorylation system (OXPHOS) complexes, 
mitochondrial nucleotide synthesis and transport, mitochondrial DNA replication and 
translation, mitochondrial protein processing and quality control, mitochondrial protein 
import, mitochondrial membrane biogenesis and maintenance, pyruvate metabolism and 
tricarboxylic acid (TCA) cycle. We have reviewed the clinical and  aboratory files of patients 
under treatment in our hospital or under the care of one of our coauthors. Furthermore, we 
have searched the PubMed database for papers describing patients with genetically 
provenmitochondrial disorders of whom the results of urinary organic acid analysis were 
included in the paper. 
 
Results 
 
Group 1: diagnoses and sampling circumstances in 388 patients with 3−MGA−uria 
Searching the database of the LGEM at the RUMC revealed 20991 urinary organic acid 
profiles measured between 1992 and 2010. In 647 (3 %) samples of 388 patients 
3−MGA−uria was detected. Of these patients 69 did not fulfil the inclusion criteria, another 
92 met the exclusion criteria (see 2.2), consequently 227 patients were eligible for further 
investigations. 
The results are summarized in Table 2, and more details about the diagnosed disorders and 
the urinary organic acid results can be found in the supplementary data. Sixty onepatients 
were diagnosed with a classical metabolic disorder, 43 patients with other, non-metabolic 
disorders (see Table 2A, B). A subgroup of 23 patients were diagnosed with an inborn errors 
of metabolism with 3−MGA as discriminative feature (see Table 2C). 
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Diagnosis n frequency Max. 3−MGA 
(mean)* 
Other 
metabolites? 
A Classical metabolic disorders 61    
Fatty acid oxidation disorder (FAOD) 22 P/D 42 (26) Y 
Methylmalonic aciduria (MMA) 4 P/D 55 (39) Y 
Propionic aciduria (PA) 6 P/D 94 (42) Y 
Glycogen storage disorder (GSD) 18 P/D 82 (44) Y 
Urea cycle disorder (UCD) 6 P/D 152 (52) Y 
Other metabolic disorder 5 SE 47 (34) Y 
B Other non-metabolic disorders 43    
Hematological disorder 4 R, SE 35 (27) N,Y 
Neuromuscular disorder (see also Table 3) 13 R, SE 50 (28) N,Y  
Genetic syndrome/ chromosomal abnormality 15 R, SE* 46 (27) N,Y 
Apparently life-threatening event (ALTE)/ 
sudden infant death syndrome (SIDS) 
6 SE 48 (33) N 
other 5 SE* 43 (34) N,Y 
C Inborn errors with 3−MGA−uria as discriminative 
feature 
23    
3−methylglutaconyl−CoA hydratase deficiency 
(AUH) 
3 R 142 
(120)*** 
N** 
TAZ defect or Barth syndrome (TAZ) 1 R 97 (55) N 
OPA3 defect or Costeff syndrome (OPA3) 1 R 43 (43) N 
TMEM7defect (TMEM70) 6 R 121 (83) N 
SERAC1 defect or MEGDEL syndrome (SERAC1) 9 R 196 (103) N 
NOS 3−MGA−uria 3 R 75 (47) N 
D remaining patients 100    
Mt disorder 49 R,SE 60 (29) N,Y 
Hypoglycemia 10 SE 42 (26) N,Y 
Ongoing investigations 41 R,SE 70 (32) N,Y 
Table 2. Diagnosis and sampling circumstances 227 patients with 3−MGA−uria. Diagnosis and 
sampling circumstances in 227 patients with 3−MGA−uria. Gene names in italics, 3−MGA−uria 
= 3−methylglutaconic aciduria, * mmol/mol creatinine, **with exception of 3-Hydroxy-
isovaleric aciduria, *** in literature values up to 1000 mmol/mol creatine are reported; P/D = 
upon presentation or deterioration, R = repetitively, SE = single episode. 
 
Of the remaining 100 patients (see Table 2D), 49 patients were diagnosed with a 
mitochondrial disorder. Of them 18 had a genetically proven diagnosis and in the other 31 
patients single or multiple OXPHOS enzyme deficiencies were found in muscle. Patients in 
whom a decreased ATPproduction was found without evidence for single or multiple 
OXPHOS enzyme deficiency were considered as “possible” mitochondrial disorder, and 
therefore not included in this group. Ten patients had (mostly isolated) 3−MGA−uria during 
a single hypoglycaemic episode throughout a febrile illness, mostly of gastroenterological 
origin, in early childhood. Despite extensive metabolic investigation no underlying 
metabolic disease was detected in these patients and they are all doing well during follow 
up of up to 15 years. In 41 patients with isolated or combined presentation of multisystem 
disorder, psychomotor retardation, leukoencephalopathy,syndromal appearance, 
myopathy, spastic paraparesis, cataract, neurodegenerative disease, polyneuropathy 
and/or movement disorders the investigations are ongoing. From the latter group 11 
patients showed decreased ATP production without OXPHOS complex deficiencies in a 
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fresh muscle biopsy, three had biochemically and histologically normal biopsies, the 
remaining 30 did not undergo muscle biopsy. 
 
 Diagnosis (affected gene) UOA: 3−MGA value(s)* UOA: other findings 
1 Congenital merosin negative muscle 
dystrophy (NA) 
32 none 
2 Congenital merosin negative muscle 
dystrophy (NA) 
24, 25, 23, 17, 8, 13 once ketotic profile, always 
EMA 
3 Congenital Actine Filament aggregation 
myopathy without nemaline rods (NA)** 
26, 12 none 
4 Duchenne Muscular Dystrophy 
(DMD)*** 
23, 13 EMA, lactate, succinic acid 
5 Lipid myopathy (NA) 22 none 
6 Multi-minicore myopathy (RYR1) 21 none 
7 Multi-minicore myopathy (RYR1) 37, 26, 24, 18 TCA intermediates, once 
ketotic profile 
8 SMA (SMN1) 41 MMA, EMA 
9 SMA (SMN1) 23 EMA, mild elevation of 
dicarbonic acids 
10 SMA (SMN1)**** 23; 18 EMA 
11 SMA (SMN1)**** 27, 27, 25, 25, 19, 19, 19 EMA, adipic and suberic 
acid, TCA cycle 
intermediates 
12 SMA (SMN1) 22 EMA 
13 Muscular Dystrophy (NA) 50, 46 none 
Table 3. Details on 13 patients with neuromuscular disorders and 3−MGA−uria. EMA = 
ethylmalonic aciduria, MMA = methylmalonic aciduria, NA = not available, SMA = spinal 
muscular atrophy, UOA = urinary organic acid analysis, * inmmol/mol creatinine (ref. 0–20) in 
chronological order; ** low serum citrulline, ***prednisone treatment, **** SCADD 
excluded genetically. 
 
Group 2: 3−MGA−uria patients with genetically proven mitochondrial disorders 
For a total of 591 patients carrying pathogenic mutations in 50 nuclear genes or the 
mitochondrial DNA we could retrieve the urinary organic acid results. This encompasses 
202 patients from our centre or under the care of one of our co-authors and 389 patients 
from the literature. The data are summarized in Table 4. 
 
Discussion 
 
3−MGA−uria is a rather common finding in patients suspected of a metabolic disorder  
3−MGA−uria was thought to be a rare finding in patients suspected of a metabolic disorder. 
Unexpectedly, we observed it in nearly 3 % of all samples received for urinary organic acid 
analysis at our centre in the last 18 years. 3−MGA−uria was frequently seen in association 
with several metabolic disorders, such as organic acidurias, glycogen storage disorders 
(GSD), fatty acid oxidation disorders (FAODs), urea cycle disorders.  
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3−MGA−uria is mostly correlated with mitochondrial dysfunction 
A relation with mitochondrial dysfunction undoubtedly accounts for most patients with 
3−MGA–uria. Ten percent of all 3−MGA−uria patients were diagnosed with FAODs (see 
Table 2A), in fact primary mitochondrial disorders. 3−MGA−uria was also found frequently 
in patients presenting with a metabolic crisis due to an organic aciduria. Propionyl-CoA has 
been shown to non-competitively inhibit pyruvate dehydrogenase complex (PDHc, 146), 
also multiple OXPHOS deficiency in different tissues was detected in organic aciduria 
patients 147. 
Mitochondrial dysfunction also may play a role in urea cycle disorder patients showing 
3−MGA−uria. It is proven in rodents, that hyperammonemia inhibits the TCA cycle enzyme 
α-ketoglutarate-dehydrogenase and activates the N-methyl D-aspartate (NMDA) receptor 
leading to disturbed calcium homeostasis and secondary mitochondrial dysfunction148.This 
theory is supported by the frequent co-finding of TCA cycle intermediates and lactate in 
our urea cycle disorder patients with 3−MGA−uria. 
We also tentatively postulate mitochondrial dysfunction as underlying cause for 
3−MGA−uria in a group of 37 patients diagnosed with other non-metabolic disorders (Table 
2B). However, we can only partly prove this, as only five of the patients underwent a 
muscle biopsy which showed disturbed mitochondrial function before the final diagnosis 
was made. On the other hand often lactic acidosis or alanine elevation pointed towards 
mitochondrial dysfunction. In 13 of these 37 patients, a muscle biopsy was only 
investigated histologically leading to the diagnosis of a neuromuscular disorder (see Tables 
2B and 3). The consistent finding of 3−MGA−uria in this patient group could be a sign of 
mitochondrial dysfunction. For two classical neuromuscular disorders mitochondrial 
dysfunction has recently been reported. In myoblasts of the mdx mouse, a well established 
mouse model of DMD, an impaired cellular energy metabolism due to abnormal calcium 
homeostasis, reduced amounts of OXPHOS complexes and ATP synthase as well as 
disorganized mitochondrial network were observed149. Furthermore, energy shortage and 
increased mitochondrial free radical production leading to cell damage was also recently 
shown in a neural cellmodel of SMA150, suggesting mitochondrial dysfunction as important 
pathology underlying SMA. 
 
3−MGA−uria in correlation with impaired cholesterol biosynthesis 
The mevalonate or Popjak shunt links cholesterol biosynthesis with leucine catabolism 
(Figure 1). In patients with Smith Lemli Opitz syndrome elevated 3−MGA-levels have been 
reported in seven of 35 patients12. We did not detect 3−MGA−uria in eight Smith Lemli 
Opitz syndrome patients on cholesterol/simvastatin treatment. 
However, the earlier reported patients, were untreated patients with very low cholesterol 
levels (< 0.129 mmol/L, reference range not given 12), suggesting that it only occurs in 
untreated patients on the severe end of the Smith Lemli Opitz syndrome -spectrum or with 
high cholesterol precursors12. We also did not detect 3−MGA−uria in three patients with 
Mevalonate kinase deficiency, another defect of cholesterol biosynthesis. However, the 
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HMG salvage pathway has recently been proven to account for the elevated 3−MGA 
production in a zebrafish model of Costeff syndrome. The authors showed, that 
simvastatin inhibited mevalonate production from extramitochondrial HMG−CoA, which 
leads to elevated 3−MGA levels (see Figure 1, 54). This shunt should explain the 3−MGA−uria 
found in 18 of our patients, later diagnosed with GSD I or IX. The finding of 3−MGA−uria 
was reported earlier in one patient with GSD 1b79 An imbalanced homeostasis between 
disturbed gluconeogenesis and cholesterol synthesis is supposed to increase the shunting 
towards 3−MGA production. One should keep the differential diagnosis of a GSD in mind 
when facing a patient with elevated lactate, 3−MGA−uria and hepatomegaly clinically 
suspected of a mitochondrial disorder. Possibly the 3−MGA−uria in two of the patients with 
haematological disorders, and the Duchenne patient is also related to cholesterol 
metabolism as the patients were treated with glucocorticosteroids for a long time. 
 
Differential diagnosis in patients with 3−MGA−uria. 
After excluding the described patient groups (see Table 2A, B, C) a group of 100 patients 
with 3−MGAuria (Table 2D) remained. Primary mitochondrial dysfunction defined by either 
single or multiple OXPHOS deficiency or genetically proven mitochondrial disorder was 
found in half of the patients. No disorder could be established in spite of extensive 
investigations in ten patients with a single hypoglycaemia during febrile illness in early 
childhood and in four patients with ALTE. These children are all doing well during long 
years of follow up. One may postulate an underlying disorder in (energy) metabolism 
which is only clinically significant in a limited time window in early childhood. The 
remaining group of 41 patients, mostly presenting with progressive neurodegenerative 
disorders, in whom investigations are ongoing is surely an interesting and challenging 
group. However, this group is clinically very heterogeneous, and most of the patients only 
showed 3−MGA−uria occasionally and mildly elevated. One should therefore not overrate 
the diagnostic value of 3−MGA−uria in these patients, but keep an eye open for all 
diagnostic features of a patient (e.g. physical examination, dysmorphic features, 
biochemical results, radiological results). 
 
Correlation of 3−MGA−uria with specific mitochondrial disorders 
Mutations in TAZ, OPA3, TMEM70 and SERAC1, respectively, are virtually always 
associated with 3−MGA−uria (88–100% of cases see Table 4). These patients show 
repetitively and consistently increased urinary 3−MGA, which is also substantially higher as 
in other disorders (see Table 2). There are no other diagnostic urinary metabolites found 
beside 3−methylglutaric acid. Hence, the 3−MGA−uria is a major finding, a hallmark of the 
phenotype and often the key to the diagnosis. These disorders, as well as 
3−methylglutaconyl−CoA hydratase deficiency (AUH defect), should be referred to as IEM 
with 3−MGAuria as discriminative feature. Interestingly, they are all related 
tomitochondrialmembrane pathology in the broadest sense. 3- MGA-uria is frequently 
seen in patients with mutations in AGK (70 %). In most cases the excretion is <40 mmol/mol 
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creatinine. One should not label these patients IEM with 3- MGA-uria as discriminative 
feature as the clinical and biochemical phenotype is too diverse. Three patients presented 
with isolated cataract 151, and all turned out to have 3−MGA−uria (F. Alkuraya, personal 
information). The other end of the spectrum of patients with AGK mutations is Sengers 
syndrome with cataracts and (cardio)myopathy with four out of seven patients being 
reported with 3−MGA−uria. 
We found 3−MGA−uria in 11 % of all patients with a proven (“primary”) mitochondrial 
disorder. There are three subgroups of patients in which 3−MGA−uria could be helpful in 
the diagnostic work up. 
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The first subgroup with a high correlation of disease mechanism and 3−MGA−uria, are the 
patients with mitochondrial deletion leading to the Pearson phenotype. Of these patients 
30 % are reported with 3−MGA−uria72-74, 152, 153. Curiously, mitochondrial deletions 
presenting with the Kearns-Sayre phenotype do not lead to 3−MGA−uria. The finding of 
3−MGA−uria in a patient presenting with refractory anemia should lead the physician to 
mitochondrial DNA deletion screening in several tissues, hence sparing the patient a bone 
marrow aspiration. 
Two other patient subgroups show 3−MGA−uria in 10.3 and 12 % of patients, respectively. 
These are patients with ATPase deficiency related pathology and patients with 
mitochondrial depletion syndromes. 
3−MGA−uria is seen less frequently in patients with complex I-related mutations (5.7 %) 
and until now not found in relation with complex II, III or IV mutations. In contrast, both 
patients with ATPase related mutations (ATP5E, ATP12) did have 3−MGA−uria, as had one 
of the MTATP6 patients. Combining this with the consistent 3−MGA−uria found in 95% of 
patients with TMEM70 defect, this makes a link of 3−MGAuria and ATPase-dysfunction or -
related processes affecting the mitochondrial membrane more likely. One should still keep 
in mind, that the investigated mutations are very rare and often only one patient in each 
category is reported. Furthermore, patients with mitochondrial depletion syndromes 
(POLG, SUCLG1, SUCLA2 and TWINKLE mutations) more often show 3−MGA−uria. Strictly 
SUCLG1 and SUCLA2 are genes involved in the TCA cycle, given the fact that they lead to a 
typicial mitochondrial depletion syndrome, we chose to group the patients here 104. In 
patients with a phenotype suggestive for a mitochondrial depletion syndrome 3−MGA−uria 
makes this suspicion stronger. One limitation of this group is, that 3−MGA−uria was mainly 
found in the patient population of the contributing authors. This could be due to the fact, 
that these Laboratories are able to quantify 3−MGA in urine and therefore are able to 
detect slight elevations (20–40 mmol/mol creatinine). Other laboratories may often report 
3−MGA−uria only if more substantial (>40 mmol/mol creatinine ) as is the case in the IEM 
with 3−MGA−uria as discriminative feature. Furthermore, there is again a limited number 
of patients reported, often in genetic or neurological journals without describing the 
metabolic findings beside lactic acidosis. In addition there are depletion syndromes with 
pure myopathic presentation in which a muscle biopsy rather than metabolic work-up is 
chosen as diagnostic approach. However, the correlation could help the physician in search 
for the diagnosis. 
3−MGA−uria has not been found in association with defects in mitochondrial translation, 
again with the limitation of small patient numbers of these newly found group of diseases. 
Mutations in DNAJC19 underlie DCMA syndrome. All described 19 patients had 
3−MGA−uria. DNAJC 19 is suspected to be involved in mitochondrial protein import. In 
contrast, we did not find 3−MGA−uria in five patients with Mohr-Tranebjaerg syndrome 
(TIMM8A), a dystonia-deafness syndrome in which a similar pathomechanism is suspected. 
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TAZ and OPA3 defect are both suspected to alter mitochondrial membrane biogenesis and 
maintenance (“fusion/fission”). Contradictory no patients with 3−MGA−uria and OPA1 
mutations, also leading to a defective fusion/fission, have been found. 
3−MGA−uria is seen in multiple acyl-CoA dehydrogenase deficiency (MADD, Glutaric 
aciduria IIc) patients with mutations in ETFDH. The defect affects fatty acid, amino acid 
and choline metabolism, but certainly mitochondrial dysfunction is present in this complex 
disorder. 
 
Conclusions 
 
3−MGA−uria is a rather common finding in patients suspected of a metabolic disorder. In 
most patients it is seen in association with mitochondrial dysfunction. The majority of 
patients can be diagnosed upon routine metabolic screening including urine 
oligosaccharide screening for the differential diagnosis of GSD. In the latter the 3−MGA 
probably stems from the cholesterol biosynthesis. The minority of patients suffers an IEM 
with 3−MGA−uria as discriminative feature, a diagnostic flowchart and more details on a 
pathomechanism based classification and nomenclature of these disorders is presented in 
an accompanying article in this issue of JIMD 154. 
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Supplementary results 
 
Group 1A: Classical metabolic disorders 
61 patients were diagnosed with classical metabolic disorders (see Table 2A).  
22 patients had 3−MGA−uria during crisis, based on which the following fatty acid 
oxidation (FAO) disorders were diagnosed: i.e. two carnitine palmitoyltransferase II 
deficiency (CPT2D), four very long-chain acyl-CoA dehydrogenase deficiency (VLCADD), 
four long-chain hydroxyacyl-CoA dehydrogenase deficiency (LCHADD), three medium-
chain acyl-CoA dehydrogenase deficiency (MCADD), four short-chain acyl-CoA 
dehydrogenase deficiency (SCADD), four multiple acyl-CoA dehydrogenase deficiency 
(MADD), one 3−hydroxy−3−methylglutary−CoA(HMG−CoA) synthase deficiency. Ten 
patients had 3−MGA−uria upon presentation with an organic aciduria (four methylmalonic 
aciduria (MMA), six propionic aciduria (PA)). In one of the MMA and all of the PA patients, 
3−MGA−uria was repeatedly seen upon metabolic derangement. The urine samples also 
exhibited the classical signs of MMA or PA, such as propionylglycine and 3-OH-propionic 
acid (PA patients), methylmalonic acid (MMA patients), 2-methylcitric acid (in both organic 
acidurias). Most of the urines also contained intermediates of the TCA cycle and elevated 
lactate. In 18 patients, a glycogen storage disorder (GSD) was diagnosed. The samples 
were taken randomly during the disease course of eight patients with GSD IX and upon 
presentation or metabolic crisis of ten GSD Ia/b patients. Often, also a mild to severe 
ketosis was seen, in nine samples elevated lactate and in six samples TCA cycle 
intermediates were reported in addition. Six patients with urea cycle disorders (UCD; i.e. 
two carbamoylphosphate synthase I deficiency (CPS1D), two argininosuccinate lyase 
deficiency (ASLD), two ornithine transcarbamylase deficiency (OTCD) showed 
3−MGA−uria upon disease presentation or metabolic deterioration during the course of 
disease. Besides the typical UCD pattern, lactate was detected in all patient samples and 
TCA cycle intermediates in three. Five patients were diagnosed with other metabolic 
disorders, i.e. guanidinoacetate methyltransferase (GAMT) deficiency, lipoproteinlipase 
deficiency, tyrosine hydroxylase deficiency, peroxisomal biogenesis disorder and 
cystinosis. 
 
Group 1B: Classical non-metabolic disorders 
43 Patients were diagnosed with other, non-metabolic disorders (see Table 2 B). Four 
patients with 3−MGA−uria were diagnosed with haematological disorders. Two patients 
with hemophagocytic lymphohistiocytosis (HLH) whose samples were taken during 
evaluation of short stature after bone marrow transplantation and extensive 
glucocorticosteroid treatment. One patients with acute lymphatic leucemia (ALL) was 
tested for a suspected inborn error of metablism because of extremely high cholesterol 
levels during partial parenteral nutrition including intravenous lipids. One patient, 
presenting with hepatomegaly and pancytopenia was later diagnosed with 
Myelodysplastic syndrome (MDS). 13 patients were diagnosed with a neuromuscular 
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disorder (for details see Table 3). In most of the patients 3−MGA was consistently elevated 
in the urine. Seven of the patients also showed ethylmalonic aciduria (EMA-uria), in two of 
them SCADD was excluded genetically. Two of these seven patients had lactic acidemia, 
none had elevated serum alanine. The patient with Duchenne muscular dystrophy was 
treated with prednisone upon sampling. A total of 15 patients were diagnosed with genetic 
disorders, i.e. cardiofaciocutaneous (CFC) Syndrome, Sphrintzen-Goldberg Syndrome, 
Pelizaeus-Merzbacher Syndrome, Kabuki, CHARGE, Noonan and ter Haar Syndrome (each 
in one patient, respectively), eight with (multiple) chromosomal abnormalities. In five of 
these patients mitochondrial dysfunction in muscle (defined as: decreased ATP production 
and/or single or multiple OXPHOS enzyme deficiencies) was reported. In the other 10 
patients, the final diagnosis was made without a muscle biopsy, hence it is unknown if they 
have a mitochondrial dysfunction. 
 
Group 2: 3−MGA−uria patients with genetically proven mitochondrial disorders 
For a total of 591 patients carrying pathogenic mutations in 50 nuclear genes or the 
mitochondrialDNA we could retrieve the urinary organic acid results. This encompasses 
202 patients from our centre or under the care of one of our co-authors and 591 patients 
from the literature. The data are summarized in Table 4. 
Five patients were diagnosed with other disorders, i.e. celiac disease, glucose galactose 
malabsorption syndrome, juvenile idiopathic arthritis (JIA), cystic fibrosis were each 
observed in one of these patients, respectively. One female patient was pregnant at the 
moment of testing, a condition in which 3−MGA−uria is known to occur81. 
Six patients had suffered from an apparently life threatening event (ALTE), two died of 
sudden infant death syndrome (SIDS) just before sampling. Beside the 3−MGA−uria, the 
urinary organic acid pattern did not show other metabolites pointing towards a specific 
inborn error of metabolism. 
In patients with mutations in genes encoding for the biogenesis and assembly of OXPHOS 
complexes, 3−MGA−uria was found in relation with the nuclear genes NDUFS7 (one out of 
three, 1/3), ATP5E (1/1), ATP12 (1/1), TMEM70 (57/60) and the mitochondrial DNA genes 
MTND2 (1/3) and MTATP6 (m.8993T>G, 1/8). In patients with mutations in genes involved 
in mitochondrial DNA replication, six POLG (6/41) and one TWINKLE (1/21) patients had 
elevated urinary 3−MGA. In correlation with genes encoding for mitochondrial nucleotide 
synthesis and transport 3−MGA−uria was seen in SUCLG1 (2/12) and SUCLA2 (5/6) patients. 
3−MGA−uria was not found in other mitochondrial depletion syndromes (mutations in 
RRM2B 0/3, DGUOK 0/9, TK2 0/10, TYMP 0/9, MPV17 0/3).  
In patients with mutations in nuclear genes involved in mitochondrial translation, elevated 
levels of 3−MGA were not found, but it was seen in four patients with mitochondrial DNA 
mutations in MTTL (tRNA Leu, m.3243A>G, 4/26). Furthermore 3−MGA−uria was seen in 
eight of sixteen patients with Pearson syndrome due to deletions in DNA, but not in other 
clinical phenotypes (e.g. Kearns Sayre syndrome, total 8/24). In patients with SPG7 
mutations, a gene involved in mitochondrial protein processing and quality control, no 
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urinary organic acid profiles were available. In patients with mutations in genes involved in 
mitochondrial protein import, 3−MGA−uria was reported in all patients with DNAJC19 
syndrome (DNAJC19, 17/17 = 100%) but not in patients with TIMM8A (0/5) mutations. 
3−MGA−uria is seen in most patients with TAZ syndrome 49/56 = 88%) and in all patients 
with mutations in SERAC1 (18/18 = 100%), both phospholipid remodelling disorders.  
In patients with defects in genes involved in mitochondrial membrane biogenesis and 
maintenance, 3−MGA−uria was a consistent feature in patients OPA3 syndrome (OPA3, 
45/45 = 100%) but not in patients harbouring OPA1 mutations (0/33). It was also a hallmark 
of patients with TMEM70 mutations (TMEM70, 57/60 = 95% ) and frequently, but less often 
in patients with mutations in AGK (7/10). AGK mutations can lead to Sengers syndrome 
(4/7), but also to isolated cataracts151. 
Furthermore 3−MGA−uria was found in patients with ETFDH mutations (3/35). 3−MGA−uria 
was not found in relation with TCA cycle (0/7) or pyruvate metabolism (0/4) disorders. 
Taken together, 3−MGA−uria is seen as a consistent feature in the 3−MGA syndromes and 
in a high percentage of patients with AGK mutations. In the remaining 386 patients, 
harbouring mutations in 45 nuclear genes or the mitochondrial DNA, 3−MGA−uria is found 
in 42 patients (11%). 
We did not detect 3−MGA−uria in eight patients with Smith Lemli Opitz Syndrome (SLOS), 
neither in three patients with mevalonate kinase deficiency 
 
Structure and assembly of C I 155-164 
Structure and assembly of C III 165-170 
Structure and assembly of C IV 171-179 
Structure and assembly of C V 64-67, 180-184 
Mitochondrial DNA replication, nucleotide synthesis and transport 185-210 
Mitochondrial DNA translation 60, 211-223 
Mitochondrial protein import 75, 224 
Mitochondrial membrane phospholipid remodelling 3, 10, 34, 39, 225-246 
Mitochondrial membrane biogenesis and maintenance 1, 45, 46, 48, 151, 247-250 
Mitochondrial other 72-74, 152, 153, 251-260 
CoQ10 related 78, 261-267 
Pyruvate metabolism 268, 269 
TCA cycle related 270-272 
Supplementary reference list for table 4. 
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Abstract  
 
Increased urinary 3−methylglutaconic acid excretion is a relatively common finding in 
metabolic disorders, especially in mitochondrial disorders. In most cases 
3−methylglutaconic acid is only slightly elevated and accompanied by other (disease 
specific) metabolites. There is, however, a group of disorders with significantly and 
consistently increased 3−methylglutaconic acid excretion, where the 3−methylglutaconic 
aciduria is a hallmark of the phenotype and the key to diagnosis. Until now these disorders 
were labelled by roman numbers (I–V) in the order of discovery regardless of 
pathomechanism. Especially, the so called “unspecified” 3−methylglutaconic aciduria type 
IV has been ever growing, leading to biochemical and clinical diagnostic confusion. 
Therefore, we propose the following pathomechanism based classification and a simplified 
diagnostic flow chart for these “inborn errors of metabolism with 3−methylglutaconic 
aciduria as discriminative feature”. One should distinguish between “primary 
3−methylglutaconic aciduria” formerly known as type I (3-methylglutaconyl-CoA hydratase 
deficiency, AUH defect) due to defective leucine catabolism and the—currently known—
three groups of “secondary 3−methylglutaconic aciduria”. The latter should be further 
classified and named by their defective protein or the historical name as follows: i) 
defective phospholipid remodelling (TAZ defect or Barth syndrome, SERAC1 defect or 
MEGDEL syndrome) and ii) mitochondrial membrane associated disorders (OPA3 defect or 
Costeff syndrome, DNAJC19 defect or DCMA syndrome, TMEM70 defect). The remaining 
patients with significant and consistent 3−methylglutaconic aciduria in whom the above 
mentioned syndromes have been excluded, should be referred to as “not otherwise 
specified (NOS) 3−MGA uria” until elucidation of the underlying pathomechanism enables 
proper (possibly extended) classification. 
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Introduction 
 
In the urine of healthy individuals 3−methylglutaconic acid (3−MGA) is found only in traces 
(0–10 mmol/mol creatinine). Increased urinary excretion of 3−methylglutaconic acid 
(3−MGA−uria), often associated with 3−methylglutaric aciduria, is a relatively common 
finding in patients with metabolic disorders in general273. In these cases, 3−MGA−uria is 
mostly found occasionally, e.g. upon presentation or during severe metabolic 
decompensation of e.g. propionic aciduria. It is not isolated but only an accompanying 
finding beside several other, more disease specific, urinary metabolites. Another patient 
group in whom 3−MGA−uria is seen in approximately 11 % of all patients (isolated or 
together with e.g. Krebs cycle intermediates), are patients with disorders of the oxidative 
phosphorylation (e.g. due to mutations in POLG273). In these patient groups 3−MGAuria is 
mostly mild (20–40 mmol/mol creatinine), only a minor finding and not the hallmark of the 
phenotype. Also patients with the mitochondrial AGK defect (or Sengers syndrome) may 
have increased 3−MGA in their urine249. 
This is different in another group of patients with significantly and consistently increased 
3−MGA excretion (40- >1000 mmol/mol creatinine). Here, the 3−MGA−uria is a major 
finding, a hallmark of the phenotype and often the key to the diagnosis. Consider e.g. the 
differential diagnosis of optic atrophy, which is very long, but the finding of 3−MGA−uria 
reduces the differential diagnosis to Costeff syndrome. The same holds even more so for 
patients with cardiomyopathy. 
 
 
Figure 1. Diagnostic flowchart for patients with increased urinary 3−methylglutaconic acid 
excretion 3−HIVA = 3−hydroxyisovaleric acid, 3−MGA = 3−methylglutaconic acid, 3−MGA−uria 
= 3−methylglutaconic aciduria, IEM = inborn error of metabolism, NOS = not otherwise 
specified, OXPHOS = oxidative phosphorylation system. 
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Therefore we propose to refer to this group of disorders as “inborn errors of metabolism 
with 3−methylglutaconic aciduria as discriminative feature”.  
Until now the different disorders with significantly elevated urinary 3−MGA excretion were 
randomly given roman numbers (I-V), without taking the underlying pathomechanism into 
account for a proper classification. Especially “the unspecified” 3−MGA−uria type IV was 
ever growing, as was the confusion it caused. Therefore we propose to use the following 
classification based upon the underlying pathomechanism (see Table 1 and Figure 1) for 
this group of “inborn errors of metabolism with 3−methylglutaconic aciduria as 
discriminative feature”. 
The former type I, 3−methylglutaconyl−CoA hydratase deficiency, is the only “primary 
3−methylglutaconic aciduria” due to the hydratase defect in leucine catabolism22, 90. In all 
other types the exact mechanism leading to 3−MGA−uria is unknown, but not directly 
related to leucine breakdown, therefore one should refer to them as “secondary 
3−methylglutaconic aciduria(s)”. Most of these disorders are recognizable, distinctive 
clinical associations, that have been described before the molecular defect had been found 
and therefore classify as syndromes (e.g. Barth syndrome, Costeff syndrome, MEGDEL 
syndrome, DCMA syndrome). Though patients with mutations in TMEM70 also show 
3−MGA−uria as consistent feature but do have a variable (and still expanding) phenotype 
one should avoid to refer to 3−MGA-syndromes when dealing with this group of disorders. 
The patients can be further subdivided and classified correctly based on the underlying 
pathomechansim as follows: i) defective phospholipid remodelling (TAZ defect or Barth 
syndrome, SERAC1 defect or MEGDEL syndrome) or ii) mitochondrial membrane 
associated disorders (OPA3 defect or Costeff syndrome, DNAJC19 defect or DCMA 
syndrome, TMEM70 defect). The remaining patients with significant and consistent 
3−MGA−uria (>40 μmol/mmol creatinine) in whom the above mentioned defects have been 
excluded, should be referred to as “not otherwise specified (NOS) 3−MGA−uria” until the 
underlying pathomechanism is elucidated leading to a more precise classification.  
This nomenclature also simplifies the diagnostic approach (see Figure 1). When facing a 
patient with increased urinary excretion of 3−MGA one should first discriminate whether 
the 3−MGA−uria is just a minor or accompanying finding or a major finding.  
 
Primary 3−MGA−uria 
If 3−MGA−uria is significantly and consistently elevated (>40 mmol/mol creatinine), the 
“Primary 3−MGA−uria” 3−methylglutaconyl−CoA hydratase deficiency or AUH defect 
(MIM #250950, former type I) can be easily diagnosed upon the finding of increased 
3−hydroxyisovaleric acid (3−HIVA) and the 2:1 ratio for cis:trans isoforms19. Furthermore 
the ratio between 3−MGA/3−MG in general is>20 in AUH defect patients and<20 in all other 
inborn errors of metabolism with 3−methylglutaconic aciduria as discriminative feature 
(personal communication R. Duran). The ratio of the two isoforms can be determined with 
proton NMR spectroscopy (Engelke et al 2006) as well as by conventional GC−MS analysis 
of organic acids in urine as the two forms appear as separate peaks in the chromatogram19. 
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We propose to use 3−methylglutaconyl−CoA hydratase deficiency or AUH defect as 
disease name, as it directly links to the underlying defective leucine catabolism. The 
patients show an adult onset of disease with progressive spasticity and dementia with a 
characteristic slowly developing radiological picture of extensive leucoencephalopathy 26. 
In all other types, “the secondary 3−MGA−urias”, the cis:trans isoforms show a 1:1 ratio and 
3−HIVA is normal. The excretion level of 3−MGA in the urine can also be helpful for the 
differential diagnosis (see Figure 2). A thorough clinical examination and a multi-organ 
screening are necessary to further subdivide the different disorders. A detailed review of 
the clinical, radiological and biochemical phenotypes of the different syndromes is beyond 
the scope of this article. We refer the interested reader to a recent review103. Table 1 
provides a short overview on the clinical, biochemical and radiological findings.  
 
 
Figure 2. 3−methylglutaconic aciduria in different metabolic disorders: How high? How 
frequent? Excretion levels of urinary 3−methylglutaconic acid (3−MGA) and percentage of 
patients showing this finding in patients with inborn errors of metabolism (IEM) with 
3−methylglutaconic aciduria (3- MGA-uria) as discriminative feature and patients with 
different types of oxidative phosphorylation system (OXPHOS) disorders. All disorders are 
represented by the abbreviations of the underlying genetic defect. Mt = Mitochondrial. C = 
Complex of the respiratory chain. CoQ = Coenzyme Q10. 
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Secondary 3−MGA−uria 
Secondary 3−MGA−uria due to defective phospholipid remodelling 
The only known X-linked disorder is TAZ defect or Barth syndrome (MIM #302060, 
former type II) presenting in males with 3−MGA−uria, (left ventricular non-compaction) 
cardiomyopathy, neutropenia, myopathy, typical facial features, hypocholesterolemia and 
a cognitive phenotype 32, 44. The TAZ gene encodes taffazin, which is involved in cardiolipin 
remodelling in the mitochondrial membrane. Disturbed cardiolipin remodelling leads to 
oxidative phosphorylation defects and is involved in apoptosis and mitochondrial 
membrane dynamics. Patients with SERAC1 defect or MEGDEL syndrome (MIM # 614739) 
present during early childhood with the unique combination of 3−MGA−uria, deafness, 
progressive spasticity and dystonia, psychomotor retardation and Leigh like syndrome on 
MRI68, 232. Mutations are found in SERAC1, encoding an enzyme involved in 
phosphatidylglycerol remodelling. The enzyme is essential for both mitochondrial function 
and intracellular cholesterol trafficking232. 
 
Secondary 3−MGA−uria due to mitochondrial membrane associated disorders  
Patients with OPA3 defect or Costeff syndrome (MIM #258501, former type III) present 
in infancy with the classical trias of 3−MGA−uria, optic atrophy and movement disorder 
(ataxia or extrapyramidal disorder)45, 46. Mutations were found in OPA3, the function of its 
gene product OPA3 is not fully elucidated, but a protective function for the respiratory 
chain has been shown recently54. Hutterite patients with DNJAC19 defect or DCMA 
syndrome (MIM #610198, former type V) show the characteristic combination of 
childhood onset dilated cardiomyopathy, non-progressive cerebellar ataxia, testicular 
dysgenesis, growth failure, and 3−MGA−uria75. Mutations are found in DNAJC19 encoding a 
protein showing homology with TIMM8A, which is involved in mitochondrial protein 
import. TMEM70 defect (#604273, no former type) patients mostly present in the neonatal 
period with a muscular hypotonia, hypertrophic cardiomyopathy, psychomotor 
retardation, 3−MGA−uria, hyperammonemia and lactic acidosis. Patients surviving the 
neonatal period later show developmental delay. The cardiomyopathy is not progressive61, 
64, 65. However, the phenotypic spectrum is variable and broadening and there seems to be 
no syndromic presentation. All patients show a deficiency of the ATPase (complex V) of the 
oxidative phosphorylation (OXPHOS) system, however TMEM70 seems to be neither a 
subunit nor an assembly factor of the ATPase. A role in insertion of ATPase into the 
mitochondrial membrane is speculated. 
 
Secondary 3−MGA−uria due to unknown pathomechanism: the “not otherwise specified 
(NOS) 3−MGA−uria” 
Some patients with significant and consistent 3−MGA−uria remain unexplained after ruling 
out all currently known causes273. This means that new inborn errors of metabolism with 
3−methylglutaconic aciduria as discriminative feature will certainly be encountered in the 
future. This may concern individual patients with significant 3−MGA−uria or patient groups 
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with a distinctive phenotype and 3−MGA−uria as a hallmark of this phenotype. We propose 
to diagnose these patients as not otherwise specified (NOS) 3−MGA−uria until the 
underlying genetic defect and pathomechanism is elucidated. It may occur that a causative 
gene of a new inborn error of metabolism with 3−methylglutaconic aciduria as 
discriminative feature is found, but the function of the protein is still unknown. In this case, 
the nomenclature consisting of the gene name followed by syndrome should already be 
used, but the new disorder should be classified as “NOS” until the pathomechanism is 
(roughly) understood. 
The proposed classification is the first to take the underlying pathomechanism of 
3−MGA−uria into account and furthermore simplifies the diagnostic approach. We would 
like to stress once again, that the term inborn error of metabolism with 
3−methylglutaconic aciduria as discriminative feature should be reserved for disorders in 
which urinary 3−MGA is found significantly and consistently elevated. 
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Summary and outlook 
 
With the exponential growth of knowledge we discover new disorders every day. Still many 
patients in the clinical practice miss an exact diagnosis and pathophysiologic explanation 
for his of her disease, which lies at the basis of any possible treatment. The physician, 
together with the biochemist and geneticist, are challenged to combine their findings, to 
recognize a distinctive disease pattern in order to finally come to the correct diagnosis. In 
this process biochemical markers are helpful tools. In this thesis we show, that 3-
methylglutaconid acid (3−MGA) is one of those useful markers. 
Chapter 1 summarizes the current knowledge about the 3−methylglutaconic acidurias 
(3−MGA−urias). In the urine of healthy individuals the organic acid 3−MGA is found only in 
trace amountss (0-20 μmol/mmol creatinine). Increased urinary excretion of 3−MGA is 
often associated with 3−methylglutaric aciduria, which is a powerful diagnostic clue for 
several rare, but highly characteristic neurometabolic syndromes like Barth syndrome or 
Costeff syndrome (MIM #250950). 
The most prominent clinical feature of the X-linked Barth syndrome or TAZ defect 
(3−MGA−uria type II, MIM # 302060) is cardiomyopathy, which is often dilated with signs of 
left ventricular noncompaction. The cardiomyopathy can have a fetal onset and finally 
necessitate heart transplantation. Patients present with (cyclic) neutropenia and skeletal 
myopathy. Typical facial features and a cognitive phenotype with normal IQ but with 
problems with visual spatial tasks and mathematics are reported. Serum 
hypocholesterinemia and oxidative phosphorylation system (OXPHOS) dysfunction in 
muscle is found frequently. The disease is caused by underlying mutations in TAZ, which 
encodes the (inner) mitochondrial membrane protein tafazzin, a remodeler of cardiolpin. 
Cardiolipin is a phospholipid specifically found in the mitochondrial inner membrane and 
therefore is present in high quantities in mitochondria-enriched tissues, such as heart and 
skeletal muscle. It is reported to function in the stabilization of the individual respiratory 
chain complexes, as well as in the OXPHOS supercomplex forming. This explains the 
OXPHOS dysfunction. A role in apoptosis has been suggested as well. 
Costeffsyndrome  or OPA3 defect (3−MGA−uria type III, MIM #258501) is an autosomal 
recessive disorder with infantile bilateral optic atrophy, extrapyramidal signs, spasticity, 
ataxia, dysarthria, and cognitive deficit in decreasing order of frequency. As in the other 
3−MGA−uria syndromes there is a strong relation with OXPHOS (dys)function. Mutations 
are found in OPA3 encoding for the OPA3 protein, which is enriched in the outer 
mitochondrial membrane. In a zebrafish model of Costeff syndrome OPA3 has recently 
been shown to have protective effects for the respiratory chain.  
In both syndromes 3−MGA−uria is the key feature leading the physician to the correct 
diagnosis, however, the pathomechanism underlying 3−MGA−uria is unknown.  
This is the case in all conditions in which 3−MGA−uria is seen with an exception of 
3−methylglutaconyl−CoA hydratase (3−MGH) deficiency or AUH defect (former 
3−MGA−uria type I, MIM #250950) where it stems from leucine degradation (Chapter 1, 
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Figure 1). However, mitochondrial dysfunction seems appears to link the disorders 
together as the common denominator. 
3−MGH deficiency or AUH defect is biochemically a classical inborn error of metabolism. 
The defect is situated in a known pathway, the degradation of leucine. The affected 
enzyme 3−MGH, catalyzes the fifth step of leucine catabolism, the conversion of 
3−methylglutaconyl−CoA to 3-hydroxy-3-methylglutaryl-CoA. This explains the finding of 
the different metabolites in urine: 3−MGA, 3−methylglutaconic acid (3−MG) and 
3−hydroxyisovaleric acid (3−HIVA). Increased 3−HIVA excretion distinguishes 
3−methylglutaconyl−CoA hydratase deficiency from the other types of 3−MGA syndromes. 
For a long time it remained unclear which clinical presentation belongs to this inborn error 
of metabolism. It was even speculated to be a non-disease. In Chapter 2 we show, that it is 
definitely not a non-disease. Instead, it is a very slowly progressive disorder leading to an 
adult onset of clinical symptoms. Clinically the patients present with progressive ataxia, 
which can be combined with dementia, spasticity or optic atrophy. When this finding leads 
to cerebral imaging, one will find an impressive white matter disease (Chapter 2, Figure 1). 
One could speculate that this is the consequence of a long term auto-intoxication by one of 
the accumulating metabolites and therefore a leucine restricted diet or a protein restriction 
as treatment could be considered. On the other hand, the clinical course is not 
characterised by episodes of metabolic derangement, so that, also in this case 3−MGA uria 
is only a marker of a yet unknown pathomechanism secondary to the disturbance in the 
leucine catabolic pathway. Disturbances in mitochondrial membrane dynamics and 
OXPHOS function may play a role in the pathomechanism as well. 
Besides these three well defined disorders there was an ever growing group of patients 
with more or less significantly and more or less consistently increased 3−MGA excretion. 
The different disorders were labelled by roman numbers (I-V) in the order of discovery, 
without including the underlying pathomechanism in the classification. The so called 
“unspecified” 3−MGA−uria type IV (MIM 250951) encompassing patients with various organ 
involvement and mostly progressive neurological impairment has been ever growing since, 
leading to biochemical and clinical diagnostic confusion. From Chapter 3 onwards we focus 
on this heterogeneous group of patients and disorders and re-establish order. 
Chapter 3 describes the clinical and biochemical phenotype of 18 children with 3−MGA−uria 
type IV and defines four clinical subgroups (encephalomyopathic, hepatocerebral, 
cardiomyopathic, myopathic). By delineating patient-groups we elucidated the genetic 
defect (mutations in POLG, SUCLA2, TMEM70, RYR1) in 10 out of 18 children. 
This is a much higher yield than the 20% of patient for which the genetic basis is found in 
the general OXPHOS patient population. This underlines the feasibility of 3−MGA−uria as a 
marker for OXPHOS dysfunction. 
In Chapter 4 we show, that dysmorphic features are commonly present in 3−MGA−uria 
type IV. Most of these appear during the course of disease, secondary to basal ganglia 
involvement (mask-like facial features), muscle wasting of the facial musculature, and 
hypotonia, leading to an elongation of the face and long prominent ears. Some of these 
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facial features are comparable with those in patients with Barth syndrome (broad and tall 
forehead, curved eyebrows; Chapter 4, Figure 1). 
In Chapter 5 we describe the association of 3−MGA−uria with sensori-neural deafness, 
encephalopathy, and Leigh-like syndrome (MEGDEL or SERAC1 syndrome, MIM #614739) 
in four patients with a disorder of the oxidative phosphorylation. In Chapter 6 we elucidate 
the genetic and functional background. MEGDEL or SERAC1 syndrome is a clinically highly 
characteristic dystonia-deafness syndrome. In the neonatal period children often are 
admitted due to suspicion of infection, however very often no infectious agent can be 
detected. Furthermore the patients often have hypoglycaemias. In infancy feeding 
problems leading to failure to thrive and delayed achievement of milestones bring the 
children under attention of the paediatrician. A certain percentage of patients also has 
(intermittently) elevated liver enzymes, cholestasis or even liver failure, mostly during the 
first year of life. Upon physical examination an axial hypotonia with hypertonia of the 
extremities is noted, as well as dystonia of the hands. The features progress significantly 
over time. Deafness is often difficult to evaluate clinically due to the severe psychomotor 
retardation and necessitates specific testing. Most children have little or no speech 
development. The cerebral MRI shows features reminiscent of Leigh syndrome (subacute 
necrotizing encephalopathy) with hyperintensities in the basal ganglia and cerebral and 
cerebellar atrophy. 
Laboratory investigations reveal significantly and consistently elevated urinary 3−MGA 
(and 3−methylglutaric aciduria). Together with the elevated lactate and alanine levels 
found in most of the patients these observations lead to the suspicion of an OXPHOS 
disorder. Investigations of the OXPHOS system in fresh muscle often show a diminished 
ATP production capacity, sometimes combined with respiratory chain complex 
deficiencies. The same holds for evaluation of OXPHOS in fibroblasts.  
However, the alterations are mostly only mild and do not have a specific pattern. This is 
comparable to the findings in patients with Barth syndrome, yet the OXPHOS dysfunction 
is more outspoken in Barth syndrome. The clinical, biochemical and radiological findings 
are described in Chapter 5 (also Chapter 6, Supplementary Table 1 summarizes the 
findings).  
Using exome sequencing in two unrelated patients, we identified mutations in SERAC1, a 
gene of unknown function. Little was known about SERAC1 , other than the presence of a 
lipase domain. This, taken together with the overlapping clinical signs and symptoms 
between Barth and MEGDEL syndrome (3−MGA−uria, OXPHOS dysfunction, 
hypocholesterinemia) lead us to perform phospholipid analysis in patients’ fibroblasts. 
This revealed elevated concentrations of phosphatidylglycerol-34:1 and decreased 
concentrations of phosphatidylglycerol-36:1 species (Chapter 6, Figure 3A,B). This 
identifies SERAC1 as the second known phospholipid remodeller beside tafazzin that is 
deficient in Barth syndrome. Cardiolipin is present in the inner mitochondrial membrane 
and has been reported to stabilize the individual respiratory chain complexes, as well as in 
the OXPHOS supercomplex forming. This explains the OXPHOS dysfunction in Barth 
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syndrome. In MEGDEL syndrome the total amount of cardiolipin is normal, while the 
subspecies composition is disturbed, which explains the OXPHOS dysfunction in MEGDEL 
syndrome (Chapter 6, Figure 4). We localized SERAC1 at the interface between the 
mitochondria and the endoplasmic reticulum in the mitochondria-associated membrane 
(MAM) fraction that is essential for phospholipid exchange between these organelles 
(Chapter 6, Figure 6, 7). 
Furthermore, we also detected low concentrations of bis(monoacyl-glycerol)-phosphate, 
suggesting that SERAC1 catalyses the first enzymatic reaction in the as yet unknown 
bis(monoacyl-glycerol)-phosphate biosynthetic pathway (Chapter 6, Figure 2). Low 
bis(monoacylglycerol)phosphate concentrations are known to lead to intracellular 
accumulation of free cholesterol, a phenomenon known from Niemann Pick C disease, a 
lysosomal storage disorder. By filippin staining of MEGDEL fibroblasts we could indeed 
show intracellular cholesterol accumulation (Chapter 6, Figure 5). This makes MEGDEL 
syndrome also the second known intracellular cholesterol trafficking disorder. 
Complementation of patient fibroblasts with wild-type human SERAC1 by lentiviral 
infection lead to a partial normalization of the mean ratio of phosphatidylglycerol-34:1 to 
phosphatidylglycerol-36:1, thereby proving the ascribed function (Chapter 6, Figure 9). 
As shown in the Chapters 1-6, 3−MGA−uria is a useful biomarker, which can lead the 
physician to the right diagnosis. However a proper classification of the growing group of 
disorders associated with 3−MGA−uria was lacking.  
In Chapter 7 we show, that 3−MGA−uria is a relatively common finding in patients with 
suspicion of metabolic disorders in general. We found it in 3% of all urine samples (nearly 
20000) sent to our laboratory in an eight year period. We therefore reviewed the 
biochemical, clinical and genetic data of all patients with 3−MGA−uria who were referred to 
our centre under the suspicion of a metabolic disorder (Chapter 7, Table 2 summarizes the 
findings). We could confirm OXPHOS dysfunction as common denominator. 
In a further approach we therefore evaluated in which specific OXPHOS disorders 
3−MGA−uria can be found. Taken together this enabled us to subdivide disorders with 
3−MGA−uria into three subgroups (see Chapter 8, Figure 1 and Table 1). In Chapter 7 we 
present this in-depth evaluation and come to a classification based on the underlying 
pathomechanisms as shown in brief below, which is presented in Chapter 8. 
1. Disorders with 3−MGA−uria as an accompanying finding 
In patients suffering from classical metabolic disorders (e.g. fatty acid oxidation disorders, 
organic acidurias, urea cycle disorders, glycogen storage disorders) 3−MGA−uria is mostly 
found occasionally, e.g. upon presentation or during severe metabolic decompensation. 
Furthermore, 3−MGA−uria is not isolated but only an accompanying finding beside several 
other, more disease specific, urinary metabolites. Indeed OXPHOS dysfunction seems to 
be the common denominator. 
2. Disorders with 3−MGA−uria as a minor finding 
In this patient group 3−MGA−uria is mostly mild (20-40 μmol/mmol creatinine), only a 
minor finding and not the hallmark of the phenotype. Mostly patients suffer from OXPHOS 
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disorders, but one should not forget to take hematological disorders, neuromuscular 
disorder, genetic syndromes or chromosomal abnormalities into account. Investigation of 
nearly 600 patients with 50 different, genetically proven, OXPHOS disorders for the 
presence or absence of 3−MGA−uria revealed, that 11% of these patient presented 
3−MGA−uria. There is no strong relation between 3−MGA−uria and specific genes, however 
there are some subgroups which seem to exhibit 3−MGA−uria more often than others. It 
was more frequently seen in complex V (ATPase) related disorders, with mitochondrial 
DNA depletion or deletion, but not in patients with single respiratory chain complex 
deficiencies (Chapter 7a, Table 4).  
3. Inborn errors with 3−MGA−uria as discriminative feature  
In this group of disorders 3−MGA−uria is a major finding, the hallmark of the phenotype 
and often the key to the diagnosis. Patients show significantly and consistently increased 
3−MGA excretion (40- >1000 μmol/mmol creatinine) which is mostly isolated.  
Therefore, we propose the following pathomechanism based classification for these 
“Inborn errors of metabolism with 3−MGA−uria as discriminative feature”. One should 
distinguish between “Primary 3−MGA−uria” formerly known as type I 
(3−methylglutaconyl−CoA hydratase deficiency, AUH defect) due to defective leucine 
catabolism and the – currently known - three groups of “Secondary 3−MGA−uria”. The 
latter should be further classified and named by their defective protein or the historical 
name as follows: i) defective phospholipid remodelling (TAZ defect or Barth syndrome, 
SERAC1 defect or MEGDEL syndrome) and ii) mitochondrial membrane associated 
disorders (OPA3 defect or Costeff syndrome, DNAJC19 defect or DCMA syndrome, 
TMEM70 defect). The remaining patients with significant and consistent 3−MGA−uria in 
whom the above mentioned syndromes have been excluded, should be referred to as “not 
otherwise specified (NOS) 3−MGA−uria” until elucidation of the underlying 
pathomechanism enables proper (possibly extended) classification.  
We have shown, that 3−MGA−uria is a useful marker for OXPHOS dysfunction in general 
and for several highly characteristic neurometabolic syndromes in particular. Exome 
sequencing studies in patients with NOS 3−MGA−uria will identify new players in the 
hitherto poorly characterised pathways related to phospholipid remodelling and 
intracellular cholesterol trafficking. Increasing knowledge on these pathways and their 
correlation with the OXPHOS will identify possible future treatment targets and improve 
counselling. Further studies should also aim to answer THE question: where does 
3−MGA−uria stem from? 
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Samenvatting 
 
Met de exponentiële groei van kennis worden vrijwel iedere dag nieuwe ziektebeelden 
ontdekt. Maar nog steeds zijn artsen vaak niet in staat om bij een individuele patiënt een 
exacte diagnose te stellen. Een juiste diagnose moet aan iedere behandeling ten grondslag 
liggen. Veelal is er onvoldoende kennis over de onderliggende ziekteprocessen. Dit 
verklaart waarom voor zoveel (stofwisselings-)ziekten nog geen behandeling beschikbaar 
is. Door de vele verschillende ziektebeelden wordt het voor artsen steeds moeilijker deze 
van elkaar te onderscheiden. De arts moet uit een overvloed aan informatie (klinische 
verschijnselen, laboratoriumuitslagen, radiologische bevindingen etc.) een ziektepatroon 
destilleren om tot de juiste diagnose te komen. Hierbij kan een biomarker helpen. 
Verhoogde uitscheiding van 3−methylglutaconzuur (3−MGA) in de urine is zo’n biomarker. 
Bij gezonde personen komt dit zuur nagenoeg niet in de urine voor. Bij patiënten met 
enkele zeldzame stofwisselingsziekten is dit juist een kenmerk van hun ziekte. 
Hoofdstuk 1 geeft een overzicht van de huidige kennis van ziektebeelden met een 
verhoogde concentratie van 3−methylglutaconzuur in de urine (3−MGA−uria). Een 
syndroom is een verzameling van steeds tezamen voorkomende klinische verschijnselen. 
Er zijn meerdere syndromen bekend die als kenmerk een 3−MGA−uria hebben. 
Bijvoorbeeld het Barth syndroom, waarbij de ziekteverschijnselen 3−MGA−uria, 
cardiomyopathie en te weinig witte bloedcellen (neutropenie) zijn. Dit ziektebeeld wordt 
veroorzaakt door foutjes (mutaties) in het TAZ gen. TAZ codeert voor het eiwit tafazzine en 
is verantwoordelijk voor het hermodelleren van cardiolipine. Cardiolipine is een stofje dat 
specifiek in de mitochondria wordt gevonden en belangrijk is voor het juist functioneren 
van de ademhalingsketen. Bij deze patiënten functioneert de ademhalingsketen niet goed, 
ze hebben een tekort aan energie, een energiestofwisselingsziekte. 
Bij het Barth syndroom wordt de arts door de unieke bevinding van 3−MGA in de urine op 
het juiste spoor gezet. Er zijn bijvoorbeeld veel verschillende vormen van cardiomyopathie, 
maar er bestaan slechts twee vormen van cardiomyopathie met 3−MGA−uria.  
Hoe de verhoogde uitscheiding van 3−MGA in de urine ontstaat is voor de meeste 
ziektebeelden onbekend. Uitzondering vormt het ziektebeeld 3−methylglutaconyl-CoA 
hydratase (3-MGH) deficiëntie. Bij deze ziekte komt het 3−MGA uit de afbraak van het 
eiwitbouwsteen (aminozuur) leucine (Hoofdstuk 1, figuur 1). Biochemisch gezien is dit een 
klassieke aangeboren stofwisselingsziekte. Lange tijd was het onduidelijk welke klinische 
symptomen bij deze aangeboren stofwisselingsziekte horen. Er waren zelfs speculaties of 
het überhaupt wel een echte ziekte was. In hoofdstuk 2 laten we zien, dat 3−MGH 
deficientie zeker een ziektebeeld is. Het is een zeer langzaam progressieve aandoening 
waarbij de klinische verschijnselen van deze aangeboren ziekte pas op volwassen leeftijd 
zichtbaar worden. De patiënten presenteren zich met een opvallend (ataktisch) 
looppatroon, vaak gecombineerd met spasticiteit en dementie. Op de MRI van de hersenen 
is een zeer uitgebreide witte stofziekte te zien (Hoofdstuk 2, figuur 1).  
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Naast deze twee goed gekarakteriseerde ziektebeelden is er een groeiende groep van 
patiënten met meer of minder uitgesproken en meer of minder consistente 3−MGA−uria. 
Tot op heden werden de verschillende ziektebeelden met romeinse getallen aangeduid, 
zonder bij deze indeling met de onderliggende pathofysiologie rekening te houden. Het 
“ongeclassificeerde type IV” was een steeds groter wordende groep van patiënten met een 
multi-systeem ziekte veelal met neurologische verschijnselen. De diversiteit van klinische 
verschijnselen in deze groep zaaide veel verwarring bij artsen en biochemici. Vanaf 
hoofdstuk 3 zullen we deze “verzamelbak” evalueren en de ziektebeelden met 3−MGA−uria 
opnieuw indelen. 
Hoofdstuk 3 beschrijft de klinische en biochemische ziekteverschijnselen van 18 kinderen 
met 3−MGA−uria, welke op basis van deze bevindingen in vier groepen kunnen worden 
onderverdeeld. Door deze indeling konden we bij 10 van 18 patiënten tot een genetische 
diagnose komen. Dit is een hoger oplossingspercentage dan bij patiënten met een 
energiestofwisselingziekte. Bij hen kan gemiddeld in slechts 20% van de gevallen een 
genetische diagnose gesteld worden. 3−MGA−uria is dus een zinvolle biomarker, die de 
arts helpt om tot de juiste diagnose te komen. 
In hoofdstuk 4 laten we zien, dat patiënten met 3−MGA−uria type IV vaak opvallende 
gelaatskenmerken hebben. Dit kan naast de 3−MGA−uria een bijzonder kenmerk van een 
syndroom zijn en daarmee ook in de diagnostiek helpen. 
In hoofdstuk 5 beschrijven we een nieuwe ziekte, het MEGDEL syndroom. Dit is een zeer 
karakteristiek ziektebeeld, gekenmerkt door 3−MGA−uria, doofheid, progressieve 
spasticiteit en bewegingsstoornis (dystonie) beginnend op de kinderleeftijd. Tevens 
hebben alle patienten specifieke afwijkingen op de MRI van de hersenen die wij kennen van 
kinderen met energiestofwisselingsziekten. In hoofdstuk 6 ontrafelen we de genetische 
oorzaak en de onderliggende pathofysiologie van dit ziektebeeld. Exome sequencing is een 
nieuwe genetische methode waardoor alle genen van de mens in een onderzoek op foutjes 
nagekeken kunnen worden. Bij twee patiënten met het MEGDEL syndroom vonden wij 
foutjes (mutaties) in hetzelfde gen, SERAC1. Het was dus aannemelijk dat mutaties in dit 
gen leiden tot het MEGDEL syndroom. De functie van het SERAC1 eiwit was op dat 
moment volledig onbekend. Om te bewijzen, dat MEGDEL syndroom door mutaties in 
SERAC1 onstaat, moesten wij de functie van dit eiwit vinden. Dit onderzoek leidde tot 
meerdere baanbrekende inzichten. Wij konden aantonen dat SERAC1 een zeer belangrijke 
rol speelt bij zowel de energiestofwisseling als ook bij het transport van cholesterol in de 
cel. Er zijn enkele overlappingen met het Barth syndroom, maar een soortgelijke ziekte 
was tot op heden onbekend. Ook over de aangetaste stofwisselingsroutes was eerder heel 
weinig bekend. 
In hoofdstuk 7 onderzoeken we bij bijna 400 patiënten met de biomarker 3−MGA−uria 
welke ziektebeelden zij hebben. Wij concluderen, dat de biomarker 3−MGA−uria een 
marker is voor een gestoorde energiestofwisseling. Er lijken zelfs enkele types van 
energiestofwisselingsziekten te bestaan waarbij deze marker vaker voorkomt. Beide 
bevindingen kunnen de arts op het juiste spoor zetten bij zijn zoektocht naar een diagnose. 
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Met alle kennis opgedaan in het kader van dit proefschrift stellen wij in hoofdstuk 8 een 
nieuwe indeling van ziektebeelden met 3−MGA−uria als kenmerk op met een bijbehorende 
nieuwe nomenclatuur voor deze groep ziekten. 
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